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ABSTRACT 
 
The D-glucose disaccharide α, α’-D-trehalose is synthesized by a variety of bacteria, 
fungi, plants and invertebrates to support cell survival by functioning as a fuel, a metabolic 
regulator or a protectant against environmental stress. Five different trehalose biosynthetic 
pathways are known to exist, one of which, the OtsA/OtsB pathway is common among 
pathogenic bacteria and fungi and is also found in parasitic nematodes. Previously reported 
otsA and otsB gene knockout (or knockdown) experiments have shown that both pathway 
enzymes are essential for M. tuberculosis cell growth and host colonization. RNAi gene 
silencing carried out in the nematode model system Caenohabditis elegans revealed that 
the T6P phosphatase is essential. Based on these findings we concluded that trehalose-
synthesizing pathogens are likely to be vulnerable to the action of small molecule inhibitors 
of T6P phosphatase. We designed a bi-module inhibitor prototype.  Accordingly, the 
phosphate group of the trehalose 6-phosphate moiety was replaced by a phosphate mimetic 
for targeting the active site of the catalytic domain, and the glucose unit was modified for 
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targeting the cap domain for induced cap closure over the active site.  Sulfate proved to be 
the most effective warhead for the substrate-binding site. T6S binding was shown by using 
Single Angle X-ray Scattering (SAXS) analysis to induce cap closure. Using glucose-6-
sulfate as the platform, a series of synthetic derivatives possessing “drug-like” functions 
tethered to the glucose ring were evaluated. Of these first generation inhibitors 4-n-
octylphenyl-α-D-glucopyranoside 6-sulfate proved to be the tightest binding T6PP 
competitive inhibitor. In parallel, we have used the glucose-6-sulfate as the scaffold in the 
design of active site-directed, irreversible inhibitors. From the adducts which were 
synthesized and tested for T6PP inactivation, 4-n-octylphenyl-2-(3-(flurosulfonyl) 
benzoylamino)-2-deoxy-α-D-glucopyranoside-6-sulfate was selected for further 
characterization, and subsequently shown to inactivate the T6PPs with stoichiometric 
covalent modification and reasonable efficiency. Bioinformatic analysis and site-directed 
mutagenesis methods were used to identify the modified residue, a stringently conserved 
lysine residue was identified. Based on this result, the design and synthesis of the second 
generation of irreversible inhibitors that are optimized this target site is planned for future 
work. 
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CHAPTER ONE 
 
TREHALOSE-6-PHOSPHATE PHOSPHATASE AS A NEW 
CANDIDATE DRUG TARGET IN FILARIAL NEMATODES AND 
PATHOGENIC BACTERIA 
 
           Some of the most chronically debilitating diseases caused by parasitic nematodes 
plague the low-income populations of Africa, Asia, and the Americas. One of these diseases 
is Lymphatic filariasis, a mosquito borne disease caused by Brugia malayi, Wuchereria 
bancrofti and Brugia timori. This disease affects around 120 million people worldwide in 
tropical and sub-tropical countries putting 1.3 billion people at risk (WHO, 2009) [1, 2]. 
Filarial infections are responsible for extreme infirmity, distress, and social stigma. In fact, 
lymphatic filariasis is a major cause of permanent and longterm disability in people 
worldwide [3]. Because of the nature of infection and the impact on people suffering from 
this disease, the Global Program for the Elimination of Lymphatic Filariasis (GPELF) was 
established in 1999 with the main goal of ending the transmission of this disease by 2020. 
Currently, the recommended treatment for lymphatic filariasis is the administration of 
albendazole together with ivermectin or diethylcarbamazine citrate. Even though these 
treatments are effective in community-wide treatment programs, they are not without 
drawbacks. One problem is the fact that these drugs can only kill microfilariae, leaving the 
adult worms intact. Consequently, the treatment must be continued during the entire 
reproductive life span of the adult worm (about 5 years) [4]. The other issue is that the drug 
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combination can prove lethal if administered to individuals with high microfilarial loads 
caused by a co-infection by Loa loa [5]. Therefore, new drugs which are not subject to 
these limitations are in demand.  
Parasitic nematode model systems are needed to facilitate the drug-discovery 
programs. The laboratory–based investigation is difficult because of the complicated life 
cycle of nematodes. C. elegans has served as a model system for research on free-living 
nematodes for decades [6-8]. Fortunately, B. malayi can be maintained in a jird host, which 
is amenable to in vitro studies at different stages of its life-cycle [9, 10].  Presently, both C. 
elegans and B. malayi serve as plausible models for research on lymphatic filarial 
nematodes.Trehalose-6-phosphate phosphatase (T6PP) (UniProt: A8NS89) is one of the 
highest-ranking targets in the top drug target candidates identified in B. malayi using a 
ranking system [11].Trehalose-6-phosphate phosphatase participates in the OtsAB 
biosynthetic pathway, which is the dominant pathway leading to the disaccharide trehalose. 
The two-step pathway consists of the trehalose-6-phosphate synthase (OtsA)-catalyzed 
reaction of -UDP-glucose and glucose-6-phosphate to generate ’-D-trehalose-6-
phosphate, which is then hydrolyzed to -D-trehalose by trehalose-6-phosphate 
phosphatase (OtsB) (Scheme 1.1). Trehalose, a sugar found in many species of plants, 
bacteria, fungi and invertebrate animals, but not in vertebraetes, is a non-reducing 
disaccharide composed of two glucose moieties. Apart from its function as a reserve 
carbohydrate, trehalose is known for its role as a stress protectant in many organisms across 
all three Kingdoms wherein it protects the organism from damage via desiccation, freezing, 
starvation, and osmotic stress.   
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            Although trehalose performs important functions in nematodes, the reduction in 
T6PP activity in C. elegans by gene knockdown is lethal not because of the absence of 
trehalose but rather because of the accumulation of trehalose-6-phosphate (T6P). One 
theory is that T6P acts as a toxic anti-metabolite, leading to organism death [12]. In 
Saccharomyces cerevisiae, T6P acts as an important signal for metabolic regulation. 
Specifically it regulates the first steps in glycolysis through the inhibition of hexokinase II, 
and its accumulation is detrimental to the organism [13]. Finally, silencing of the T6PP-
encoding tpp gene in B. malayi caused the arrested growth of the larvae [14]. We therefore 
concluded that trehalose phosphate phosphatase (T6PP) is essential to B. malayi and other 
Scheme 1.1 OtsAB biosynthetic pathway. 
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T6P-producing organisms, and that inhibition by a small drug-like molecule could be an 
effective strategy for the development of a therapeutic agent.  
In Mycobacterium tuberculosis, trehalose is the major free sugar in the cytoplasm; 
it is a constituent of cell wall glycolipids, and it is required for the transport of mycolic acid 
during cell wall biogenesis. Mycobacterium tuberculosis causes Tuberculosis (TB), an 
infectious disease. In 2010, there were an estimated 8.5–9.2 million cases of TB and 1.2–
1.5 million deaths. TB is the second leading cause of death from an infectious disease 
worldwide (WHO, 2011) [15]. Resistance to anti-TB drugs, a problem recognized in the 
very early days of the chemotherapeutic era, has become a global threat.   New drugs which 
act on new drug targets can counteract existing drug resistance.  There are three potential 
pathways to synthesize trehalose in mycobacteria, the previously mentioned OtsAB 
pathway (which utilizes glucose and glucose-6-phosphate to generate T6P catalyzed by 
trehalose synthase, then hydrolyzed to trehalose by T6PP), the TreYZ pathway (which 
makes trehalose from the hydrolysis of glycogen), and the TreS enzyme (which can convert 
maltose to trehalose) (Scheme 1.2) [16]. However, the OtsAB pathway is the dominant 
pathway required for M. tuberculos’s growth in laboratory culture and for its virulence in 
a mouse model [17]. Trehalose-6-phosphate phosphatase (TPP) is an essential enzyme for 
growth of mycobacteria, which has been identified to be a potential anti-tuberculosis drug 
target.  
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                 Scheme 1.2 Three pathways for trehalose biosynthesis in M. tuberculosis 
   
  T6PP is a member of the haloalkanoate dehalogenase (HAD) superfamily of 
phosphatases. HAD phosphatases catalyze the hydrolysis of organophosphate esters using 
a two-step reaction sequence, which employs nucleophilic catalysis by one active site Asp 
residue and acid/base catalysis by a second Asp nucleophile (Figure 1.1). The phosphoryl 
group is activated for transfer by a Mg2+ cofactor and by an active site Thr/Ser and Lys 
residue (Figure 1.1). Based on the known structure of the close structural homolog sucrose 
6-phosphate phosphatase (S6PP) (Figure 1.2) it is evident that the T6PP is comprised of a 
Rossmann-fold catalytic domain and an -fold cap domain. The catalytic domain 
contains the catalytic scaffold (represented in Figure 1.1) that mediates the two phosphoryl 
transfer steps, whereas the cap domain binds the organic leaving group (trehalose in the 
case of T6P) that is displaced in the first step.  
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Figure 1.1. The reaction pathway (top) and active site of the HAD phosphatase 
(bottom). 
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The goal of the work reported herein was to carry out structure-function analysis to 
define the T6PP substrate binding for inhibitor targeting which will provide the foundation 
for future drug design. The working hypothesis is that small molecule inhibitors will block 
T6PP activity in vivo and this in turn will lead to the accumulation of the T6P and result in 
death of the host organism. My first objective is to identify the steric and electrostatic 
features of the T6PP substrate binding site region and my second objective is to use this 
information to guide the design of tight binding inhibitors. The X-ray structure 
 
Figure 1.2. The structure of S6PP in the unliganded cap-open conformation 
and in substrate-bound, cap-closed conformation. The catalytic domain is 
shown in gray and the cap domain in magenta. Bound substrate stabilizes the 
enzyme in the cap-closed conformation. 
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determinations will be carried out in Karen Allen’s laboratory at Boston University. To 
facilitate the structure determinations I will supply recombinant wild-type and mutant 
T6PP and synthetic substrate analogs (inhibitors) for co-crystallization. I will use the 
structural data obtained in combination with the Ki values measured for the inhibitors to 
locate the residues that can provide the largest amount of favorable binding energy. These 
results will be used to refine inhibitor design.  
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CHAPTER TWO 
CLONING, EXPRESSION, PURIFICATION AND KINETICS OF 
TREHALOSE-6-PHOSPHATE PHOSPHATASE HOMOLOGUES 
 
 
 2.1 Introduction 
The T6PPs that I have selected for study (based on availability of genomic DNA 
for T6PP gene cloning) are Mycobacterium tuberculosis (bacterial causative agent of 
tuberculosis), Shigella boydii (bacterial causative agent of dysentery), Salmonella 
typhimurium (causative agent of Salmonellosis), Ascaris suum (pig roundworm). We 
assumed that by generating recombinant T6PP from several different pathogens for 
examination we might increase our chances for successful crystallization and structure 
determination. Furthermore, each of the chosen T6P phosphatase orthologs can serve as a 
unique subject for inhibitor development and for in vivo inhibition. The gene encoding the 
T6PP from Brugia malayi (parasitic human roundworm causative agent of elephantiasis) 
was cloned by our collaborators (the Carlow laboratory at New England Biolabs). They 
have provided wild-type and mutant B. malayi T6PP for X-ray structure determination and 
for inhibitor evaluation.  
 
2.2 Materials and Methods 
2.2.1 General Methods 
            All chemicals and buffers were purchased from Sigma-Aldrich. The sources of the 
gene cloning materials are as follows: primers (Invitrogen); T7 Express Iq Competent E. 
coli (High Efficiency) competent cells, T4 DNA ligase, restriction enzymes (New England 
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biolabs) and Pfu, Turbo polymerases (Strategene); pET23a and pET28a vector kits 
(Novagen); Qiaprep Spin Miniprep Kit (Qiagen). DEAE Sepharose was from Amersham 
Biosciences. Butyl and Phenyl-Sepharose resins were purchased from Sigma-Aldrich, 
whereas the Ni-NTA resin was from Qiangen. Snakeskin pleated dialysis tubing was 
purchased from Thermo Scientific. SDS-PAGE analysis was performed with a 12% -16% 
acrylamide running gel and a 4% stacking gel (37.5:1 acrylmide:biacryamide ratio) 
(BioRad, Hercules, CA). Protein solutions were concentrated using a 10K Amicon Ultra 
Centrifugal filter (Millipore). The nucleotide sequence of each cloned gene or mutant gene 
was determined by GENEWIZ, Inc. Electro-spray mass-spectrometry (ES-MS) 
determinations were carried out by the University of the New Mexico Mass Spectrometry 
Facility. Protein concentrations were determined using the Bradford assay kit from Sigma-
Aldrich. 
 
2.2.2 Preparation of Recombinant Wild-type T6PPs 
 
2.2.2.1 Preparation of Recombinant Wild-type Mycobacterium tuberculosis T6PP 
 
          The gene encoding Mt-T6PP was amplified by using the polymerase chain 
reaction (PCR). The reaction mixture contained M. tuberculosis genomic DNA (ATCC 
25177), Deep Vent DNA Polymerase and with the forward (5'-GTGAGAGG 
GTGGCATATGCGCAAGTTGGGC-3') and reverse (5'-CATGGCCGTCCTCCTC 
GAGGACGGTCGGAG-3') oligonucleotide primers containing NdeI and XhoI 
restriction sites, respectively. Gene amplification was carried out under the following 
conditions: 50 μL reactions contained 5 μL 10×Pfu buffer, 4 μL dNTP mix (2.5mM), 1 
μL Deep Vent DNA Polymerase, 2 μL forward primer (50 μM), 2 μL reverse primer 
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(50 μM), 2 μL template/genomic DNA (20ng/μL) and 34 μL DI H2O. The initial 
denaturation was carried out at 94°C for 10 min followed by 25 cycles of denaturation 
at 94 °C for 1 min, annealing at 51.5 °C for 2 min and extension at 72 °C for 5 min. 
The final extension was carried out at 72 °C for 10 min. The PCR products were 
digested with NdeI and XhoI restriction enzymes at 37 °C for 3 h, and the digested 
products were harvested by agarose gel electrophoresis. At the same time, pET-15b (+) 
tev (Boston University) and pET-23a (+) vectors were  digested by NdeI and XhoI 
restriction enzymes at 37 °C for 3h, and the digested products were harvested in the 
same manner. Digested DNA was ligated to corresponding digested pET-15b (+) tev 
and pET-23a (+) vectors at room temperature for 5-7 h, and the cloned products were 
verified by DNA sequencing. Both of the pET-15b (+) tev-T6PP and pET-23a (+) -
T6PP constructs were transformed into T7 Express Iq Competent E. coli (High 
Efficiency) cells from New England BioLabs. Over-expression of Mt-T6PP was 
induced with 0.4 mM IPTG (isopropyl β-D-thiogalactoside) overnight at 37 °C and 175 
rpm in LB cultures at logarithmic phase growth (OD600=0.4-0.6). 
          Cells containing Mt-T6PP were harvested at 6500 rpm for 15 min and the 
collected pellet was suspended in 20 mM HEPES buffer (pH =7.5) containing 100 mM 
NaCl, 5 mM MgCl2 and 2 mM DTT. The suspended cells were lysed by disruption 
using a French Pressure Cell and the lysate was centrifuged at 20,000 rpm for 15 min. 
For the His-tagged Mt-T6PP (from pET15b (+) tev-T6PP), the supernatant was loaded 
onto a nickel nitrilotriacetic acid (Ni-NTA) agarose affinity column, which was pre-
equilibrated with 20 mM HEPES buffer (pH =7.5) containing 100 mM NaCl, 5 mM 
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MgCl2, 2 mM DTT and 40 mM imidazole. The column was subsequently washed with 
the same buffer for 3-5 column volumes before the recombinant protein was eluted 
with similar buffer containing 500 mM imidazole. The purity of eluted protein was 
analyzed by 12% SDS-PAGE (Coomassie blue staining). Recombinant Mt-T6PP 
protein was dialyzed against 20 mM HEPES buffer (pH 7.5) containing 5 mM MgCl2, 
100 mM NaCl and 2 mM DTT in order to remove imidazole. The dialyzed protein was 
subjected to steady-state kinetic analysis. For protein that was used for crystallization, 
the concentrated, dialyzed protein was loaded onto a HiPrep Sephacryl S200 HR size-
exclusion column that had been equilibrated with 20 mM HEPES buffer (pH=7.5) 
containing 5 mM MgCl2 and 2 mM DTT, and eluted with the same buffer. Protein 
concentration was determined using the Bio-Rad protein assay with bovine serum 
albumin as the standard 
           For purification of native Mt-T6PP, the protein was first precipitated from the 
supernatant derived from centrifugation of the lysed cells using ammonium sulfate. The 
fraction containing Mt-T6PP was then resuspended using 20 mM Hepes (pH=7.5) 
buffer containing 5 mM MgCl2, 100 mM NaCl, 2 mM DTT and 17 % (NH4)2SO4, and 
applied to a Butyl sepharose (BS) column with a binding buffer containing 20 mM 
HEPES (pH=7.5), 5 mM MgCl2, 100 mM NaCl, 2 mM DTT and 17 % (NH4)2SO4. The 
column was eluted with a linear gradient of 17%-0% (NH4)2SO4 in buffer (10 column 
volumes). The fraction containing Mt-T6PP was collected and dialyzed against 20 mM 
HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT to remove the 
ammonium sulfate. The protein solution was then loaded onto a DEAE column and 
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eluted with 0-1 M KCl in buffer (10 column volume). The Mt-T6PP-containing fraction 
was then loaded onto a BS column, running the same gradient as before to obtain pure 
protein. Lastly, the fraction containing pure Mt-T6PP was collected and dialyzed 
against 20 mM HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT. The 
protein solution was then chromatographed on a Sephacryl S-200 HR column using 20 
mM HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT as eluant.  
 
2.2.2.2 Preparation of Recombinant Wild-type Shigella boydii T6PP       
           The gene encoding the Sb-T6PP protein was amplified by PCR using DNA 
synthesized by GenScript, Deep Vent DNA polymerase, along with a gene-specific 
oligonucleotide forward primer (5'CCTCGCGAATGCATCTAGATCCCAT3') and 
reverse primer (5'CAGGCCTCTGCAGTCGACGG3') containing NdeI and XhoI 
restriction sites, respectively. The pET-28a and pET-23 vectors, digested by NdeI and 
XhoI restriction enzymes, were ligated to the PCR product previously digested with the 
same restriction enzymes. For pET-15b-TEV vector, it was digested by NdeI and 
BamHI restriction enzymes and ligated to the PCR product previously digested with 
the same restriction enzymes. The ligation product was used to transform T7 Express 
Iq Competent E. coli cells (High Efficiency) that were then grown on an agar plate 
containing kanamycin for the pET-28a construct and an agar plate containing ampicillin 
for the pET-23a construct. A selected colony was checked for T6PP expression and the 
isolated plasmid was sequenced to verify the correct gene sequence. Sb-T6PP was 
further prepared using the same method described for Mt-T6PP preparation.  
            For the purification of His-tagged and native Sb-T6PP, the same methods as 
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described previously in Mt-T6PP purification were used. For the purification of His-
tag removed As-T6PP, TEV protease was used to cut the tag from the His-tagged As-
T6PP. Mass spectrometry was used to confirm cleavage of the tag.  
 
2.2.2.3 Preparation of Recombinant Wild-type Ascaris suum T6PP 
            The DNA coding the As-T6PP protein was amplified by PCR using template 
DNA synthesized by GenScript in PUC-57 with Deep Vent DNA polymerase and an 
oligonucleotide forward primer (5'CGCGAATGCATCTAGATCCCATATGACT3') and 
reverse primer (5'GATCGGATCCAATTTATTCAGTGGCTCGTT3') containing NdeI 
and XhoI restriction sites. The pET-15b-tev and pET-23a vectors, digested by NdeI and 
XhoI restriction enzymes, were ligated to the PCR product that had been purified and 
digested with the same restriction enzymes. The ligation product was used to transform 
T7 Express Iq Competent E. coli (High Efficiency) cells that were then grown on an 
agar plate containing kanamycin for the pET-15B-tev construct and an agar plate 
containing ampicillin for the pET-23a construct. A selected colony was checked for 
T6PP expression, and the isolated plasmid was sequenced to verify the correct gene 
sequence. Cells were cultured for protein production using the same method previously 
described for Mt-T6PP.  
            For the purification of His-tagged As-T6PP, the same method described 
previously for Mt-T6PP purification was used. For the purification of native As-T6PP, 
TEV protease was used to cut the tag from the His-tagged As-T6PP. Mass spectrometry 
was used to confirm cleavage of the tag.  
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2.2.2.4 Preparation of Recombinant Wild-type Salmonella typhimurium T6PP 
             The gene encoding St-T6PP was amplified by using the polymerase chain 
reaction (PCR). The reaction mixture contained Salmonella typhimurium genomic 
DNA (ATCC 700720D), PfuTurbo DNA Polymerase and with the forward (5'- 
AGACCCATATGGCAGAACCGTTA-3') and reverse (5'- CACAACCCTCGAGCCG 
CTTT-3') oligonucleotide primers containing NdeI and XhoI restriction sites, 
respectively. Gene amplification was carried out under the following conditions: 50 μL 
reactions contained 5 μL 10×Pfu buffer, 4 μL dNTP mix(2.5mM), 1 μL Deep Vent DNA 
Polymerase, 2 μL forward primer (50 μM), 2 μL reverse primer (50 μM), 2 μL 
template/genomic DNA (20ng/μL) and 34 μL DI H2O. The initial denaturation was 
carried out at 94°C for 2 min followed by 30 cycles of denaturation at 95 °C for 30 s, 
annealing at 55.2 °C for 30 s and extension at 72 °C for 1.5 min. The final extension 
was carried out at 72 °C for 10 min. The PCR products were digested with NdeI and 
XhoI restriction enzymes at room temperature overnight, and the digested products 
were harvested by agarose gel electrophoresis. At the same time, pET-15b (+) tev 
(Boston University) was also digested by NdeI and XhoI restriction enzymes at room 
temperature overnight, and the digested products were harvested in the same manner. 
Digested DNA was ligated to corresponding digested pET-15b (+) tev vector at room 
temperature for 5-7 h, and the cloned products were verified by DNA sequencing. The 
pET-15b (+) tev-T6PP construct was transformed into T7 Express Iq Competent E. coli 
(High Efficiency) cells from New England BioLabs. Over-expression of St-T6PP was 
induced with 0.4 mM IPTG (isopropyl β-D-thiogalactoside) overnight at 37 °C and 175 
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rpm in LB cultures at logarithmic phase growth (OD600=0.4-0.6). 
             Cells containing St-T6PP were harvested at 6500 rpm for 15 min and the 
collected pellet was suspended in 25 mM HEPES buffer (pH =8.0) containing 25 mM 
NaCl, 5 mM MgCl2. The resuspended cells were lysed by disruption using a French 
Pressure Cell and the lysate was   centrifugated at 20,000 rpm for 15 min. For the His-
tagged St-T6PP (from pET15b (+) tev-T6PP), the supernatant was loaded onto a nickel 
nitrilotriacetic acid (Ni-NTA) agarose affinity column, which was pre-equilibrated with 
25 mM HEPES buffer (pH =8.0) containing 25 mM NaCl, 5 mM MgCl2, and 10 mM 
imidazole. The column was subsequently washed with the same buffer for 3-5 column 
volumes before the recombinant protein was eluted with similar buffer containing 500 
mM imidazole. The purity of eluted protein was analyzed by 16% SDS-PAGE 
(Coomassie blue staining). Recombinant St-T6PP protein was dialyzed against 25 mM 
HEPES buffer (pH 8.0) containing 5 mM MgCl2, 25 mM NaCl in order to remove free 
phosphate. The dialyzed protein was subjected to steady-state kinetic analysis. For 
protein that was used for crystallization, the concentrated, dialyzed protein was loaded 
onto a HiPrep Sephacryl S200 HR size-exclusion column that had been equilibrated 
with 25 mM HEPES buffer (pH=8.0) containing 5 mM MgCl2, and eluted with the 
same buffer. Protein concentration was determined using the Bio-Rad protein assay 
with bovine serum albumin as the standard. 
 
2.2.3 T6PPs Molecular Weight Determination 
           The theoretical subunit molecular mass of each recombinant T6PP was calculated 
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from the amino acid composition using the ExPASy Molecular Biology Server program 
Compute pI/MW (http://web.expasy.org /compute_pi/). The approximate subunit mass of 
each recombinant T6PP was determined by SDS-PAGE analysis (Figure 2.1, Figure 2.2) 
using protein molecular weight standards from New England Biolabs Inc. The exact 
subunit mass was determined by MS-ES mass spectrometry. The molecular mass of the 
native T6PP was determined by FPLC gel filtration column chromatography against 
protein standards (13.7-220 kDa from GE Healthcare). The 1.6 cm x 60 cm Sephacryl S-
200HR column (GE Healthcare) was eluted at 4 oC with the same type of buffer solution 
that used for purification. The native molecular weight was derived from the measured 
elution volume by extrapolation of the plot of the elution volume of the molecular weight 
standard versus log molecular weight.  
 
2.2.4 Steady-state kinetic constant determinations 
2.2.4.1 Method for determination of Mt-T6PP steady-state kinetic constants  
           Phosphatase activity was measured using the EnzChek Phosphate Assay Kit. 
Reactions solutions 500 μL in volume contained 25 µL 20× reaction buffer, 5 µL purine 
nucleoside phosphorylase (0.5 U) and 28 nM of purified enzyme. The Absorbance at 360 
nm was measured to determine the amount of free phosphate produced, which was linear 
in the range of 0.05– 1 mM trehalose-6-phosphate. The steady-state kinetic parameters (Km 
and kcat) were determined by fitting the initial velocity data measured at varying substrate 
concentration (varied in the range Km – 10Km) to the equation: 
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 V0 = (Vmax[S])/([S]+Km) 
 
Where V0 is the initial velocity, Vmax the maximum velocity, [S] the substrate 
concentration, and Km the Michaelis constant for the substrate, using the SigmaPlot 
Enzyme Kinetics Module. The kcat values were calculated from Vmax and [E] according 
to the equation kcat = Vmax/[E], where [E] is the enzyme concentration. 
 
2.2.4.2 Method for determination of Sb-T6PP Steady-state kinetic constants 
          To test for Sb-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as 
described previously) was used. Reactions with a final volume of 500 μL contained 25 
μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 28 nM of 
purified enzyme. The absorbance at 360 nm was measured to determine the amount of 
free phosphate produced, which was linear in the range of 0.5– 3 mM trehalose-6-
phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the 
same method previously described for Mt-T6PP.  
 
2.2.4.3 Method for determination of As-T6PP steady-state kinetic constants 
          To test for Sb-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as 
described previously) was used. Reactions with a final volume of 500 μL contained 25 
μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 28 nM of 
purified enzyme. The absorbance at 360 nm was measured to determine the amount of 
free phosphate produced, which was linear in the range of 50– 500 mM trehalose-6-
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phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the 
same method previously described for Mt-T6PP.  
 
2.2.4.4 Method for determination of St-T6PP steady-state kinetic constants 
             To test for St-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as 
described previously) was used. Reactions with a final volume of 300 μL contained 15 
μL 20× reaction buffer, 3 μL purine nucleoside phosphorylase (0.3 U) and 33 nM of 
purified enzyme. The absorbance at 360 nm was measured to determine the amount of 
free phosphate produced, which was linear in the range of 0.13– 1.2 mM trehalose-6-
phosphate [1]. The kinetic parameters Km, kcat and kcat/Km were determined by using 
the same method previously described for Mt-T6PP.  
 
2.2.4.5 Method for determination of Bm-T6PP steady-state kinetic constants 
             To test for Bm-T6PP phosphatase activity, the EnzChek Phosphate Assay kit 
(as described previously) was used. Reactions with a final volume of 500 μL contained 
25 μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 8 nM of 
purified enzyme. The absorbance at 360 nm was measured to determine the amount of 
free phosphate produced, which was linear in the range of 0.0625-5 mM trehalose-6-
phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the 
same method previously described for Mt-T6PP.  
 
2.3 Results and Discussion 
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2.3.1 Preparation of the recombinant T6P Phosphatases 
 His6-tagged T6P phosphatases were expressed in E. coli and purified by affinity 
chromatography. The SDS-PAGE gels of the purified proteins are shown in Figure 2.3.1 
and 2.3.1. Typical yields (mg protein/g cell pellet) are as follows: As-T6PP 2.7, Mt-T6PP 
5.3, Sb-T6PP 3.7, St-T6PP 11.7.  
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    Ladder   St-T6PP 
Figure 2.2.  SDS -PAGE analysis of purity of the purified his-tagged 
St-T6PP. From left to right, Lane 1: Ladder; Lane 2: St-T6PP. 
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Figure 2.1.  SDS -PAGE analysis of purity of the purified his-tagged 
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2.3.2 ES-MS Determination of the exact mass of the purified proteins 
              ES-MS analysis of the purified proteins yielded the following results: His-tagged 
Mt-T6PP (theoretical 44.051 kDa) 44.052 kDa; Native Mt-T6PP (theoretical 41.720 kDa) 
41.720 kDa; His-tagged Sb-T6PP (theoretical 31.297 kDa) 31.297 kDa; Tev cleaved His-
tagged Sb-T6PP (theoretical 29.459 kDa) 29.459 kDa; His-tagged As-T6PP (theoretical 
56.717 kDa) 56.718 kDa; Tev cleaved His-tagged As-T6PP (theoretical 54.581kDa) 54.582 
kDa.  His-tagged St-T6PP ((theoretical 31.576 kDa) 31.576 kDa. The mass spectra are 
shown in the figures below.   
 
 
 
 
 
Figure 2.3 Mass spec of His-tagged Mt-T6PP (theoretical  mass: 44.051 kDa).    
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Figure 2.4 Mass spec of native Mt-T6PP (theoretical mass: 41.720 kDa).    
Figure 2.5 Mass spec of His-tagged Sb-T6PP (theoretical mass: 31.297 kDa).    
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Figure 2.6 Mass spec of Tev cleaved His-tagged Sb-T6PP (theoretical mass: 29.459 
kDa).    
Figure 2.7 Mass spec of His-tagged As-T6PP (theoretical mass: 56.717 kDa).    
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Figure 2.8 Mass spec of Tev cleaved His-tagged As-T6PP (theoretical mass: 
54.581 kDa).    
Figure 2.9 Mass spec of His-tagged St-T6PP (theoretical mass: 31.576 kDa).    
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2.3.3 T6PPs Substrate Specificity Profile 
             The ability of purified T6PPs to catalyze the conversion of some similar 
monosaccharide (glucose-6-phosphate) and disaccharide phosphates (sucrose-6-phosphate) 
and p-nitrophenyl phosphate (a generic substrate for HAD phosphatases) were tested. 
Under the reaction conditions employed (10 mM phosphate ester substrate, 1 mM MgCl2, 
0.1 Mm sodium azide and  50 M Mt-T6PP mM in 50 mM Tris buffer at pH 7.5 and 25 
oC), No activity was observed above the detection limit of one catalytic turnover per hour. 
The one exception is Mt-T6PP which displayed marginal activity towards -D-glucose-1-
phosphate (kcat =0.0022±0.0002 s-1 and Km = 8 ± 1 mM. Earlier, Mt-T6PP was reported 
to display activity with α-D-glucose-1-phosphate, α-D-mannose-1-phosphate and 
mannose-6-phosphate [2].  
              In general, the T6PPs show stringent substrate specificity which is unusual for 
HAD phosphatases.   Even the dissacharide sucrose-6-phosphate, which is highly similar 
to trehalose-6-phosphate, both of them are disaccharide and have phosphate at one of the 
6 positions of the monosaccharide moiety.  Trehalose-6-phosphate has 1,1, α, α linkage, 
but sucrose -6-phophatete has 2,1, α-linkage, besides, Trehalose-6-phosphatete was formed 
by two glucose, but sucrose-6-phospahte has a glucose and a fructose [Figure 4]. However, 
none of the T6PPs shows activities on it.  Besides, p-nitrophenyl phosphate is a widely 
used “activated” substrate for detecting phosphatase activity in HAD phosphatases, yet 
remarkably none of the T6PPs showed activities with it.  
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Next, the T6PPs phosphatase activities were tested using their biological substrate 
trehalose-6-phosphate [Figure 2.10]. Their kcat, Km and kcat/Km values were determined at 
pH 7.5 and 25 ℃ [Table 2.1] 
 
T6PP Source kcat (s-1) Km (μM) kcat/Km (M-1s-1) 
Brugia malayi 5 24±2 360±60 6.9×104  
Mycobacterium tuberculosis 10±0.9 500±100 1.9×104  
Shigella boydii 16±0.8 690±70 2.3×104  
Ascaris suum 3.6±0.5 230±70 1.6×104  
Salmonella typhimurium   6.2±0.3 310±40 1.9×104 
 
Figure 2.10. Structures of trehalose-6-phospahte and sucrose-6’-phosphate 
Table 2.1 Steady-state kinetic constants for wild-type T6PPs-catalyzed hydrolysis of 
trehalose 6-phosphate at pH 7.5 and 25 ℃. See Materials and Methods for details 
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         The kcat value is governed by the two partial reactions: the first is the phosphoryl 
transfer from the bound substrate (T6P) to the Asp nucleophile, and the second step is the 
hydrolysis of the aspartyl-phosphate intermediate by the attack of a water molecule [3]. A 
second Asp residue (denoted Asp + 2 because it is positioned two residues from the Asp 
nucleophile) functions as a general acid/base residue to protonate the leaving group in the 
first partial reaction and deprotonate the water nucleophile in the second partial reaction 
[Figure 2.11] [4]. 
 
          
           The kcat/Km value, the substrate specificity constant, is determined by both the 
substrate binding affinity and the efficiency that the bound substrate (aspartyl-phosphate 
intermediate) is converted to the product (phosphate). The kcat/Km value is very useful for 
identifying substrates that have physiologically relevant activities since the concentration 
of the substrate in the cell is likely to be sub-saturating. HAD phosphatases that function 
as regulators of the level and composition of organophosphate metabolite pools typically 
have Km values in the milli-molar range and kcat/Km values in the 1 x 103 to 1 x 104 M-1 s-1 
range, where those that target single physiological substrate typically display a kcat/Km 
value in the range of 1 x 105 to 1 x 107 M-1 s-1. The kcat values typically fall in the range of 
Figure 2.11. Catalytic mechanism for T6PP. 
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1-20 s-1 range and the Km values from low micromolar to low millimolar. Accordingly, the 
T6PPs display a moderate, but certainly a physiologically relevant level of catalytic 
efficiency towards T6P. It is the high level of substrate specificity displayed each of the 
T6PPs that stands-out.  
 
2.3.4   Quaternary structure determination 
            The native masses were determined by using size exclusion (HiPrep Sephacryl 
S200 HR) column chromatography in conjunction with protein molecular weight standards. 
The results are as follows: native Mt-T6PP 39.1 kDa (monomer); native Sb-T6PP 28.8 kDa 
(monomer); native As-T6PP 61.9 kDa (monomer) 
 
 
2.3 Conclusion 
          There is an urgent need to discover novel antifilarial and antibacterial drug targets to 
assail the parasite especially when the risk of development of resistance to mainstay drugs 
is mounting. In trehalose biosynthesis, T6PP seems to be novel drug target as gene-
knockout experiments have shown that it is the pathway trehalose-6-phosphate 
phosphatase (T6PP) that is essential (owing to build-up of toxic levels of T6P) to the 
survival of the host organism (parasitic nematodes and bacteria). Thus, in the present study 
we have cloned, expressed, purified and characterized four orthologs of trehalose-6-
phospahte phosphatase from different organisms, A. suum, and B. malayi T6PPs are from 
nematodes, M. tubercleosis T6PP is form mycobacteria, and S. boydii, S. typhimurium 
T6PPs are from bacteria, which will be used for further characterization and inhibition 
studies. 
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CHAPTER THREE 
TREHALOSE-6-PHOSPHATE PHOSPHATASE INHIBITOR 
DESIGN, SYNTHESIS AND EVALUATION 
 
3.1 Background 
            Although the HADSF fold is dominant among eukaryotic and prokaryotic 
phosphatases, it has yet to be fully exploited for drug discovery. This stands in contrast to 
the phosphotyrosine phosphatase (PTP) family of phosphatases, for which great progress 
has been made in drug-like lead-inhibitor design and focused library-screening-based drug 
discovery [1-7]. To date only two reports of HADSF phosphatase inhibitor discovery have 
been described. First, the human small C-terminal domain phosphatase (Scp), which 
catalyzes the dephosphorylation of the C-terminal domain of eukaryotic RNA polymerase 
II, was screened against a pilot library of the NIH clinical collection (400 compounds) and 
the spectrum collection (2000 compounds). Among the hits, the drug Rabeprazole was 
found to have the tightest binding (IC50 = 5 μM) [8]. X-ray structural analysis revealed that 
this inhibitor binds to a shallow hydrophobic pocket adjacent to the catalytic site. In a 
second instance, the structure of the HADSF eyes absent-2 phosphatase was subjected to 
virtual screening of the InterBioScreen library and the top hits were shown by in vitro assay 
to have IC50 values ranging from 4-66 μM [9]. In-silico modeling suggests Mg2+ 
coordination of a chelating substituent augmented by favorable electrostatic interactions 
with substituents that occupy the catalytic site. Notably, both Scp and the eyes absent-2 
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phosphatase belong to a subclass of HADSF phosphatases that do not possess cap domains. 
Importantly, the potential for targeting a larger region of the protein contributed by the 
catalytic domain and the cap domain has yet to be explored.  
3.2 Research Strategy 
The initial strategy used for T6PP inhibitor design is based on the expectation 
catalysis by this enzyme might be prevented by binding a substance to the catalytic domain, 
to the cap domain, or to both domains in either a cap-open or cap-closed conformations. 
Thus, in this effort we have focused on the selection of potential inhibitors that might target 
the binding sites of the cap-closed and cap-open T6PP conformers. Specifically, the initial 
inhibitor approach centers substances that contain phosphate-mimetic groups, which can 
bind to the active site of the catalytic domain, tethered to organic moieties, which can ligate 
with the binding site of the cap domain. “Bivalent” inhibitors of this type have the potential 
of being high affinity and high specificity T6PP targeting agents [10]. In this chapter, we 
focus on the selection and evaluation of phosphate-mimetic groups to replace the 
C(6)phosphate group of trehalose. The corresponding inert substrate analogs were 
synthesized and then used as inhibitors of T6PP-catalyzed T6P hydrolysis.  
 
3.3 Inhibitor Selection and Synthesis 
     As described above, in the active sites of HAD phosphates the substrate phosphoryl 
substituent coordinates the Mg2+ cofactor and forms a number (>10) of hydrogen bonds 
with donors located in the active site of the catalytic domain. Crystallographic snapshots 
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of liganded active sites posed in the trigonal bipyramidal phosphorane transition-state 
configuration suggest that favorable binding interactions are maximized when the ligand 
conforms to the active site mold [11]. As a consequence of this analysis, we have designed 
several T6P analogs that contain the trehalose skeleton, which should be appropriate for 
binding to the cap domain of T6PPs. In addition these potential inhibitors contain groups 
that possess charge and Mg2+ and hydrogen bonding characteristics that are analogous to 
those of the phosphate moiety in T6P. Specifically, the inhibitors explored in this 
investigation, including the trehalose-6-sulfate 1, -methylenephosphonate 2, and -
fluoromethylenephosphonate 3 [Scheme 3.1], contain groups that have been shown to 
resemble phosphate moieties present in substrates for kinases and phosphatases [12-21]. In 
addition, in this study we have tested the ability of trehalose-6-methyleneboronate 4 and 
its in situ derived hydroxide adduct to target the T6PP catalytic sites. To our knowledge, 
boronates have not been tested as phosphomimetics. However, their ability to act as 
mechanism-based inhibitors of arginase and β-lactamase [22, 23] suggest that they might 
participate in formation of stable complexes with HAD catalytic sites. In the case of 
arginase, the trigonal boronate group plays the role of the Arg guanidinium moiety in 
reaction with the metal-ion bridged hydroxide to form a stable transition-state analog 
Scheme 3.1. Structures of T6PP inhibitors explored in this effort. 
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complex. In the case of β-lactamase, the active site Ser nucleophile forms a covalent adduct 
with the boronate group in a peptide-mimetic [24, 25]. We reasoned that by analogy the 
T6PP Asp nucleophile might form a covalent adduct with the boronate group in 4.  
 
3.4 Results and Discussion 
3.4.1 Determination of the Source(s) of T6PP Substrate Binding Energy 
             The five T6P phosphatases were compared for their ability to bind substrate analog 
(sucrose-6-phosphate), substrate fragments (trehalose and glucose-6-phosphate), 
tetrahedral Pi analog (tungstate) and metavanadate, a potential trigonal bipyramidal-
forming transition ligand). The abilities of the respective ligands to bind to the respective 
T6PP active sites were determined by testing them as inhibitors of catalyzed T6P hydrolysis 
by using steady-state kinetic techniques. The results are reported in Table 3.1. HAD 
phosphatases differ in the ability to form the (nucleophilic) Asp carboxylate adduct with 
the vanadate and/or with the vanadate complex of the alcohol complex. With the exception 
of As-T6PP, the T6P phosphatase is not inhibited by vanadate. Tungstate binding is also 
variable among HAD phosphatases. Based on the results reported in Table 3.1 we can 
conclude that tungstate binds tightly to Bm-T6PP and Mt-T6PP, moderately to As-T6PP 
and does not bind with significant affinity to Sb-T6PP and St-T6PP.  
The absence of significant binding affinity observed for sucrose-6-phosphate with 
all five T6P phosphatases accounts for its lack of substrate activity, as was first reported in 
Chapter 2. Cleary, overall fit is important for substrate binding as well as catalysis. The 
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absence of significant binding of trehalose to the T6P phosphatases suggests that the 
trehalose moiety, alone, does not make a sizable contribution to the substrate binding 
affinity as reflected in Ki values too large to measure using steady-state kinetic techniques. 
Yet, it must be kept in mind that the trehalose moiety is required for productive binding, or 
in other words, for formation of the catalytically active enzyme-substrate complex (i.e., for  
turnover) (viz., glucose-6-phosphate is not turned over).  
 
           Likewise, the T6P fragment glucose-6-P does not bind with significant affinity to 
the five T6P phosphatases. This observation suggests that binding to the individual 
substrate fragments is not strong enough to overcome the loss in entropy associated with 
complex formation. As will be developed further in the following section, this deduction 
lead us to design inert substrate analog inhibitors having a phosphate mimetic group located 
at the C(6) position of trehalose.  
Inhibitor SbT6PP Ki StT6PP Ki MtT6PP Ki BmT6PP Ki AsT6PP Ki 
Sucrose-6-P NDa NDa NDa NDa NDa 
Glucose-6-P NDa NDa NDa NDa NDa 
K2WO4 NDb NDb 19± 4.0±0. 120±20  
Trehalose NDa NDa NDa NDa NDa 
Na3VO4 NDa NDa NDa NDa 55±9  
20 mM Trehalose 
+ 1.3 mM Na3VO4 
- - - ~1.3 mM - 
a No Inhibition detected for catalyzed hydrolysis of [T6P] =Km in the presence of 10 mM inhibitor.                                                     
b No inhibition detected for catalyzed hydrolysis of 600 μM T6P in the presence of 2 mM inhibitor                                                                                                                           
cThis value was calculated, when the initial velocity is half of that without trehalose and Na3VO4                                                                                          
in the presence of  200 μM T6P. 
Table 3.1. Inhibition constant (Ki) of product, product analog or substrate analog 
measured for T6PPs from   various organisms.  
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3.4.2 Analysis of the T6PP Active Site  
           As described in Chapter 1, the phosphoryl group of the HADSF phosphatase 
substrate engages in coordination bond formation with the Mg2+cofactor, in hydrogen bond 
formation between the bridging oxygen and the (acid/base) Asp in its protonated state, in 
ion pair formation with the conserved Lys, and hydrogen bond formation with the 
conserved Thr/Ser. At the outset of my work the only known T6PP X-ray structure was that 
of  (Archeae) Thermoplasma acidophilum T6PP complexed with the Mg2+ cofactor, but 
recently our collaborators at Boston University (Karen Allen and co-workers) solved the 
structure of the (nematode) Brugia malayi T6PP complexed with Mg2+ [26] (see Figure 
3.1). Despite the addition of the N-terminal MIT domain to the Bm-T6PP, the (HADSF) 
phosphatase cap and core domains are quite similar in fold to those of Tm-T6PP.  (Figure 
3.1).  
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Ta-T6PP 
Bm-T6PP 
Bm-T6PP MIT 
domain hidden 
Figure 3.1 Comparison of the structures of T6PP from Thermoplasma 
acidophilum and Brugia malayi. The Bm-T6PP MIT domain 
(palegreen) and helical linker (forestgreen) are hidden in the structure 
to the right to highlight the similarity in structures of the respective 
HADSF phosphatases. 
  
40 
 
           Likewise, the phosphate binding sites are conserved as illustrated in Figure 3.2. The 
T6P phosphate group can be manually docked into position making favorable electrostatic 
contacts with the Mg2+, Thr, Lys and possibly the protonated Asp (acid/base).  
 
 
 
 
 
 
 
Figure 3.2 Cartoon representation Ta-T6PP (left panel) and Bm-T6PP (right panel) 
phosphate binding site generated in Pymol. The N-terminal MIT domain of the Bm-T6PP 
is not shown. Conserved elements of secondary structure are colored the same in the two 
structures, as are the phosphate binding residues whose side chains are shown in stick, and 
Mg2+ the cyan sphere. 
 
          How then to orient the trehalose? The trehalose moiety should fit snuggly within the 
substrate binding pocket formed by the interfaced cap and catalytic domains. The trehalose 
binding sites of the T6P phosphatases will be described in Chapter 4. Instead, in this chapter 
I focus on the route to identification of stable functional groups that bind to the phosphate 
binding site with high affinity. Ms. Christine Harvey, a graduate student in the Dr. Karen 
Allen lab at BU created T6P-docked structures (manual) for Ta-T6PP and (Bm-T6PP model 
looks the same) shown in Figure 3.3, highlighting the phosphate binding site. 
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Figure 3.3 Two representations of the X-ray structure of Ta-T6PP manually docked                                       
with T6P.  
 
3.4.3 Binding Affinities of Inert T6P Analogs: Evaluation of Phosphate Mimetic 
Groups. 
           Inert T6P analogs, 1-4 in which the C(6)phosphate is replaced with an approximate 
isosteric and isoelectronic functional group (resistant to hydrolytic cleavage), were 
prepared as outlined in Scheme 3.2 and described in Section 3.4.3  and tested as competitive 
inhibitors (vs. T6P) of the five T6P phosphatases. The steady-state competitive inhibition 
constants (Ki) determined for these substrate analog inhibitors are reported in Table 3.2. 
The plots of the kinetic data sets obtained for each inhibitor-T6PP pair are provided in the 
Appendix (page 187-201). 
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           The Ki values varied between inhibitors tested with the same T6PP and between T6P 
phosphatases tested with the same inhibitor. The results show that the sulfate group is 
superior overall in attracting favorable binding energy from the phosphate binding sites of 
T6P phosphatases. The results also show that subtle differences exist between the binding 
sites of the T6PP orthologs which impact inhibitor binding affinity. 
           The sulfate group, like the phosphate group, has tetrahedral geometry and like the 
phosphate group monoanion, it carries a single negative charge. The S-O-C(6) bridging 
oxygen atom of trehalose-6-sulfate (T6S) 1 can potentially serve as a hydrogen bond 
Inhibitor Bm-T6PP Mt-T6PP 
 
Sb-T6PP 
 
As-T6PP St-T6PP 
1 82 ± 7 μM 130 ± 20 μM 330 ± 40 μM 49 ± 5 μM 180 ± 10 μM 
2 490 ± 90 μM 500 ± 100 μM >2 mM 520 ± 80 μM >2 mM 
3 280 ± 50 μM 470 ± 90 μM >2 mM 490 ± 70 μM >2 mM 
4 No Inhibition No Inhibition No Inhibition No Inhibition No Inhibition 
Table 3.2. KIs (Competitive Inhibition Constant) values of trehalose with different 
warheads. 
No Inhibition: No inhibition observed at the presence of 10 mM inhibitor. 
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acceptor in analogy to the P-O-C(6) bridging oxygen atom of the T6P. The methylene group 
of the trehalose-6-methylene phosphate 2 inhibitor of coarse cannot engage in such 
interaction, thus accounting at least in part for lower binding affinity.  The substitution of 
the methylene hydrogen atom(s) for fluorine(s) is known to enhance the binding of the 
phosphonate inhibitor to tyrosine phosphate phosphatases. The trehalose-6- 
monofluoromethylene phosphonate 3 did indeed show improved binding affinity, yet still 
not enough and my attempts to prepare the trehalose-6- difluoromethylene phosphonate for 
testing were not successful.  
           Also during this work I have tested the ability of trehalose-6-methyleneboronate 4 
and its in situ derived hydroxide adduct to target the T6PP catalytic sites. Disappointingly, 
no inhibition was found.  
             In summary, T6S proved to be a moderately tight binding substrate analog inhibitor 
which we exploited as the “ligand of choice” in X-ray structure determinations, Structure-
Activity Relationship (SAR) analysis and Small Angle X-ray Scattering (SAXS) analysis.  
The SAR studies are reported in Chapter 4 whereas the SAXS studies are reported in this 
Chapter.  
 
3.4.3 Synthetic Routes to the T6P Analogs 1-4.  
          The synthetic routes utilized for preparation of 1-4, potential inhibitors of T6PP, are 
displayed in Scheme 3.2. The key intermediate employed in all of the pathways is the 
selectively protected and desymmetrized trehalose derivative 5, generated by using the 
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route described earlier by Berndt and his coworkers [28]. For example, 5 was transformed 
to trehalose-6-sulfate (1) by treatment with the pyridine sulfur trioxide complex to produce 
the benzyl-protected derivative 6, which was then subjected to hydrogenolysis to form 1. 
Similar methods, involving Swern oxidation of 5 to from aldehyde 7 followed by 
phosphono-olefination with methylene bis-phosphonate esters ((EtO)2OP)2CH2 and 
((EtO)2OP)2CHF, hydrogenation/hydrogenolysis, and phosphonate ester cleavage, were 
employed to produce the respective methylene- and fluoromethylene-phosphonate 
derivatives 2 and 3. Finally, boronate derivative 4, was prepared by using a sequence that 
began with Wittig olefination of aldehyde 7, iridium promoted hydroboration with of the 
resulting olefin 12 with pinacolborane, and hydrogenolysis/bronate hydrolysis. 
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3.4.4 Examination of Substrate (Analog) Induced Conformational Changes in T6P 
Phosphatases Using SAXS   
          As was described in Chapter 1, a catalytic cycle for a HADSF phosphatase involves 
a sequence of conformational changes in which the cap and core domains move relative to 
Scheme 3.2. Synthesis of reversible inhibitors. 
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one another in order to allow substrate to bind (open), catalysis to occur (closed) and 
products to disassociate (open). If the T6P binds to the T6PP in the open conformation, and 
additional binding energy is gained from the ligand in the closed conformation, the T6P 
acts to stabilize the enzyme in its catalytically active closed conformation. This is an 
example of substrate-induced fit. For the purpose of testing domain-scale conformational 
changes in the T6PP, the T6S inhibitor was used in place of T6P as titrant in SAXS solution-
based experiments.   
           The SAXS data collection and analysis were carried out by my labmate Dr. Tyrel 
Bryan. The maximum diameter was determined using the p(r) distribution and Rg values 
calculated for each protein with and without inhibitor T6S (Table 3.3). These values among 
the scattering and Kratky plots were used to investigate the predisposition to close the cap 
due to ligand binding. Because the T6PP proteins tested are C2 HAD proteins; theoretical 
scattering profiles representing the two conformers of a different C2 HAD protein were 
generated to investigate differences among the scattering profiles due to cap position 
relative to core domain (Figure 3.5). The two nematode T6PP proteins (A. suum, and B. 
malayi) displayed no evidence of change in structure due to binding T6S. In each case the 
proteins scattering curves look identical between the native protein and protein in the 
presence of inhibitor (Figure 3.6, 3.7). To further support no change in domain position, 
the dmax values and Rg values are the same between the two samples in both cases. This 
result can be accredited to the addition of the MIT-domain in the nematode structures 
compared to the smaller orthologs with a significantly smaller sequence addition to the N-
terminus  (M. tubercleosis T6PP) and the absence of “extra” N-terminal sequence in the 
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case the two T6PP orthologs from S. boydii and S. typhimurium.                
             As expected with a significantly smaller insert or without the additional domain, 
movement can be observed in the presence of T6S when compared to the native samples 
(Figure 3.9, 3.10). Although the change in dmax in each case are small, the change in Rg 
and the presence of distinct scattering patterns suggest closure of the cap.  
 
 
 
 
 
Protein Ligand Guinier 
Region Rg 
 P(r) 
Distribution  
Rg 
dmax (Ǻ)  
A. suum --- 
T6S 
30.60 ± 0.07 
30.50± 0.10 
31.5  
31.5  
107 
107 
DNM 
B. Malayi --- 
T6S 
27.20± 0.22 
27.28 ± 0.18 
26.6 
27.4 
89 
89 
DNM 
S. boydii --- 
T6S 
23.50 ± 0.28 
22.30 ± 0.13 
23.7 
22.9 
82 
80 
 
MOVE 
M. tubersleosis --- 
T6S 
32.51 ± 0.37 
34.62 ± 0.22 
32.9 
35.0 
114 
119 
 
MOVE 
S. 
typhimurium 
--- 
T6S 
23.96 ± 0.09 
23.18 ± 0.16 
24.8 
23.2 
84 
81 
 
MOVE 
Table 3.3 p(r) distribution and Rg values calculated for each protein with and without 
the inhibitor T6S 
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Bm-T6PP (PDB: 4OFZ)                        As-T6PP                                       Mt-T6PP 
 
Sb-T6PP                                                              St-T6PP 
 
Figure 3.4: Structures of T6PPs were generated by using Phyre 2 except 
Bm-T6PP. Blue: HAD cap domain, Magenta: HAD core domain, Green: 
connector, Orange: MIT-like domain. 
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In the case of Mt-T6PP, It has bigger dmax when binding with T6S inhibitor 
(increased by 5 Å). We hypothesize that its extra N-terminal “domain” was pushed away 
when inhibitor T6S induces the cap closure of Mt-T6PP (Scheme 3.3). 
 
 
 
 
 
 
Scheme 3.3.  Simulation of Mt-T6PP domain movement. Blue: HAD 
cap domain; Magenta: HAD core domain; Orange: N-terminal 
“domain”; Cyan: T6S. Left: Mt-T6PP without inhibitor T6S, cap open 
Right: Mt-T6PP with inhibitor T6S, cap closure. 
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Figure 3.5: (A) Superposition of  Bt4131 (PDB: 1YMQ, blue) and T. maritima phosphatase 
(PDB: 1NF2, red) to compare cap-closed and cap-open conformers. (B) CRYSOL generated 
scattering curves from the two PDB structures were generated to observe curve difference 
associated with cap movement (color scheme corresponds to crystal representation colors).  
Figure 3.6: Kratky plot of A. suum T6PP native (black) and with T6S (red). At low q the 
two scattering graphs are identical suggesting no change in the largest particle dimension.   
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Figure 3.7: Kratky plot of B. malayi T6PP native (black) and with T6S (red). 
The two scattering graphs are identical at low and mid q suggesting no change 
in dimensions in the presences of T6S.   
Figure 3.8: Kratky plot of M. tuberculeosis T6PP native (black) and with T6S 
(red) showing a difference in conformations for the apo and T6S bound Mt-
T6PP. 
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Figure 3.9: Kratky plot of S. boydii T6PP native (black) and with T6S (red). Similar 
to the theoretical changes due to cap-closure S.b T6PP show distinct low-q patterns 
due to binding the inhibitor T6S.  
Figure 3.10: Kratky plot of S. typhimurium T6PP native (black) and with T6S (red). 
S.t T6PP show distinct conformations (cap-closed / cap-open) w/wo the inhibitor 
T6S, respectively.  
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3.5 Material and Methods 
3.5.1 Inhibitor Synthesis 
General information: Except specified, all commercial solvents and reagents were 
purchased from Sigma-Aldrich and used without further purification. Analytical thin-layer 
chromatography (TLC) was performed on Sorbent Technologies silica gel plates with 
fluorescence F254 indicator and column chromatography was performed using the indicated 
solvent on Merck 60 silica gel (230-400 mesh). 1H (300 and 500 MHz), 13C NMR (75 MHz 
and 125 MHz), and 31P (121.5 MHz) NMR spectra were recorded on Bruker Avance 500 
and Bruker Avance III 300 spectrometers. 1H, 13C and 31P NMR data are reported as follows: 
for 1H NMR chemical shifts are reported in ppm relative to HDO and multiplicities are 
given as s = singlet, d = doublet, t = triplet, q = quartet, m =multiplet, coupling constant 
(J); 13C NMR chemical shifts are reported in ppm using NH4HCO3 as standard; for 31P 
NMR chemical shifts are reported in ppm using 50% aq H3PO4 as standard. 
Synthesis of 6-O-sulfonato-α,α-D-trehalose 
 
Scheme 1. Reagents and conditions. (a) SO3/C5H5N, C5H5N, 5 h (b) Pd(OH)2/C, 
MeOH/H2O, r.t. 24 h. 
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Compound 61 
 
To a solution of SO3/C5H5N complex (432 mg, 2.7 mmol) in freshly distilled pyridine 
(5mL), a solution of 5 2 (1.345g, 1.35 mmol) in freshly distilled pyridine (5 mL) was added. 
The mixture was stirred for 5 h at room temperature, then the reaction mixture was 
neutralized with Na2CO3(aq) (1 M, 10 mL) and concentrated under reduced pressure. The 
salts were triturated with anhydrous MeOH and filtered. The filtrate was concentrated in 
vacuo and the crude product was purified by silica gel column chromatography (30:1 
MeOH/EtOAc) affording 6 (1.35g, 93%) as a white powder. TLC (MeoH:EtOAc, 30:1, 
v/v): Rf=0.30; 1H NMR (MeOD): 3.50-3.58(3H, m), 3.62(1H, t, J=9.45 Hz), 4.00-4.07(2H, 
m), 4.09-4.12(2H, m), 4.14-4.18(2H, m), 4.34-4.37(1H, m), 4.42-4.45(2H, m), 4.61-
4.80(9H, m), 4.87-4.90(2H, m), 5.26-5.27(2H, m), 7.10-7.30(35H, m); 13C NMR (MeOD): 
68.19, 70.6,71.9, 72.8, 74.8, 75.0, 75.2, 76.4, 76.6, 77.2, 796, 80.0, 81.7, 81.8, 83.3, 83.4, 
94.9, 129.3, 129.4, 129.53, 129.59, 129.6, 129.7, 129.80, 129.88, 130.0, 130.1, 130.2, 130.3, 
140.1, 140.2, 140.4, 140.6, 140.7, 141.0; HRMS(ES) m/z: [M-Na]
－
calcd. for C61H63O14S
-
, 
1051.3939; found, 1051.4022. 
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Compound 11 
 
6 (0.96g, 0.89 mmol) was dissolved in MeOH/H2O (1:1, V/V, 40 mL) and to this was added 
20% Pd(OH)2/C (1.26g) and palladium was activated by repeat purge flush cycles with 
hydrogen. The mixture was stirred under 1 atm pressure at room temperature for 24 h. Then 
the mixture was filtered through a Celite pad, the filtrate was concentrated in vacuo and 
the crude product was purified by column chromatograph (1:4:4, water/isopropanol/ethyl 
acetate) to give the desired, fully deprotected sugar, as white powder (366 mg, 93%). TLC 
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.40; 1H NMR (D2O): 3.39-3.52(2H, 
m), 3.60-3.67(2H, m), 3.72-3.86(5H, m), 3.97-4.02(1H, m), 4.23-4.26(2H, m), 5.16- 
5.18(2H, m); 13C NMR (D2O): 60.3, 66.7, 69.1, 69.5 70.0, 70.68, 70.74, 72.0, 72.19, 72.25; 
HRMS(ES) m/z: [M－Na]－calcd. for C12H21O14S
－
,421.0652; found, 421.0648. 
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Synthesis of Trehalose-6-phosphonate 
 
Scheme 1. Reagents and conditions. (a) oxalyl chloride, DMSO, DCM, -60℃, TEA; r.t., 3 
h；(b) n-BuLi, THF, -78℃, 2 h. (c) H 2, Pd/C, EtOH, rt; (d) TMSBr, MeCN/C5H5N, r.t. 4 
h; H2O, overnight. 
Compound 7 3 
 
To a solution of oxalyl chloride (490 mg, 3.86 mmol) in freshly distilled DCM (10 ml) at -
60℃under argon, was added dimethyl sulfoxide (603 mg, 7.72 mmol) dropwise. After 
stirring for 30 min at -60℃, a solution of 5 (2.4g, 2.57 mmol) in 5ml freshly distilled DCM 
was added dropwise, the resulting mixture was sirred at -60℃for 1 h, then TEA (1.04 g, 
10.3 mmol) was added, and the mixture was allowed to reach to room temperature over a 
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period of 30 min, then stirred at room temperature for 3 h. The solvent was concentrated 
in vacuo and the crude product was purified by silica gel column chromatography (20:1 
DCM/MeOH) affording 7 (2.15g, 90%). TLC (DCM): Rf=0.20; 1H NMR (CDCl3): 3.41-
3.45(2H, m), 3.55-3.61(3H, m), 3.65(1H, dd, J1=3.5 Hz, J2=9.5 Hz), 3.75(1H, t, J= 9.65), 
4.07(1H, t, J=9.3 Hz), 4.14(1H, t, J=9.7 Hz), 4.20(1H, dd, J1=3.5 Hz, J2=9.8 Hz ), 4.44(1H, 
d, J=11.8 Hz), 4,52(1H, d, J=10.4 Hz), 4.59-4.63(2H, m), 4.71-4.78(4H, m), 4.86-4.97(4H, 
m), 5.05-5.08(2H, m), 5.20(1H, d, J=3.4 Hz), 5.28(1H, d, J=3.0 Hz), 7.26-7.45(35H, m), 
9.39(1H, s); 13C NMR (CDCl3): 61.0, 63.9, 64.0, 65.7, 66.2, 66.5, 67.6, 68.0, 68.1, 68.6, 
68.8, 70.6, 71.3, 71.7, 72.3, 74.5, 74.8, 87.4, 88.1, 120.4, 120.6, 120.6, 120.7, 120.8, 120.9, 
121.0, 121.1, 121.2, 121.3, 121.4, 121.4, 121.4, 121.5, 130.4, 130.8, 131.2, 131.3, 131.4, 
131.7, 190.7; HRMS(ES) m/z: [M+Na]+ calcd. for C61H62O11Na+, 993.4190; found, 
993.4256. 
Compound 8 
 
n-BuLi (371 μL, 2.5M in hexanes)was added to a suspension of tetraethyl 
methylenediphosphonate (294 mg, 1.02 mmol) in anhydrous THF(4 ml) at -78℃. The 
mixture was allowed to warm to -20℃ over a period of 1 h, then the mixture was cooled to 
-78℃, and a solution of the aldehyde 7 (600 mg, 0.619 mmol) in THF(2 ml) was added 
dropwise. After stirring for 30 min at -78℃, the reaction mixture was allowed to warm to 
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room temperature slowly, and kept stirring at room temperature overnight. Then saturated 
NH4Cl(aq) was added, the aqueous phase was extracted with Et2O, and the combined 
organic extracts were dried using anhydrous Na2SO4, the solvent was removed in vacuo, 
and the crude product was purified by silica gel column chromatography (20:1 
DCM/MeOH) affording 8 (2.15g, 90%). TLC (DCM): Rf=0.20; 1H NMR (CDCl3): 
1.32(6H, t, J=8.1Hz), 3.43(1H, dd, J1=3.4 Hz, J2=10.25 Hz), 3.55(1H, dd, J1=3.4 Hz, 
J2=10.25 Hz), 3.60-3.63(2H, m), 3.72(1H, t, J=9.6 Hz), 4.03-4.21(8H, m), 4.42-5.06(14H, 
m), 5.16(1H, d, J=3.35Hz), 5.29(1H, d, J=3.3Hz), 5.99-6.07(1H, m), 6.92-7.00(1H, m), 
7.27-7.43(35H, m); 13C NMR (CDCl3): 9.31, 9.35, 54.6, 61.1, 63.4, 63.6, 63.7, 65.8, 65.9, 
66.5, 68.1, 68.5, 68.6, 68.7, 70.7, 71.8, 72.3, 74.4, 74.8, 74.9, 86.8, 87.4, 110.1, 111.6,120.4, 
120.5, 120.6, 120.9, 121.0,121.2, 121.3,121.5, 130.6, 130.7,130.9, 131.0, 131.3, 131.6, 
131.8, 141.3; 31P NMR(CDCl3): 18.6;  HRMS(ES) m/z: [M+Na]+ calcd. for C66H73O13PNa+, 
1127.4687; found, 1127.4668. 
Compound 10 4 
 
A mixture of compound 8 (413.4 mg, 0.38 mmol), and Pd/C (10%) (161 mg, 0.16 mmol) 
in ethanol (5 mL) was stirred under H2 (1 atm) for 24 h. After completion, the catalyst was 
removed by filtration through Celite, and filtrate was concentrated in vacuo. The crude 
product was purified by silica gel column chromatography to give 10 (180 mg, 100%). 
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TLC (water/isopropanol/ethyl acetate, 1:4:20, v/v/v): Rf=0.20; 1H NMR (MeOD): 1.32(6H, 
t, J=7.1Hz), 1.56-1.66(1H, m), 1.77-1.87(1H, m), 1.96-2.06(1H, m), 2.09-2.16(1H, m), 
3.07(1H, t, J=9.4 Hz), 3.33(1H, t, J=9.2 Hz), 3.35(1H, dd, J1=2.5 Hz, J2=8.9 Hz ), 3.68(1H, 
dd, J1=4.9 Hz, J2=11.4 Hz ), 3.75(1H, t, J=9.4 Hz), 3.78-3.84(4H, m), 4.05-4.12(4H, m), 
5.05(1H, d, J=3.5 Hz), 5.08(1H, d, J=3.6 Hz); 13C NMR (MeOD): 17.5,17.6, 21.9, 26.6(d, 
JC,P=18.7 Hz ), 63.4, 64.1, 72.7, 73.0, 73.2, 4.0, 74.2, 74.7 75.4, 76.5, 96.0, 96.2; 31P 
NMR(D2O): 34.2; HRMS(ES) m/z: [M+Na]+ calcd. for C17H33O13PNa+, 499.1556; found, 
499.1544. 
Compound 2 5 
 
To a soluton of 10 (77 mg, 0.16 mmol) in anhydrous acetonitrile (2.5 ml) was added 
pyridine (25 μl) and bromotrimethylsilane(495 mg, 3.24 mmol) under N2. After stirring at 
room temperature for 4 h, the solvent and bromotrimethylsilane were removed in vacuo, 
then 3 ml of DI H2O was added and stirring was continued at room temperature overnight. 
The aqueous phase was washed with CH2Cl2, and the aqueous phase was lyophilized, the 
crude product was purified by silica gel column chromatography to give 2 (49 mg, 72%). 
TLC (water/isopropanol/ethyl acetate, 1:2:4, v/v/v): Rf=0.20; 1H NMR (D2O): 1.40-
1.62(2H, m), 1.70-1.87(2H, m), 3.04(1H, t, J=9.4 Hz), 3.22(1H, t, J=9.5 Hz), 3.38-3.45(2H, 
m), 3.47-3.66(6H, m), 4.90(1H, d, J=1.4 Hz), 4.91(1H, d, J=1.4 Hz); 13C NMR (D2O): 23.6, 
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24.4, 60.5, 69.6, 69.9, 70.9, 71.1, 71.3, 72.1, 72.4, 73.1, 93.0, 93.3; 31P NMR( D2O): 29.3; 
HRMS(ES) m/z: [M-H+]
－
calcd. for C13H25O13P, 419.0955; found, 419.0941. 
Synthesis of compound 3: 
 
Scheme 3. Reagents and conditions. (a) ((EtO)2PO)2CHF, n-BuLi, THF, -78℃, 2 h；r.t. 
overnight (b) H2, Pd(OH)2, 24 h. (c) TMSBr, MeCN/C5H5N, r.t. 4 h; H2O, overnight. 
Compound 9 6 
 
To a solution of ((EtO)2PO)2CHF (1.4 g, 1.4 mmol) in anhydrous THF (8 ml) at -78℃ was 
added a solution of n-butyl lithium (0.4 ml, 2.5 M in THF). The mixture was allowed to 
stir at -78℃for 1 h and then a solution of 7 (337 mg, 1.1 mmol) in anhydrous THF (2 ml) 
was added and the reaction mixture was stirring at -78℃for 1 h, then it was allowed to 
slowly warm to room temperature in a period of 1 h. The mixture was allowed to stir at 
room temperature overnight and the next day the reaction was quenched with aqueous 
ammonium chloride and then the aqueous layer was extracted with EtOAc, then the organic 
layer was extracted with brine, the organic layer was then dried with anhydrous sodium 
sulfate, filtered, and then the filtrate was concentrated in vacuo The crude product was 
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purified by silica gel column chromatography to give 9 (1.3 g, 71%). TLC (hexane/ethyl 
acetate, 1:1, v/v): Rf=0.3; 1H NMR (CDCl3): 1.20-1.27(6H, m), 3.37-3.71(7H, m), 3.97-
4.20(7H, m), 4.38-5.08(14H, m), 5.15(1H, d, J=3.5 Hz), 5.24(1H, d, J=3.5 Hz), 6.00-
6.19(1H, m), 7.28-7.40(35H, m); 13C NMR (CDCl3): 9.1, 56.2, 61.1, 63.5, 65.3, 66.4, 68.0, 
68.7, 70.6, 70.8, 72.3, 74.1, 74.6, 74.8, 86.9, 87.7, 120.3, 120.5, 120.6, 120.9, 121.3, 130.7, 
131.0, 131.1, 131.6, 131.9, 156.0; 31P NMR(CDCl3): 4.8 (d, JF,P=245 Hz); 
Compound 11 6 
 
To a solution of 9(1.14g, 1.02 mmol) in ethanol (15 ml)was added a catalytic amount of 
20% palladium hydroxide on carbon(432mg, 0.408 mmol) and 3 drops of acetic acid; the 
reaction was then subjected to a hydrogen atmosphere (1 atm) and was allowed to stir for 
24 h. Then the reaction mixture was filtered through a pad of Celite to remove all palladium 
using methanol as the eluent followed by removal of all solvent in vacuo. The crude product 
was purified by flash chromatography to give 11 (403 mg, 80%). TLC 
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.40; 1H NMR (D2O): 1.35-1.40(6H, 
m), 1.81-2.05(1H, m), 2.40-2.56(1H, m), 3.31(1H, t, J=9.4 Hz ), 3.45(1H, t, J=9.4 Hz), 
3.62(1H, dd, J1=3.8 Hz, J2=9.9 Hz), 3.69(1H, dd, J1=3.8 Hz, J2=9.9 Hz), 3.74-3.88(6H, m), 
4.00(1H, t, J=9.9 Hz), 4.23-4.34(4H, m), 5.15(1H, dd, J=3.8 Hz), 5.19(1H, dd, J=3.8 Hz) ; 
13C NMR (D2O): 15.6, 15.7, 31.5, 31.7, 60.5, 64.9(d, JC,P=27.8 Hz ), 65.1(d, JC,P=26.9 Hz ), 
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66.4, 66.6, 69.9, 70.9, 71.1, 72.1, 72.5, 72.6, 73.4, 93.1, 93.4; 31P NMR(D2O): 20.8 (d, 
JF,P=187.5 Hz). 
Compound 3  
 
To a soluton of 11 (57 mg, 0.116 mmol) in anhydrous acetonitrile (2 ml) was added pyridine 
(20 μl) and bromotrimethylsilane(353 mg, 2.3 mmol) under N2. After stirring at room 
temperature for 4 h, the solvent and bromotrimethylsilane were removed in vacuo, then 3 
ml of DI H2O was added and stirring was continued at room temperature overnight. The 
aqueous phase was washed with CH2Cl2, and the aqueous phase was lyophilized, the crude 
product was purified by flash chromatography to give 3 (40 mg, 78%). TLC 
(water/isopropanol/ethyl acetate, 1:1:1, v/v/v): Rf=0.40; 1H NMR (D2O): 1.72-1.96(1H, 
m), 2.26-2.41(1H, m), 3.30(1H, t, J=9.4 Hz ), 3.43(1H, t, J=9.3 Hz), 3.58-3.68(2H, m), 
3.72-3.86(5H, m), 3.96(1H, t, J=9.8 Hz), 4.62-4.67(1H, m), 5.15(1H, dd, J=3.9 Hz), 
5.17(1H, dd, J=4.0 Hz) ; 13C NMR (D2O): 32.69(d, J=82.4 Hz ), 60.5, 67.6(d, J=45.3 Hz), 
69.7, 70.9, 71.1, 71.2, 72.1, 72.5, 73.4, 93.0, 93.4. 31P NMR (D2O): 13.2 (d, JF,P=155.2 Hz). 
HRMS (ES) m/z: [M-H+]
－
calcd. for C13H24FO13P, 437.0860; found, 437.0861. 
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Synthesis of trehalose-6-boronate 
 
Scheme 4. Reagents and conditions. (a) Ph3PMeBr, n-BuLi, THF, -78℃; -78℃－ -20℃, 1 
h; -78℃－r.t., 40 min; r.t. overnight (b) Pinacoborane, [Ir(cod)Cl]2, dppm, CH2Cl2, 24 h. (c) 
H2, Pd/C, MeOH, 24 h. 
Compound 12  
 
n-BuLi (240 μL, 2.5 M in hexanes) was added to a suspension of methyltriphenylph- 
osphonium bromide (250 mg, 0.7 mmol) in THF(2 ml) at -78℃. The reaction mixture was 
slowly warm to -20℃over a period of 1 h, then it was cooled back to -78℃, and a solution 
of compound 7 (194 mg, 0.2 mmol) was added dropwise. After 40 min, the reaction mixture 
was allowed to warm to room temperature slowly, and kept stirring at room temperature 
overnight. Then saturated NH4Cl (aq) was added, the aqueous phase was extracted with 
Et2O, and the combined organic extracts were dried using anhydrous Na2SO4, the solvent 
was removed in vacuo, and the crude product was purified by silica gel column 
chromatography (5:1 hexane/ethyl acetate) affording 12 (124 mg, 64%). TLC 
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(hexane/ethyl acetate, 7:1): Rf=0.20;  1H NMR (CDCl3): 3.35(1H, t, J=9.6 Hz), 3.45(1H, 
dd, J1=2.6 Hz, J2=10.6 Hz), 3.58(1H, dd, J1=2.7 Hz, J2=10.6 Hz), 3.65-3.68(2H, m), 
3.76(1H, t, J=9.5 Hz), 4.11-4.18(2H, m),  4.25-5.12(16H, m), 5.28-5.37(4H, m), 7.32-
7.47(35H, m); 13C NMR (CDCl3): 61.2, 63.6, 64.8, 65.7, 65.8, 66.5, 68.0, 68.3, 68.6, 68.7, 
70.7, 72.1, 72.5, 74.4, 74.8, 75.6, 87.0, 87.4, 110.5, 120.4, 120.5, 120.7, 120.8, 120.9, 121.1, 
121.3, 121.4, 128.3, 130.8, 131.2, 131.2, 131.4, 131.8, 131.9; HRMS(ES) m/z: [M+Na]+ 
calcd. for C62H64O10Na+, 991.4397; found, 991.4424. 
Compound 13 7 
 
A round-bottom flask charged with [Ir(cod)Cl]2(7.3 mg, 1.5 mol%) and bis(dipheny- 
lphosphino) methane(8.4 mg, 3 mol%) was flushed with argon. CH2Cl2 (2.5 ml), 
pinacolborane (112 mg, 0.874 mmol), and 12 (707 mg, 0.728 mmol) were added 
successively at room temperature. The mixture was then stirred at room temperature for 24 
h. The reaction was quenched with methanol and water, the product was extracted with 
ether, and dried over MgSO4. The solvent was removed in vacuo, and the crude product 
was purified by silica gel column chromatography (10:1 to 5:1, Hexane/Ethyl acetate) 
affording 13 (531 mg, 67%). TLC (Hexane/Ethyl acetate, 6:1): Rf=0.30; 1H NMR (CDCl3): 
0.68-0.91(2H, m), 1.26(6H, s), 1.27(6H, s), 1.58-1.71(1H, m), 1.89-2.00(1H, m), 3.34(1H, 
  
65 
 
t, J=9.3 Hz), 3.44(1H, dd, J1=1.5 Hz, J2=10.4 Hz), 3.53-3.60(2H, m), 3.63-3.73(2H, m), 
4.02-4.16(3H, m), 4.18-4.23(2H, m), 4.41- 5.04(14H, m), 5.22(1H, d, J=3.5 Hz), 5.33(1H, 
d, J=3.5 Hz), 7.16-7.39(35H, m); 13C NMR (CDCl3): 24.9, 24.9, 25.8, 68.4, 70.6, 71.9, 
72.7, 73.0, 73.5, 75.0, 75.1, 75.6, 77.3, 79.2, 80.0, 81.6, 81.7, 81.8, 82.9, 92.9, 93.3,127.5, 
127.6, 127.7, 127.9, 128.0, 128.3, 138.0, 138.3, 138.4, 138.6, 138.7, 138.9, 139.0; 
HRMS(ES) m/z: [M+Na]+calcd.for C68H77BO12Na+, 1119.5406; found, 1119.5450; 
[M+K]+ calcd. for C68H77BO12K+, 1135.5145; found, 1135.5183. 
Compound 4 
 
A mixture of compound 13 (300 mg, 0.27 mmol), and Pd/C (10%) (116 mg, 0.11 mmol) in 
methanol (5 mL) was stirred under H2 (1 atm) for 24 h. After completion, the catalyst was 
removed by filtration through Celite, and filtrate was concentrated in vacuo. The crude 
product was purified by flash chromatography to give 4 (107 mg, 100%). TLC 
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.80; 1H NMR (D2O): 0.83-1.05(2H, 
m), 1.65-1.82(2H, m), 3.41-3.47(2H, m), 3.61-3.69(2H, m), 3.74- 3.78(6H, m), 5.15(1H, d, 
J=4.1 Hz), 5.17(1H, d, J=4.0 Hz); 13C NMR (CDCl3): 23.5, 24.5, 60.2, 69.3, 70.6, 70.7, 
70.9, 71.8, 71.9, 72.2, 75.3, 92.9, 93.0; HRMS(ES) m/z: [M+Na]+calcd.for C13H25BO12Na+, 
407.1337; found, 407.1344. 
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3.5.2 References for synthesis 
1. Vidal S., Garcia M., Montero J.L., Morere A. Synthesis and Biological Evaluation 
of New Mannose 6-Phosphate Analogues. Bioorganic & Medicinal Chemistry, 
2002, 10, 4051–4056. 
2. Berndt F., Sajadi M., Ernsting N. P., Mahrwald R., Covalent linkage of N-methyl-
6-oxyquinolinium betaine to trehalose. Carbohydrate Research, 2011, 346, 2960–
2964. 
3. Omura K., Swern D. Oxidation of alcohols by "activated" dimethyl sulfoxide. A 
preparative, steric and mechanistic study.  Tetrahedron, 1978, 34, 1651. 
4. Belakhov V., Dovgolevsky E., Rabkin E., Shulami S., Shoham Y., Baasov T. 
Synthesis and evaluation of a mechanism-based inhibitor of KDO8P synthase. 
Carbohydrate Research, 2004, 339, 385–392. 
5. Vidil C., Morère A., Garcia M., Barragan V., Hamdaoui B., Rochefort H., Montero 
J. L. Synthesis and Biological Activity of Phosphonate Analogs of Mannose 6-
Phosphate (M6P) Eur. J. Org. Chem., 1999, 2, 447-450. 
6. Cui P., McCalmont W. F., Tomsig J. F., Lynch K. R., Macdonald T. L. α- and β-
Substituted phosphonate analogs of LPA as autotaxin inhibitors Bioorg. Med. 
Chem., 2008, 16, 2212-2225. 
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7. Yamamoto Y., Fujikawa R., Umemoto T., Miyaura N. Iridium-catalyzed 
hydroboration of alkenes with pinacolborane Tetrahedron, 2004,  60, 10695–10700. 
3.5.3 SAXS measurements and data analysis  
           Synchrotron X-ray scattering data were collected at the SSRL 4-2 BioSAXS 
beamline (SLAC, Menlo Park CA). Data were collected with a MarCCD225 detector at 
wavelength of 1.3 Å, at a distance of 1.7 m at 10 ºC, which corresponds to a scattering 
vector range of 0.007 Å-1 < q < 0.55 Å-1, where q = 4πsinθ/λ; 2θ is the scattering angle. 
Samples were placed into a cooled 96-well plate (40 µL sample volume), sample injection 
was automated and data collection was done in a quartz capillary tube. For each sample 15 
exposure frames of 1 sec were collected for each sample and corresponding buffer. Frames 
were carefully inspected for aggregation and radiation damage induced by the X-ray source. 
Scattering profiles were generated either by automated buffer subtraction using beamline 
automated data processing software (SAXSpipe) or manually using beamline software 
SasTool.  
             For each protein sample (five different orthologs) scattering profiles were collected 
on at least four protein concentrations ranging between 0.5 - 10 mg/mL. To experimentally 
investigate cap closure, data were collected on each protein w/wo protein inhibitor T6S. 
Inhibitor concentration was dependent on calculated Ki constants for each protein, to 
ensure saturation T6S concentration were 10x Ki.  Scattering was tested and corrected (if 
necessary) for moderate intermolecular interaction. During each collection period both 
water and lysozyme (50 mM HEPES, 150 mM NaCl pH 7.0) scattering patterns were 
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collected for calibration of MW. For each sample the radius of gyration (Rg) was calculated 
using   Guinier approximation (Guinier and Fournet, 1955) and using GNOM (Svergun, 
1992), which provides the distant distribution function p(r).  The p(r) function displays a 
histogram or the distances within the particle, whereas dmax is represented as the maximum 
dimension of the particle. 
 
3.5.4 KI measurement 
            The steady-state competitive inhibition constant KI was determined for inhibitors 
by fitting the initial velocity data, measured as a function of trehalose 6-phosphate (0.5 Km 
to 5Km) [29] and inhibitor (0, KI, 2KI) concentration to the following using SigmaPlot 
Enzyme Kinetics Module: 
 
where vo is the initial velocity, vmax the maximum velocity, [S] the substrate concentration 
and Km the Michaelis-Menten constant calculated for trehalose 6-phosphate, [I] is the 
inhibitor concentration and KI is the inhibition constant. 
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3.5.5 EnzChek Phosphate Assay 
              T6PP-catalyzed T6P hydrolysis was monitored continuously by using the 
EnzChek Phosphate Assay kit. In this assay phosphate formation is coupled to the 
phosphorylase reaction of MESG catalyzed by purine nucleoside phosphorylase. 
(a)  
(b)  
  
Scheme 3.4. T6PP –coupled enzyme assay utilizing PNP; (a) T6PP-catalyzed hydrolysis 
of trehalose 6-phosphate; (b) Enzymatic conversion of MESG to ribose 1-phosphate and 
2-amino-6-mercapto-7-methylpurine by purine ribonucleoside phosphorylase(PNP). 
Conversion of MESG to 2-amino-6-mercapto-7-methylpurine shifts absorbance from 330 
to 360 nm, respectively. The accompanying change in the absorption maximum at 360 nm 
allows quantitation of inorganic phosphate (Pi) consumed in the reaction. 
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CHAPTER FOUR 
SYNTHESIS AND EVALUATION OF FIRST GENERATION 
TREHALOSE-6-PHOSPHATE PHOSPHATASE REVERSIBLE 
BIOMODULAR INHIBITORS 
4.1. Background 
              Carbohydrates play an important role in biological systems, including serving as 
precursors for building diverse polymers, storing short-term energy, providing structural 
building materials, serving as molecular "tags" to allow recognition of specific cells and 
molecules. Many diseases are associated with malfunctioning biochemical processes 
involving carbohydrates, and the ability to interfere in such processes by targeting the 
enzyme catalyst, is of great biomedical importance.  
              Trehalose, a natural alpha-linked disaccharide formed by an α,α-1,1-glucoside 
bond between two α-glucose units, is synthesized by a variety of bacteria, plants, fungi and 
invertebrates to support cell survival by functioning as a fuel, a metabolic regulator or a 
protectant against environmental stress. Five different trehalose biosynthetic pathways are 
known to exist (OtsA/B or TPS/TPP pathway, TS pathway, TreY/TreZ pathway, TreP 
patheay, TreT pathway) [1], one of which, the OtsA/B pathway is common among 
pathogenic bacteria and fungi as well as in parasitic nematodes. The OtsA/B pathway, 
which utilizes glucose and glucose-6-phosphate to generate trehalose-6-phosphate 
catalyzed by trehalose synthase, then hydrolyzed to trehalose by trehalose-6-phosphate 
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phosphatase (T6PP). Previously reported otsA and otsB gene knockout (or knockdown) 
experiments have shown that both pathway enzymes are essential for growth of M. 
tuberculosis in laboratory culture, and for its virulence in a mouse model [2]. The T6P 
synthase and phosphatase are also required for trehalose production in the filamentous 
fungus Fusarium graminearum, however only the T6PP proved to be indispensable for 
development and virulence [3]. RNAi gene silencing carried out in the nematode model 
system Caenohabditis elegans revealed that the T6PP is essential, however only when the 
T6P synthase-encoding gene is functional [4].  
          Based on these findings we concluded that trehalose-synthesizing pathogens are 
likely to be vulnerable to the action of small molecule inhibitors of their T6PPs. In Chapter 
Three trehalose-6-sulfate (T6S) was identified as an inert T6P analog having moderate 
binding affinity and the ability to induce cap-domain closure in the bacterial T6P 
phosphatases.  In the study described below, a structure-guided search for inhibitors of 
T6PPs from important target pathogens was carried out. The effort was aimed at 
uncovering a versatile T6PP inhibitor prototype that could be modified to target specific 
T6PPs of pathogens from various taxonomic groups. For this purpose, I selected several 
members of different structural families of potential T6PP inhibitors. These were designed 
and synthesized, and determination of binding affinities of these substances was carried 
out.  
In parallel, the residues forming the substrate binding region at the T6PP cap 
domain were compared and probed for contributions to substrate binding by kinetic 
analysis of residue-directed mutants. 
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4.3 Results and Discussion 
4.3.1. Substrate Recognition: Diversity in the T6PP Cap Domain Residue Usage and 
Function  
           Following the determination of the structure of the Bm-T6PP (with the Mg2+ 
cofactor bound), the residues which form the substrate-binding region of the cap domain 
could be identified. This work was carried out in collaboration with Dr. Karen Allen and 
co-workers at Boston University and Dr. Tilde Carlow and co-workers of New England 
BioLabs. My role was to measure the steady-state kcat and Km for wild-type and mutant 
Bm-T6PP-catalyzed hydrolysis of T6P and the Ki for T6S inhibition.  
The conserved fold of the Ta-T6PP and Bm-T6PP structures provided more 
confidence in the threading models that could be generated from the T6PP ortholog 
sequences. Of the bacterial T6PP orthologs, Mt-T6PP proved to be the only one that is 
sufficiently robust to withstand amino acid replacement. Therefore, the SAR analysis 
carried out on Bm-T6PP was also carried out on Mt-T6PP. This work was carried out in 
collaboration with my labmate Dr. Tyrel Byran, who helped generate the mutant genes and 
gene products.  
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Figure 4.1 Putative substrate interacting residues in B. malayi T6PP analyzed by 
mutagenesis and kinetics. The residues targeted for replacement are shown in stick. 
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Figure 4.2 Putative substrate interacting residues in M. tuberculosis T6PP 
analyzed by mutagenesis and kinetics. The residues targeted for replacement are 
shown in stick. 
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Note: The residues in Bm-T6PP and Mt-T6PP are at the same position base on sequence alignment if they 
are in the same row. 
M. tuberculosis T6PP B. malayi T6PP 
Construct 
kcat 
(s-1) 
Km 
(μM) 
kcat/Km 
(M-1s-1) 
KI trehalose- 
6-sulfate(μM) 
 
Construct 
kcat 
(s-1) 
Km 
(μM) 
kcat/Km 
(M-1s-1) 
KI trehalose- 
6-sulfate(μM) 
wild type 10±1 540±110 1.9×104 130±20 wild type 24 ± 2 360 ± 60 6.9 x 104 82 ± 7 
     59 28 ± 1 260 ± 20 1.1 x 105 - 
Catalytic Asp residues   Catalytic Asp residues 
D147A NAa — — — D213A NAa - - - 
     D215A ~0.0004 - - - 
Catalytic domain residues Catalytic domain residues 
F148A 0.28±0.02 2200±400 1.3×102 360±70      
     Y221A 1.0 ± 0.05 330 ± 50 3.0 x 103 1,300 ± 100 
E157A 25±0.6 230±20 1.1×105 71±6      
     Y225A 5.5 ± 0.1 150 ± 10 3.6 x 104 400 ± 40 
R187K 0.11±0.01 3800±400 29 >4 mMb      
     N228A 18 ± 0.8 40 ± 8 4.5 x 105 16 ± 2 
     W280A 19 ± 2 150 ± 30 1.2 x 105 270 ± 50 
Cap residues    Cap residues 
E251A 0.99±0.06 1500±200 6.4×102 >4 mMb Q332A 0.22 ± 0.001 200 ± 40 5.5 x 102 1,000 ± 200 
     R337A 0.28 ± 0.03 400 ± 100 1.5 x 103 700 ± 100 
K253A 0.098±0.002 6800±300 14 >4 mMb K334A 0.06 ± 0.007 500 ± 120 1.1 x 102 150 ± 20 
H260A 0.28±0.03 1100±300 2.5×102 780±170      
     S329A 4 ± 0.2 250 ± 50 1.5 x 104 240 ± 30 
R262A 0.13±0.01 2100±300 63 2400±500      
     E384A 2.9 ± 0.2 100 ± 20 3.0 x 104 200 ±30 
N263A 23±0.7 890±70 2.6×104 320±40      
     E386A 2.3 ± 0.1 82 ± 15 2.8 x 104 150 ± 20 
T288A 11±0.6 1400±200 8.2×103 1700±200      
     T339A 15.3 ± 1.0 200 ± 40 7.7 x 104 35 ± 5 
R291A 0.39±0.07 2900±900 1.3×102 >4 mMb      
     D336A 0.094 ± 0.004 46 ± 6 2.0 x 102 33 ± 5 
E292A 15±0.5 540±60 2.7×104 380±50      
E295A 0.16±0.01 1500±200 1.1×102 190±20      
R297A 3±0.2 730±90 4.1×103 460±40 D378A 10.6 ± 0.6 270 ± 30 3.9 x 104 320 ± 30 
Table 4.1. Steady-state kinetic constants and dissociation constants for inhibitors for 
wild-type and variant M. tuberculosis or B. malayi T6PP-catalyzed hydrolysis of 
trehalose 6-phosphate. 
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  The structure of the Bm-T6PP and threading model of the Mt-T6PP are shown in 
Figures 4.1 and 4.2, respectively. In each figure the residues identified for alanine 
replacement by mutagenesis are highlighted. The change in steady-state kcat value observed 
for the mutant reflects the impact that the alanine substitution has on the efficiency that 
bound T6P is converted to product and released. Nonproductive binding (orientation of the 
reaction center is not optimized for catalysis) and/or disruption of the cap closure over the 
catalytic site and/or alteration of the electrostatic environment of the catalytic site can result 
in reduction in the kcat value compared to that of the wild-type T6PP. The kcat/Km value 
reflects substrate binding and catalysis. If the magnitude of reduction in kcat value and 
kcat/Km value is the same then it follows that the T6P binding affinity has been unaltered. 
On the other hand, if the kcat/Km value is decreased x-fold over the decrease observed in 
the kcat value, then it follows that the substrate binding affinity is decreased x-fold. An 
independent measure of the change in substrate binding affinity upon Ala mutagenesis is 
the change in the inhibition constant for the inert substrate analog trehalose-6-sulfate (T6S). 
The kcat and kcat/Km values for wild-type and mutant and Bm-T6PP and Mt-T6PP are listed 
in Table 4.1 along with the competitive inhibition constants (Ki) measured for T6S vs T6P.  
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    Figure 4.3. Alignment of Mycobacterium T6PP sequences 
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             Figure 4.4 An alignment of nematode T6PP sequences. 
 
          As expected, replacement of the catalytic Asp147 resulted in the loss of all detectable 
activity (Table 4.1). The replacements of Phe148, Arg187, Glu251, Lys253, Arg262, 
Thr288, Arg291, Glu295 resulted in a dramatic change in Km for T6P suggesting a role in 
substrate binding. Mutations in Phe148, Arg187, Glu251, Lys253, His260, Arg262, Arg291, 
E295 resulted in large decreases in kcat (36-, 91-, 10-, 100-, 36-, 77-, 26-, 77-fold, 
respectively) suggesting a role in catalysis. Each of these residues except for Phe148 are 
found in the cap domain (Figure 4.2) and may interact with the sugar moiety in order to 
orient the substrate for catalysis.  
            We also used inhibitor binding studies to test if any of the protein variants differed 
in their affinity for substrate. To assess substrate affinity, the substrate analogue trehalose 
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6-sulfate was used to measure KI for all of the T6PP variants (Table 4.1). Trehalose 6-
sulfate was shown by steady-state inhibition kinetics to be a competitive inhibitor of wild 
type T6PP with a KI of 130 μM against trehalose 6-phosphate as substrate. The variants 
except E295 that have dramatic increased Km showed dramatic increases in KI for trehalose 
6-sulfate: Phe148, Arg187, Glu251, Lys253, Arg262, Thr288, Arg291 (Table 4.1, Figure 
4.2). From these experiments, Phe148, Arg187, Glu251, Lys253, Arg262, Thr288, Arg291 
are likely to be involved in binding trehalose 6-phosphate, while E295 and His260 may 
play other roles in catalysis. These roles may include desolvation, steric restraint of the 
substrate for catalysis, or the positioning of other residues required for enzyme activity.  
In order to design and synthesize more drug like inhibitors we need to learn from 
the nature. Base on previous works,  carbohydrates binding to proteins is often 
accompanied by stacking interaction with aromatic residue [8-10]  Our previous work also 
suggests that mutating the aromatic residues in the sugar binding sites of  B. malayi T6PP 
result in low binding affinity (16 fold decreased) with T6S (trehalose-6 sulfate)  inhibitor 
[11]. These observations suggest that inhibitors which possess variously substituted 
hydrophobic aryl and/or alkyl groups attached to the 1, 2, 3 and 4 positions of the glucose-
6-sulfate backbone might display enhanced binding to the T6PPs. This reasoning led to the 
selection of the carbohydrate analogs displayed in Scheme 1 as members of the library that 
was prepared and screened in this effort. 
  
85 
 
 
In the study described below, a structure-guided search for inhibitors of T6PPs from 
important target pathogens was carried out. The effort was aimed at uncovering a versatile 
T6PP inhibitor prototype that could be modified to target specific T6PPs of pathogens from 
various taxonomic groups. For this purpose, selected several members of different 
structural families of potential T6PP inhibitors were designed and synthesized. A 
determination of binding affinities of these substances was carried out.  
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4.3.2 Synthesis 
 
Scheme 4.1.  
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Inhibitor Preparation. Phenyl α-D-glucopyranoside (1) and phenyl -D-
glucopyranoside (2a) are commercially available substances and glucose derivatives 2b 
[12], 2c [13], 2d [14] and 4 [15], and glucose-6-sulfate 5a [16] were synthesized by using 
the referenced procedures. The routes utilized for preparation of the other members of the 
T6PP inhibitor library, displayed in Schemes 2-10 below and described completely in the 
Experimental, begin with either commercially available or previously synthesized starting 
materials. Each substance was shown to be >95% pure by using NMR spectroscopy and 
HPLC analysis. 
 
Scheme 4.2.  
 
Scheme 4.3.  
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Scheme 4.4.  
 
Scheme 4.5. 
 
 
Scheme 4.6.  
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Scheme 4.7.  
 
Scheme 4.8.  
 
 
 
 
Scheme 4.9.  
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Scheme 4.10.  
 
 
4.3.3 Catalytic hydrolysis of Compound 7 by T6PP 
                The catalytic activities of the T6PPs toward p-nitrophenyl phosphate (PNPP), a 
common substrate of phosphatases, glucose-6-phosphate and phenyl β-D-glucose-6-
phosphate (7) were determined. In this series, only 7 was found to serve as a substrate for 
these phosphatases with kcat values of 1.4×10-2, 0.96×10-2, 0.71×10-2, 0.71×10-2 s-1 and or 
the respective Bm-T6PP, Mt-T6PP, Sb-T6PP, As-T6PP and St-T6PP. These values compare 
to the kcat values observed for hydrolysis of T6P catalyzed by the T6PPs, which fall in the 
range of 4-24 s-1, which shows that the phenyl glucopyranoside base compounds can bind 
to T6PPs, where the binding affinity comes from the introducing phenyl group. 
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Table 4.2 Steady-state kinetic constants for T6PPs-catalyzed hydrolysis of compound 7.   
T6PP Source kcat (s-1) 
Brugia malayi 1.4×10-2 
Mycobacterium tuberculosis 0.96×10-2 
Shigella boydii 0.71×10-2 
Ascaris suum 0.71×10-2 
Samonella typhimurium 0.41×10-2 
 
4.3.4 Inhibition measurement using High Throughput Screening 
    An initial evaluation of the inhibitory activities of a large number of the 
substances shown in Scheme 1 (see Table 1) toward T6PP catalyzed hydrolysis reactions 
of T6P was carried out by using a high throughput screen. For this purpose, the initial 
velocities were determined for reactions of T6P promoted by Bm-T6PP, Mt-T6PP, Sb-T6PP, 
As-T6PP and St-T6P in the presence of 1mM inhibitor (V’) and absence of inhibitor (Vo). 
Each well of a 96-well plate contained 50 μL of a solution containing 5-25 nM freshly 
purified T6PP, T6P (400 μM for Mt-T6PP, Sb-T6PP and StT6PP, 200 μM for Bm-T6PP 
and As-T6PP) and 1 mM inhibitor and buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 5 mM 
MgCl2, and 5% glycerol for Mt-T6PP; 50 mM HEPES pH 7.5, 25 mM NaCl, 2 mM MgCl2, 
and 5% glycerol for Sb-T6PP; 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1mM DTT 
and 5% glycerol for As-T6PP; 25 mM Tris pH 7.5, 25 mM NaCl, 2 mM MgCl2, 1 mM 
DTT for Bm-T6PP; and 50 mM HEPES pH 8.0, 25 mM NaCl, 5 mM MgCl2, and 5% 
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glycerol for St-T6PP. The plate was incubated at room temperature for 5 min at which time 
5 μL of each solution in each well was transferred to individual wells of another 96 well 
plate, each containing containing 45 μL the appropriate buffer. After adding 100 μL BioMol 
Green (Enzo Life Sciences) to each well and incubating for 30 min absorbance of each well 
at 625 nm were measured using a SpectraMax i3 Multi-Mode Microplate Detection 
Platform. The initial velocity ratios (V’/Vo) obtained by using this procedure are given in 
Table 4.3. 
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 Compound Bm-T6PP Mt-T6PP Sb-T6PP As-T6PP St-T6PP 
T6S 0.13 0.43 0.22 0.21 0.01 
Trehalose 0.98 0.83 1.01 0.97 0.88 
1 0.96 0.88 0.86 0.97 1 
2a 1.12 0.81 0.9 1 0.87 
2b 1 0.88 0.92 0.97 0.77 
2c 0.99 1.04 0.92 0.81 1.09 
2d 0.85 0.95 1 0.96 0.9 
3 0.59 0.96 0.8 0.98 0.85 
4 1.05 1.17 0.85 0.96 1 
5a 0.93 0.97 0.75 0.94 0.84 
5b 0.8 0.91 1 1.07 1.04 
5c 0.42 1.17 0.76 0.71 0.64 
5d 0.53 1.01 1 0.96 0.95 
5e 0.67 1.16 0.84 1.04 0.99 
5f 0.68 1.11 0.95 0.99 0.97 
6a 0.07 0.83 0.74 0.86 0.47 
6b 0.72 0.83 0.79 0.9 0.54 
6c 0.85 0.85 0.85 0.91 0.8 
6d 0.98 0.98 0.9 0.76 0.97 
7 0.79 0.94 0.94 0.98 0.77 
8a 0.52 0.94 0.76 0.92 0.81 
8b 0.58 0.58 0.84 0.9 0.85 
8c 0.55 1.09 1 0.94 0.96 
8d 0.74 0.8 0.92 0.88 0.89 
8e 0.64 1.27 0.77 0.83 0.68 
8f 0.63 1 1.03 0.74 0.94 
8g 0.87 0.94 0.88 0.9 0.85 
8h 0.79 1.17 0.96 0.99 0.85 
8i 1.05 0.67 0.81 0.78 0.95 
8j 1 0.87 1.06 0.81 0.87 
8k 0.89 0.89 0.85 0.9 0.73 
8l 0.69 0.69 0.46 0.63 0.77 
8m 0.68 0.85 0.67 0.76 0.79 
8p 0.07 0.42 0.04 0.02 0.01 
Table 4.3. Inhibition measurement using HTS 
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4.3.5 Competitive inhibition test 
             We also tested the inhibition of 8p on Sb-T6PP using EnzChek Phosphate Assay, 
which turns out to be competitive inhibitor. The initial velocities (v) for T6PPs catalyzed 
hydrolysis of trehalose 6-phosphate (0.5 Km- 3 Km) at presence of different concentrations 
of inhibitor (0, 0.5 Ki, 1.7 Ki, 2.5 ki, 3.3Ki) were measured at 25 °C using EnzCheck 
Phosphate Assay Kit (Invitrogen). The assay solutions that contained 1 mM MgCl2, 0.1 
mM sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG in 50 
mM Tris-HCl (pH 7.5). Absorbance changes were monitored at 360 nm (Δε = 9.8 
mM−1cm−1). 
Inhibitor: 8p, Enzyme: Sb-T6PP, Units: V: μM/s, S (T6P): μM 
 
  
  
 
Figure 4.5. 8p’s competitive inhibition on Sb-T6PP 
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4.3.6 Inhibition Constants 
Analysis of the screening results given in Table 1 showed that the glucaose-6-
sulfate derivatives 5c, 6a, 8a, 8b and 8i, each of which contain a hydrophobic group at the 
glycosidic position, display high T6PP inhibitory activities. This finding prompted a more 
detailed investigation of the inhibition constants of these substances. For this purpose, 
initial velocities (v) of the T6PP catalyzed hydrolysis reactions of T6P (0.5-3 Km) at 25 °C 
in the presence of different concentrations (0, Ki, 2Ki) of inhibitors 5c, 6a, 8a, 8b and 8i 
were determined using the EnzCheck Phosphate Assay Kit (Invitrogen). In addition to 
enzyme (T6PP), substrate (T6P) and inhibitor, the assay solutions contain 1 mM MgCl2, 
0.1 mM sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG 
in 50 mM Tris-HCl (pH 7.5). Absorbance changes were monitored at 360 nm (Δε = 9.8 
mM−1cm−1). Initial velocity data, measured as a function of trehalose 6-phosphate (0.5 to 
5Km) and inhibitor (0, KI, 2KI) concentrations, were fitted using the SigmaPlot Enzyme 
Kinetics Module to the following equation: 
 
where vo is the initial velocity, vmax the maximum velocity, [S] the substrate concentration 
and Km the Michaelis Menten constant calculated for trehalose 6-phosphate, [I] is the 
inhibitor concentration and KI is the inhibition constant. This treatment gave the Ki values 
listed in Table 4.4. 
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   Because the initial screening results (Table 4.3) demonstrated that 4-octlyphenyl 
-D-glucose-6-sulfate (8p) is the most active inhibitor of the five T6PPs, the closely related 
4-butyl- and 4-hexylphenyl and 4-octylpheny- and -hexylphenyl and 4-octylphenyD 
glucopyranoside-6-sulfate, 8n, 8o, 9a and 9b, respectively, were prepared and subjected to 
kinetic studies. It is clear from viewing the results in Table 3 that the strategy of 
incorporating both a negatively charged 6-sulfate and hydrophobic glycosidic group into 
the glucose skeleton does lead to the design of highly active inhibitors of the T6PPs. 
Moreover, a comparison of the activities of 8p and 9a shows the spacial disposition of the 
glycosidic alkylphenyl group plays an important role in biding to the phosphatases.  
Table 4.4. Competitive inhibition constants 
 
Inhibitor B. malayi M. tuberculosis S. boydii A. suum S. typhimurium  
5c 320±30                                                                    1800±260 
6a 160±20 - - - - 
8a 830±100 - - - - 
8b - 1600±270 - - - 
8i - 1700±350 - - - 
8n NI NI  >400 
f NI >400 h 
8o >200 a >400 
b 140±20 >200 g >400 i 
8p 61±10 >300 
c 13±2 180±20* 120±20 
9a 5.3±0.6 >300 
d 21±3 84±10* 56±6 
9b 82±10* >400 
e 78±9 350±30* 280±30 
 
 
 
 
 
*: Slow-onset inhibition observed, preincubation time: 2 minutes at room temperature; 
- : Did not test; 
NI: No inhibition observed when T6P = Km in the presence of 400 μM inhibitor; 
a : 19% inhibition observed in the presence of 200 μM 8o; 
b : 2% inhibition observed in the presence of 400 μM 8o; 
c : 16% inhibition observed in the presence of 300 μM 8p; 
d : 36% inhibition observed in the presence of 300 μM 9a; 
e : 4% inhibition observed in the presence of 400 μM 9b; 
f : 4% inhibition observed in the presence of 400 μM 8n; 
g : 15% inhibition observed in the presence of 200 μM 8o; 
h : 5% inhibition observed in the presence of 400 μM 8n; 
i : 4% inhibition observed in the presence of 400 μM 8o; 
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Interestingly, the inhibitors 8p, 9a, 9b showed slow-onset inhibition on As-T6PP, 
and this phenomenon was also observed in the inhibition of Bm-T6PP by 9b. The N-
terminal MIT domain of As- and Bm-T6PP lock the enzyme conformation, such that the 
binding site is relatively fixed. Besides, the high flexibility of the aliphatic chain of the 
inhibitors result in several conformational forms, one of which makes up only a small 
proportion of all forms and interacts with the enzyme at the relatively fixed binding site.  
4.3.7 SAXS studies 
            We also used Small Angle X-ray Scattering “SAXS” techniques to examine the 
inhibitor 9a’s effect on T6PPs domain movement. Surprisingly, it makes the cap domain 
more open than its apo form (Table 4.5, 4.6). We hypothesize that the inhibitor may simply 
be sitting in the wedge formed in the open cap-core domain conformation.  
 
 
 
 
 
 
 
 
 
Table 4.5. Calculated SAXS values for S. boydii T6PP w/wo ligands. Rg were calculated using 
Giunier region and with Parod's, dmax was calculated using P(r) Distribution. All values were 
calculated using PRIMUS. 
Protein  Ligand  Rg (Guinier) Rg  (P(r) 
distribution) 
dmax (nm) 
S. boydii  --- 23.50 ± 0.28 23.7 82 
 T6S 22.30 ± 0.13 22.9 80 
 9A 24.78 ± 0.27 24.1 84 
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 Figure 4.6: Guinier region for S. boydii T6PP w/wo ligand. T6PP with T6S, T6PP with 9a, and 
T6PP (from top to bottom, respectively).  
Figure 4.7: Scattering plot overlay of S. boydii T6PP w/wo ligand. (green) T6PP with T6S, 
(blue) T6PP with 9a, and (black) T6PP. Modifications within low and mid q suggest 
conformation changes as an effect of ligand binding. 
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Figure 4.8: Kratky plot overlay of S. boydii T6PP w/wo ligand. (green) T6PP with T6S, (blue) 
T6PP with 9a, and (black) T6PP. From Kratky plots the resulting proteins are clearly folded in 
solution. 
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Protein  Ligand  Rg (Guinier) Rg  (P(r) 
distribution) 
dmax (nm) 
S. typhimurium --- 23.96 ± 0.09 24.8 84 
 T6S 23.18 ± 0.16 23.2 81 
 9A 25.16 ± 0.18 25.8 86 
 
Table 4.6: Calculated SAXS values for S. typhimurium T6PP w/wo ligands. Rg were calculated 
using Giunier region and with Parod's, dmax was calculated using P(r) Distribution. All values 
were calculated using PRIMUS. 
Figure 4.9: Guinier region for S. typhimurium T6PP w/wo ligand. T6PP with T6S, T6PP with 
9A, and T6PP (from top to bottom, respectively).  
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Figure 4.10: Scattering plot overlay of S. typhimurium T6PP w/wo ligand. (Green) T6PP 
with T6S, (blue) T6PP with 9A, and (black) T6PP. Modifications within low and mid q 
suggest conformation changes as an effect of ligand binding. 
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             Tables (Table 4.5 and 4.6) and graphs (Graphs 4.6-4.11) represent each protein 
(S.boydii and S.typhimurium) with two ligands (T6S, and 9A) and without ligand.  T6S 
represents the protein in the closed conformation whereas the native used as a control to 
investigate the conformation change upon binding ligand. Each protein was tested with 9A 
to investigate changes in conformation upon binding. Results suggest that when binding 
9A observable changes in conformation are present although the change in Rg and dmax 
suggest a larger increase in size compared to both native and T6S liganded. The results 
conclude that substrate binds to the proteins and because changes in Rg are in the direction 
of cap movement suggest that binding occurs in active site. The explanation for the increase 
in size (Rg, and dmax) can be explained through interference in favorable interactions 
Figure 4.11: Kratky plot overlay of S. typhimurium T6PP w/wo ligand. (Green) T6PP with 
T6S, (blue) T6PP with 9A, and (black) T6PP. From Kratky plots the resulting proteins are 
clearly folded in solution. 
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between substrate/protein (T6S-complex) or domain/domain (native complex). Although 
the substrate binds and interferes with catalysis; the extended conformation can be 
expressed by an accommodation of substrate in active site.  
 
4.3.8 Inhibition Specificity 
           In order to test 9a’ inhibition specificity, we test its inhibition on several sugar 
phosphatases. Yibv [17], which is from E. coli, can hydrolyze a wide scope of sugar 
phosphates, substrates like glucose-6-phosphate, imido-di-phosphate, fructose-1-phophate, 
ribose-5-phosphate, acetyl-phosphate, glycerol-1-phospahte, glycerol-2-phospahte. 
BT1713 [18], which is from Bacteroides thetaiotaomicron, is a 2-keto-3-deoxy-D-glycero-
D-galacto-9-phosphonononic acid (KDN-9-P) phosphatase in the biosynthetic pathway of 
the 9-carbon alpha-keto acid, 2-keto-3-deoxy-D-glycero-D-galactonononic acid (KDN). It 
can also hydrolyze 2-keto-3-deoxy-8-phospho-d-manno-octulosonicacid (KDO-8-P), N-
acetylneuraminate-9-phosphate (Neu5Ac-9-P), pNPP, glucose-6-phosphate, PEP, tyrosine 
phosphate, and gluconate-6-phosphate. The other enzyme that we tested is GmhB (EFI 
501036) [19], from Pseudomonas putida KT2440, is a D,D-heptose 1,7-bisphosphate 
phosphatase, it can convert the D-glycero-beta-D-manno-heptose 1,7-bisphosphate 
intermediate into D-glycero-beta-D-manno-heptose 1-phosphate. D-Fructose-1,6-
bisphosphate is also its substrate. I didn’t observe any inhibition in the presence of 1/3 
Km’s substrate and 200 μM of 9a (Table 4.7, Figure 4.12).  
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Enzyme Substrate Km 
(μM) 
[S] 
(μM) 
V0  ([9a] = 0) 
(μM/s) 
V0  ([9a] = 200  μM) 
(μM/s) 
Yibv Ribose-5-phosphate 2400 800 0.0589/0.0582 0.0613/0.0596 
BT1713 KDN9P 100 33 0.0730/0.0827 0.0740/0.0829/0.0794 
GmhB  
(EFI 501036) 
D-glycero-beta-D-manno-
heptose 1,7-bisphosphate 
17.6 6 0.0944/0.1178 0.0965/0.1164 
GmhB  
(EFI 501036) 
D-Fructose-1,6-
bisphosphate 
151 53.3 0.0166/0.0169 0.0173/0.0177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7 9a’s inhibition specificity test on sugar phosphate phosphatases. 
Figure 4.12. Reaction curves of sugar phosphatases catalyzed hydrolysis in the presence or 
absence of 9a. 
 
 
BT1713 
Substrate: KDN9P 
[9a] = 0 
[9a] =200 μM 
Yibv 
Substrate: Ribose-5-phosphate [9a] = 0 
[9a] =200 μM 
GmhB (EFI 501036) 
Substrate = D-Fructose-1,6-bisphosphate 
[9a] = 0 
[9a] =200 μM 
GmhB (EFI 501036) 
Substrate: D-glycero-beta-D-manno-heptose 1,7-bisphosphate 
[9a] = 0 
[9a] =200 μM 
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4.3.9 Molecular Modeling 
               
            To better understand the binding mode between T6PP and the newly identified 
inhibitors, molecular docking studies were performed on compound 9a with Bm-T6PP by 
using AutoDock Vina, 9a is the most potent (5.3 μM) within this series while displaying 
significant activity against Bm-T6PP. Computations were aimed at elucidating the 
structural requisites responsible for binding at Bm-T6PP active sites.   
          Bm-T6PP (PDB ID: 4OFZ) is in complex withe Mg2+ ions required for catalytic 
activity. According to docking results (Figure 4.13), 9a sits in the interface of cap and 
catalytic domains. Where the sulfate warhead sits in the phosphate binding site, and the 4-
n-Octyl phenyl hydrophobic group is sitting in the hydrophobic pocket of Bm-T6PP. This 
hydrophobic region widely exist in carbohydrate processing enzymes. Although the sugar 
molecules may be considered to be polar, the carbon atom at the five epimeric position of 
Figure 4.13. Docking model generated pose of 9a bound to Bm-T6PP. 
Hydrophobicity surface: dodger blue for the most hydrophilic, to white, to 
orange red for the most hydrophobic. 
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the ring and at the adjacent exocyclic position form a contiguous hydrophobic region. 
Where nearby this region of sugar processing enzyme form a hydrophobic surface in order 
to stabilize the substrate binding [20].  
           As shown in Figure 4.14, the cofactor Mg2+ is coordinated by the carboxylate group 
of the loop 1 Asp (213) nucleophile, the backbone amine carbonyl of the loop 1 Asp 
acid/base and by the carboxylate of the Asp (424) on loop 4, and sulfate oxygen anion of 
the inhibitor 9a. The Mg2+ functions to prevent charge repulsion between the sulfate  
 
 
 
       
Warhead and the Asp 213, Asp 424. Besides coordination of the metal center, additional 
key interactions are established by our reference compound within the active site.  The 
sulfate warhead forms electrostatic interaction with Lys398 and hydrogen binding with 
Trp280 and Thr425. More importantly, the 4-n-octyl-phenyl group of 9a establishes 
Figure 4.14. . Binding mode of compound 9a (green) within the Bm-T6PP 
active site. 
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hydrophobic contacts with the hydrophobic side chains of L383, V345, Y221 and is 
involved in a parallel-displaced π−π interaction with Y221. The hydroxyl groups of the 
inhibitor 9a are also involved in hydrogen bonding with Q332 and Y221. Overall, these 
results support the theory according to which bimodular inhibitor 9a inhibit Bm-T6PP by 
employing the binding affinity of warhead sufate with catalytic domain and π−π stacking 
interaction and hydrophobic interaction. 
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4.4 Material and Methods 
4.4.1 Inhibitor Synthesis 
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General. Except when specified, all solvents and reagents were purchased and used 
without further purification. Analytical thin-layer chromatography (TLC) was performed 
on silica gel plates containing F254 fluorescence indicator and column chromatography was 
performed using the indicated eluants on silica gel (230-400 mesh). 1H (300 and 500 MHz), 
13C NMR (75 MHz and 125 MHz), and 31P (121.5 MHz) NMR spectra were recorded on 
Bruker Avance 500 and Bruker Avance III 300 spectrometers. 1H, 13C and 31P NMR data 
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are reported as follows: for 1H NMR chemical shifts are reported in ppm relative to HDO, 
multiplicities are given as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
and coupling constant (J) are in Hz; 13C NMR chemical shifts are reported in ppm relative 
to NH4HCO3 as a standard; 31P NMR chemical shifts are reported in ppm relative to 50% 
aq H3PO4 as a standard. Phenyl α-D-glucopyranoside (1) and phenyl -D-glucopyranoside 
(2a) were purchased from Carbosynth Limited. n-Octyl β-D-glucopyranoside was 
purchased from Sigma-Aldrich. 2b,1 2c,2 2d,3 44, 5a5 were synthesized by using procedures 
previously described in the corresponding references. 
4-Sulfatomethylphenyl -D-Glucopyranoside (3). A solution of 3-formylphenyl 
2,3,4,6-O-triacetyl-D-glucopyranoside (10)6 (0.976 g, 2.2 mmol) in 50 mL of a 1:1 
mixture of THF/EtOH containing NaBH4 (42 mg, 1.1 mmol) was stirred at r.t. until 
complete disappearance of starting material occurred (TLC). The mixture was poured into 
ice-water, the pH was adjusted to 7.0 and extracted with chloroform. The extracts were 
dried and concentrated in vacuo, giving a residue that was dissolved in anhydrous DMF (4 
mL). To this solution at -20 ℃ was added a solution of SO3.pyridine (0.7 g, 4.4 mmol) in 
2 mL anhydrous DMF. The resulting solution was stirred at r.t. for 12 h and concentrated 
in vacuo, giving a residue that was subjected to silica gel chromatograph (10:1 to 5:1 
DCM/MeOH) to give 3-sulfatomethylphenyl 2,3,4,6-O-triacetyl-D-glucopyranoside (11) 
(0.857 g, 73%). 1H NMR (300 MHz, CDCl3) 7.14 (t, J = 8.1, 1H), 6.98-6.96 (m, 2H), 6.82-
6.79 (m, 1H), 5.22-5.00 (m, 4H),4.91 (s, 2H), 4.18 (dd, J1 = 12.6, J2 = 5.4, 1H), 4.07-4.02 
(m, 1H), 3.85-3.79 (m, 1H), 1.95 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H), 1.91 (s, 3H). 13C NMR 
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(300 MHz, CDCl3) 170.4, 169.9, 169.3, 169.2, 156.6, 138.5, 129.3, 122.7, 116.4, 116.0, 
98.6, 72.5, 71.7, 70.9, 68.9, 68.0, 61.7, 20.5, 20.5, 20.4.  
Following addition sodium (38 mg, 1.64 mmol) to 70 mL of anhydrous methanol, a 
solution of 11 (768 mg, 1.6 mmol) in anhydrous methanol (4.5 mL) was added dropwise. 
After stirring at r.t. for 2 h, the mixture was neutralized with solid carbon dioxide, and 
concentrated in vacuo, giving a residue that was subjected to silica gel chromatography to 
give 0.485 g (78%) of 3. 1H NMR (300 MHz, CD3OD) 7.30 (t, J = 8.1, 1H), 7.21-7.20 (m, 
1H), 7.10-7.06 (m, 2H), 5.01 (s, 2H), 4.95 (d, J = 6.9, 1H), 3.93 (dd, J1 = 12.0, J2 = 1.2, 
1H), 3.74 (dd, J1 = 12.0, J2 = 4.5, 1H), 3.50-3.47 (m, 4H). 13C NMR (75 MHz, CD3OD) 
159.1, 139.4, 130.4, 122.8, 117.3, 102.3, 78.0, 77.9, 74.9, 71.3, 70.4, 62.4. HRMS (ESI) 
calcd for C13H18O10S [M－H]
－ m/z 365.0542, found 365.0535. 
   Methyl α-D-Glucopyranoside-6-sulfonate (5b). To a solution of methyl α-D-
glucopyranoside (0.58 g, 3.0 mmol) in anhydrous DMF (9 mL) at -20℃，was added a 
solution of SO3.pyridine (0.50 g, 3.15 mmol) in 1 mL anhydrous DMF, The resulting 
solution was stirred at r.t. for 12 h and concentrated in vacuo, giving a residue that was 
subjected to silica gel chromatograph to give 0.435g (50%) of 5b. 1H NMR (300 MHz, 
CD3OD) 4.69 (d, J = 3.9, 1H), 4.29 (dd, J1 = 10.8, J2 =1.8, 1H), 4.16 (dd, J1 =10.8, J2 = 5.7, 
1H), 3.77-3.71 (m, 1H), 3.64 (t, J = 9.2, 1H), 3.45-3.41 (m, 1H), 3.43 (s, 3H), 3.56-3.33 
(m, 1H). 13C NMR (75 MHz, CD3OD) 101.2, 74.9, 73.4, 71.6, 71.53, 68.3, 55.6. HRMS 
(ESI) calcd for C7H14O9S [M-H]
－ m/z 273.0208, found 273.0278. 
Phenyl α-D-Glucopyranoside-6-sulfonate (5c). This substance was prepared 
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starting with phenyl α-D-glucopyranoside (1) using the same procedure employed for the 
preparation of 5b. Yield 42%. 1H NMR (500 MHz, CD3OD) 7.30-7.27 (m, 2H), 7.16-7.15 
(m, 2H), 7.01 (t, J = 7.5, 1H), 5.45 (d, J = 3.5, 1H), 4.22 (dd, J1 = 10.0, J2 = 4.0, 1H), 4.17-
4.15 (m, 1H), 3.88 (t, J = 9.5, 1H), 3.77-3.70 (m, 1H), 3.59 (dd, J1 = 10.0, J2 = 4.0, 1H), 
3.52 (t, J1 = 10.0, 1H). 13C NMR (125 MHz, CD3OD 158.6, 130.5, 123.5, 118.3, 99.4, 74.6, 
73.2, 72.5, 71.1, 67.8. HRMS (ESI) calcd for C12H16O9S [M-H]
－ m/z 335.0407, found 
335.0438. 
Methyl 2-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5d). This substance was 
prepared starting with 2-O-benzyl-α-D-glucopyranoside7 using the same procedure 
employed for the preparation of 5b. Yield 43%. 1H NMR (300 MHz, CD3OD) 7.46-7.41 
(m, 2H), 7.40-7.32 (m, 3H), 4.80 (d, J = 12.0, 1H), 4.68 (d, J = 12.0, 1H), 4.66 (d, J = 3.9, 
1H), 4.29 (dd, J1 = 7.8, J2 = 2.1, 1H), 4.17 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.79 (t, J = 9.3, 1H), 
3.75-3.70 (m, 1H), 3.39-3.37 (m, 1H), 3.37 (s, 3H), 3.36-3.34 (m, 1H). 13C NMR (75 MHz, 
CD3OD) 139.8, 129.4, 129.2, 128.8, 99.2, 80.9, 74.1, 74.0, 71.6, 71.4, 68.2, 55.5. HRMS 
(ESI) calcd for C14H20O9S [M-H]
－ m/z 363.0750, found 363.0738. 
Methyl 3-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5e). This substance was 
prepared starting with 3-O-benzyl-α-D-glucopyranoside8 using the same procedure 
employed for the preparation of 5b. Yield 50%. 1H NMR (300 MHz, CD3OD) 7.44-7.41 
(m, 2H), 7.33-7.16 (m, 3H), 4.86 (s, 2H), 4.65 (d, J = 3.6 Hz,1H), 4.28 (dd, J1 = 10.8, J2 = 
1.8, 1H), 4.16 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.78-3.72 (m, 1H), 3.62-3.60 (m, 1H), 3.55-3.45 
(m, 2H), 3.41 (s, 3H). 13C NMR (75 MHz, CD3OD) 140.5, 129.1, 129.0, 128.4, 101.4, 83.5, 
  
113 
 
76.2, 73.5, 71.7, 71.4, 68.2, 55.6. HRMS (ESI) calcd for C7H14O9S [M-H]
－ m/z 363.0750, 
found 363.0739. 
Methyl 4-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5f). This substance was 
prepared starting with 4-O-benzyl-α-D-glucopyranoside9 using the same procedure 
employed for the preparation of 5b. Yield 51%. 1H NMR (500 MHz, CD3OD) 7.44-7.43 
(m, 2H), 7.33-7.30 (m, 2H), 7.27-7.24 (m, 1H), 4.93-4.91 (m, 1H), 4.75 (m, 1H), 4.67 (d, 
J = 3.5, 1H), 4.25 (s, 2H), 3.81-3.75 (m, 1H), 3.45-3.43 (m, 2H), 3.40 (s, 3H). 13C NMR 
(75 MHz, CD3OD) 139.9, 129.4, 129.2, 128.6, 101.2, 79.3, 75.9, 75.5, 73.6, 70.6, 67.8, 
55.7. HRMS (ESI) calcd for C14H20O9S [M-H]
－ 
m/z 363.0750, found 363.0740. 
Benzyl α-D-Glucopyranoside-6-sulfonate (6a). This substance was prepared from 
benzyl α-D-glucopyranoside10 using the same procedure described for the preparation of 
5b. Yield 47%. 1H NMR (300 MHz, CD3OD) 7.45-7.43 (m, 2H), 7.34-7.30 (m, 3H), 4.88 
(d, J = 3.6, 1H), 4.77 (d, J = 11.7, 1H), 4.56 (d, J = 11.7, 1H), 4.26 (dd, J1 =10.8, J2 = 3.8, 
1H), 4.15 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.83-3.80 (m, 1H), 3.72 (t, J = 9.3, 1H), 3.46-3.37 
(m, 2H). 13C NMR (75 MHz, CD3OD) 138.7, 129.3, 129.2, 128.7, 99.1, 74.7, 73.2, 71.8, 
71.4, 70.3, 62.1. HRMS (ESI) calcd for C13H18O9S [M-H]
－ m/z 349.0593, found 349.0585. 
n-Octyl β-D-Glucopyranoside-6-sulfonate (6b). This substance was prepared 
starting with n-octyl β-D-glucopyranoside using the same procedure described for the 
preparation of 5b. Yield 56%. 1H NMR (300 MHz, CD3OD) 4.33-4.23 (m, 2H), 4.13 (dd, 
J1 = 11.1, J2 = 5.6, 1H), 3.90-3.83 (m, 1H), 3.56-3.44 (m, 2H), 3.38-3.33 (m, 2H), 3.18 (t, 
J = 7.2,1H), 1.64-1.56 (m, 2H), 1.38-1.26 (m, 10H), 0.90 (t, J = 6.6, 3H). 13C NMR (75 
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MHz, CD3OD) 104.3, 77.7, 75.9, 75.0, 71.4, 71.0, 68.2, 33.0, 30.8, 30.6, 30.4, 27.1, 23.7, 
14.4. HRMS (ESI) calcd for C14H28O9S [M-H]
－ m/z 371.1376, found 371.1373. 
1-Naphthyl β-D-Glucopyranoside-6-sulfonate (6c). This substance was prepared 
starting with 1-naphthyl β-D-glucopyranoside (purchased from Carbosynth Limited) using 
the same procedure described for the preparation of 5b. Yield 45%. 1H NMR (500 MHz, 
CD3OD) 8.38-8.36 (m, 1H), 7.79-7.77 (m, 1H), 7.50-7.44 (m, 3H), 7.40-7.37 (m, 1H), 
7.24-7.22 (m, 1H), 5.10 (d, J = 7.5, 1H), 4.39 (m, 1H), 4.21 (dd, J1 = 11.0, J2 = 5.5, 1H), 
3.77-3.67 (m, 2H), 3.59-3.50 (m, 2H). 13C NMR (125 MHz, CD3OD 154.4, 135.8, 128.4, 
127.3, 127.1, 127.0, 126.3, 123.2, 123.0, 110.6, 102.6, 77.7, 75.9, 75.0, 71.2, 68.1. HRMS 
(ESI) calcd for C16H18O9S [M-H]
－ m/z 385.0593, found 385.0589. 
(4-Phenyl-1H-1,2,3-triazole) β-D-Glucopyranoside-6-sulfonate (6d). This 
substance was prepared starting with 2d using the same procedure described for the 
preparation of 5b. Yield 55%. 1H NMR (300 MHz, D2O) 8.35 (s, 1H), 7.68-7.65 (m, 2H), 
7.46-7.42 (m, 3H), 5.74 (d, J = 9.0, 1H), 4.47-4.43 (m, 1H), 4.37-4.35 (m, 1H), 4.05-4.02 
(m, 2H), 3.78-3.74 (m, 2H), 13C NMR (75 MHz, D2O) 147.5, 129.0, 128.9, 125.6, 121.0, 
87.4, 76.7, 75.7, 75.3, 72.2, 68.8. HRMS (ESI) calcd for C14H17N3O8S [M-H]
－ m/z 
386.0664, found 386.0666. 
Phenyl β-D-Glucopyranoside-6-phosphate (7). To a solution of phenyl β-D-
glucopyranoside (2a) (1.08 g, 4.0 mmol) in 5.08 mL of a 2.5:1:0.1 mixture of 
acetonitrile/pyridine/water at 0℃ was added POCl3 (1.6 mL, 8 mmol). The resulting 
solution was stirred at 0 ℃ for 2 h and poured onto 20 g of ice. After the ice melted, the pH 
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of the mixture was adjusted to 7.0 by slowly adding 1 M aqueous NaOH. The resulting 
solution was concentrated in vacuo, giving a residue that was subjected to silica gel 
chromatograph (ethyl acetate/isopropyl alcohol/H2O/NH3•H2O = 5/5/2/0.2, v/v/v/v) to give 
7 (0.38 g, 29%). 1H NMR (300 MHz, D2O) 7.42-7.37 (m, 2H), 7.16-7.12 (m, 3H), 5.13(d, 
J = 7.2, 1H), 4.08-4.06 (m, 2H), 3.68-3.59 (m, 4H). 13C NMR (75 MHz, D2O) 156.5, 129.9, 
123.3, 116.5, 100.2, 75.3, 75.1, 73.0, 68.7, 62.8. 31P NMR (121.5 MHz, D2O) 3.32. HRMS 
(ESI) calcd for C12H17O9P [M-H]
－ m/z 335.0532, found 335.0529. 
Phenyl β-D-Glucopyranoside-6-sulfonate (8a). This substance was prepared using 
starting with 2a using the same procedure described for the preparation of 5b. Yield 49%. 
1H NMR (300 MHz, CD3OD) 7.32-7.27 (m, 2H), 7.13-7.10 (m, 2H), 7.04-6.99 (m, 1H), 
4.90 (d, J = 7.5, 1H), 4.39 (dd, J1 = 10.8, J2 = 1.4, 1H), 4.19 (dd, J1 = 10.8, J2 = 5.7, 1H), 
3.69 (t, J = 7.4, 1H), 3.51-3.48 (m, 3H). 13C NMR (75 MHz, CD3OD) 159.1, 130.4, 123.4, 
117.8, 102.3, 77.6, 75.9, 74.8, 71.2, 68.1. HRMS (ESI) calcd for C12H16O9S [M-H]
－ m/z 
335.0437, found 335.0429. 
4,4’-Biphenyl β-D-Glucopyranoside-6-sulfonate (8b). This substance was 
prepared starting with 4,4’-biphenyl β-D-glucopyranoside11 using the same procedure 
described for the preparation of 5b. Yield 49%. 1H NMR (500 MHz, CD3OD) 7.54-7.51 
(m, 4H), 7.38-7.34 (m, 2H), 7.26-7.23 (m, 1H), 7.16-7.15 (m, 2H), 4.90 (d, J = 7.0, 1H), 
4.37 (m, 1H), 4.14 (dd, J1 = 11.0, J2 = 6.0, 1H), 3.68 (t, J = 7.3, 1H), 3.50-3.40 (m, 3H). 13C 
NMR (125 MHz, CD3OD) 158.6, 142.0, 136.7, 129. 8, 129.0, 127.6, 118.2, 102.4, 77.7, 
76.1, 74.9, 71.3, 68.2. HRMS (ESI) calcd for C18H20O9S [M-H]
－ m/z 411.0705, found 
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411.0746. 
2,6-Dimethoxy-4-formylphenyl β-D-Glucopyranoside-6-sulfonate (8c). To a 
solution of 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide (0.824 g, 2 mmol) in 
CH2Cl2 (8 mL), containing tetrabutylammonium bromide (0.76 g, 2 mmol) and 
syringaldehyde (1.09 g, 6mmol) was added 8 mL of 1 M NaOH. The resulting mixture was 
stirred vigorously at 35 ℃ for 6 h. The mixture was diluted with EtOAc and the organic 
phase was separated, washed three times with a 1 M NaOH aqueous solution, water and 
brine, dried and concentrated in vacuo. The resulting residue was dissolved in 20 mL of a 
1:1 mixture of THF/MeOH containing anhydrous K2CO3 (0.5 g). The resulting mixture was 
stirred for 20 h at r.t. and concentrated in vacuo, giving a residue that was subjected to 
silica gel chromatography to give 2,6-dimethoxy-4-formylphenyl β-D-glucopyranoside 
(12)14 (364 mg, 53%). 1H NMR (300 MHz, CD3OD/D2O (v/v, 1/2)) 9.91 (s, 1H), 7.39 (s, 
2H), 5.24 (d, J = 7.2, 1H), 4.02 (s, 6H), 3.87-3.78 (m, 2H), 3.65-3.58 (m, 3H), 3.42-3.39 
(m, 1H). 13C NMR (75 MHz, CD3OD/D2O (v/v, 1/2)) 195.0, 154.2, 140.6, 133.6, 108.4, 
103.8, 77.7, 77.0, 74.9, 70.4, 61.6, 57.2. 
 The target 8c was prepared from 12 using the same procedure as described for the 
preparation of 5b. Yield 58%. 1H NMR (300 MHz, D2O) 9.44 (s, 1H), 6.90 (s, 2H), 5.07 
(d, J = 5.7, 1H), 4.30-4.18 (m, 2H), 3.82 (s, 6H), 3.64-3.60 (m, 4H). 13C NMR (75 MHz, 
D2O) 194.3, 152.6, 138.8, 132.1, 107.1, 102.7, 75.4, 74.1, 73.5, 69.1, 66.8, 56.1. HRMS 
(ESI) calcd for C15H20O12S [M-H]
－ m/z 423.0597, found 423.0599. 
3,4-Difuorophenyl β-D-Glucopyranoside-6-sulfonate (8d). 3,4-Difuorophenyl β-
D-glucopyranoside (13) was prepared using the same procedure as that for 2,6-dimethoxy-
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4-formylphenyl β-D-glucopyranoside (12).12 Yield 45%. 1H NMR (300 MHz, D2O) 7.14-
7.04 (m, 1H), 7.01-6.94 (m, 1H), 6.85-6.81 (m, 1H), 4.77 (d, J = 5.1, 1H), 3.83 (dd, J1 = 
12.0, J2 = 2.0, 1H), 3.63 (dd, J1 = 12.0, J2 = 5.4, 1H), 3.45-3.31 (m, 4H). 13C NMR (75 MHz, 
MeOD) 155.4 (d, JC,F  = 6.6), 150.90 (dd, JC,F1  = 319.1, JC,F2  = 13.7 ), 147.8 (dd, JC,F1 = 
313.8, JC,F2 = 14.0), 118.2 (d, JC,F = 18.7), 113.9, 107.6 (d, JC,F =20.3), 102.8, 78.1, 77.8, 
74.1, 71.2, 62.4. 
The target 8d was prepared from 13 using the same procedure as that for 5b. Yield 
33%. 1H NMR (300 MHz, MeOD) 7.10-7.01 (m, 1H), 6.94-6.92 (m, 1H), 6.86-6.79 (m, 
1H), 4.45 (d, J = 10.8, 1H), 4.29-.20 (m, 1H), 4.03-3.82 (m, 2H), 3.65 (t, J = 9.0, 1H), 3.53-
3.38 (m, 2H). 13C NMR (75 MHz, MeOD) 155.2 (d, JC,F = 4.7), 150.9 (dd, JC,F1 = 298.4, 
JC,F2 = 4.7), 147.74 (dd, JC,F1 = 312.2, JC,F2 = 12.8), 118.3 (d, JC,F = 18.8), 113.9, 107.8 (d, 
JC,F = 19.2), 102.4, 75.8, 75.5, 73.5, 70.0, 68.0. HRMS (ESI) calcd for C12H14F2O9S [M-H]
－ m/z 371.0248, found 371.0239. 
4-Nitrophenyl β-D-Glucopyranoside-6-sulfonate (8e). This substance was 
prepared using the same procedure as that for 5b starting with 4-nitrophenyl β-D-
glucopyranoside.13 Yield 31%. 1H NMR (300 MHz, MeOD) 8.19 (d, J = 9.3, 2H), 7.24 (d, 
J = 9.3, 2H), 5.08 (d, J = 7.2, 1H), 3.40 (dd, J1 = 11.1, J2 = 1.8, 1H), 4.17 (dd, J1 = 11.1, J2 
= 6.0, 1H), 3.85-3.80 (m, 1H), 3.57-3.47 (m, 3H). 13C NMR (75 MHz, MeOD) 163.6, 143.7, 
126.6, 117.7, 101.3, 77.3, 75.9, 74.5, 71.0, 68.0. HRMS (ESI) calcd for C12H15NO11S [M-
H]
－ m/z 380.0288, found 380.0284. 
4-Aminophenyl β-D-Glucopyranoside-6-sulfonate (8f).14 To a solution of 8e (120 
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mg, 0.3 mmol) in DI water (6 mL), was added Pd(OH)2/C (32 mg, 0.06 mmol). The 
resulting mixture was stirred under a H2 atmosphere for 2 h. The mixture was ﬁltered 
through Celite pad and the filtrate was concentrated in vacuo, giving 8f (105 mg, 100%). 
1H NMR (500 MHz, D2O) 7.06-7.03 (m, 2H), 6.91-6.88 (m, 2H), 4.98 (d, J = 8.0, 1H), 
4.38-4.35 (m, 1H), 4.29-4.26 (m, 1H), 3.82-3.80 (m, 1H), 3.63-3.55 (m, 3H). 13C NMR 
(125 MHz, D2O) 143.9, 132.4 111.3, 111.0, 94.2, 68.3, 66.6, 65.8, 62.0, 59.7. HRMS (ESI) 
calcd for C12H17NO9S [M-H]
－ m/z 350.0546, found 350.0536. 
4-Acetamidophenyl β-D-Glucopyranoside-6-sulfonate (8g).14 A mixture of 8f (95 
mg, 0.27 mmol) in 4.5 mL H2O containing K2CO3 (112 mg, 0.81 mmol) was stirred at 0 oC 
before adding Ac2O (77 μL, 0.81 mmol) dropwise. Following stirring at for 3 h at 0 oC, the 
mixture was concentrated in vacuo, giving a residue that was subjected to silica gel 
chromatography, to give 8g (65 mg, 62%). 1H NMR (300 MHz, D2O) 7.34 (d, J = 8.7, 2H), 
7.13 (d, J = 8.7, 2H), 5.08 (d, J = 7.2, 1H), 4.38-4.35 (m, 1H), 4.23 (dd, J1 = 11.4, J2 = 5.4, 
1H), 3.87-3.83 (m, 1H), 3.62-3.56 (m, 3H), 2.13 (s, 3H). 13C NMR (75 MHz, D2O) 172.9, 
154.1, 132.0, 123.9, 117.1, 100.5, 75.3, 73.9, 72.8, 69.1, 66.8, 22.6. HRMS (ESI) calcd for 
C14H19NO10S [M-H]
－ m/z 392.0651, found 392.0645. 
2-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8h). This substance was 
prepared using the same procedure as that for 5b starting with 2-formylphenyl β-D-
glucopyranoside.15 Yield 39%. 1H NMR (500 MHz, D2O) 10.03 (s, 1H), 7.72-7.64 (m, 2H), 
7.27-7.17 (m, 2H), 5.20 (d, J = 7.5, 1H), 4.38-4.35 (m, 1H), 4.26-4.23 (m, 1H), 3.87-3.86 
(m, 1H), 3.69-3.58 (m, 3H). 13C NMR (125 MHz, D2O) 186.1, 151.9, 130.2, 121.4, 117.6, 
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116.1, 108.7, 92.8, 68.3, 66.9, 65.6, 61.9, 59.7. HRMS (ESI) calcd for C13H16O10S  
[M-H]
－ m/z 363.0386, found 363.0379. 
   3-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8i). 3-Formylphenyl β-D-
glucopyranoside (14) was prepared from 3-hydroxybenzaldehyde and 2,3,4,6-tetra-O-
acetylglucosyl bromide using the same procedure as that for 12. Yield 29%. 1H NMR (300 
MHz, CD3OD) 9.88 (s, 1H), 7.54-7.34 (m, 4H), 4.96 (d, J = 6.3, 1H), 3.88-3.84 (m, 1H), 
3.67 (dd, J1 = 12.0, J2 = 5.1, 1H), 3.48-3.39 (m, 4H). 13C NMR (75 MHz, CD3OD) 193.9, 
159.5, 139.2, 131.3, 125.0, 124.1, 117.7, 102.0, 78.1, 77.8, 74.7, 71.2, 62.3. 
The target 8i was prepared from 14 substance was prepared using the same 
procedure as that for 5b. Yield 39%. 1H NMR (300 MHz, D2O) 9.83 (s, 1H), 7.63-7.49 (m, 
3H), 7.41-7.37 (m, 1H), 5.14 (d, J = 6.6, 1H), 4.33-4.29 (m, 1H), 4.15 (dd, J1 = 11.4, J2 = 
5.7, 1H), 3.87-3.82 (m, 1H), 3.58-3.50 (m, 3H). 13C NMR (125 MHz, D2O) 188.6, 149.8, 
130.1, 123.6, 118.0, 116.4, 109.6, 92.9, 68.2, 66.8, 65.6, 61.9, 59.7. HRMS (ESI) calcd for 
C13H16O10S [M-H]
－ m/z 363.0386, found 363.0384. 
4-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8j). 4-Formylphenyl β-D- 
glucopyranoside (15) using a previously described procedure.16 The target 8j was prepared 
starting with 15 using the same procedure as that for 5b. Yield 59%. The precursor 4-
formylphenyl β-D-glucopyranoside was synthesized by using the procedure previously 
described.16 1H NMR (300 MHz, D2O) 9.81 (s, 1H), 7.93 (d, J = 8.7, 2H), 7.27 (d, J = 8.7, 
2H), 5.30 (d, J = 6.9, 1H), 4.46-4.43 (m, 1H), 4.31 (dd, J1 = 11.4, J2 = 5.1, 1H), 4.01-3.97 
(m, 1H), 3.73-3.64 (m, 3H). 13C NMR (75 MHz, D2O) 188.5, 155.3, 126.1, 124.3, 110.0, 
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92.8, 68.8, 67.5, 66.2, 62.6, 60.3. HRMS (ESI) calcd for C13H16O10S [M-H]
－ m/z 363.0386, 
found 363.0381. 
2-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8k). To a solution of 
2-formylphenyl β-D-glucopyranoside-6-sulfonate (8h) (98 mg, 0.26 mmol) in MeOH (2 
mL) at 0℃, was added NaBH4 (40 mg, 1.03 mmol) The mixture was warmed to room 
temperature and stirred for 1 h, The diluted with water, and concentrated in vacuo giving a 
residue that was subjected to silica gel chromatography, giving 8k (61 mg, 64%). 1H NMR 
(500 MHz, D2O) 7.38-7.35 (m, 2H), 7.22-7.21 (m, 1H), 7.15-7.12 (m, 1H), 5.10 (d, J = 
7.5, 1H), 4.73-4.65 (m, 2H), 4.35-4.32 (m, 1H), 4.23-4.20 (m, 1H), 3.83-3.82 (m, 1H), 
3.65-3.55 (m, 3H). 13C NMR (125 MHz, D2O) 122.6, 122.4, 122.2, 116.3, 108.3, 93.5, 68.3, 
66.7, 65.7, 61.9, 59.7, 52.1. HRMS (ESI) calcd for C13H18O10S [M-H]
－ m/z 365.0548, 
found 365.0540. 
3-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8l). This substance 
was prepared from 3-formylphenyl β-D-glucopyranoside-6-sulfonate (8i) using the same 
procedure as that for 8k. Yield 80%. 1H NMR (500 MHz, D2O) 7.37-7.36 (m, 1H), 7.10-
7.07 (m, 3H), 5.10 (d, J = 4.5, 1H), 4.61-4.59 (m, 2H), 4.36-4.34 (m, 1H), 4.20 (dd, J1 = 
11.0, J2 = 5.0, 1H), 3.86-3.85 (m, 1H), 3.61-3.56 (m, 3H). 13C NMR (125 MHz, D2O) 126.2, 
123.0, 119.5, 114.9, 108.6, 108.1, 93.1, 68.2, 66.7, 65.7, 62.0, 59.7, 56.4. HRMS (ESI) 
calcd for C13H18O10S [M-H]
－ m/z 365.0548, found 365.0538. 
4-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8m). This substance 
was prepared from 4-formylphenyl β-D-glucopyranoside-6-sulfonate (8j) using the same 
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procedure as that for 8k. Yield 58%. 1H NMR (500 MHz, D2O) 7.35-7.33 (m, 2H), 7.12-
7.10 (m, 2H), 5.09 (d, J = 4.5, 1H), 4.56-4.55 (m, 2H), 4.34-4.32 (m, 1H), 4.22-4.20 (m, 
1H), 3.84-3.83 (m, 1H), 3.58-3.54 (m, 3H). 13C NMR (125 MHz, D2O) 149.0, 127.8, 122.1, 
109.5, 93.1, 68.2, 66.7, 65.7, 61.9, 59.7, 56.2. HRMS (ESI) calcd for C13H18O10S [M-H]
－ 
m/z 365.0548, found 365.0538. 
4-n-Butylphenyl β-D-Glucopyranoside-6-sulfonate (8n). 4-n-Butylphenyl β-D- 
glucopyranoside (16) was prepared from 4-n-butylphenol using the same procedure as that 
for 12. Yield 30% in two steps. 1H NMR (300 MHz, CD3OD) 7.18-7.07 (m, 4H), 4.98 (d, 
J = 7.2, 1H), 3.98-3.94 (m, 1H), 3.80 (dd, J1 = 11.1, J2 = 4.5, 1H), 3.61-3.53 (m, 4H), 2.59 
(t, J = 7.7, 2H), 1.62-1.57 (m, 2H), 1.40-1.33 (m, 2H), 0.96 (t, J = 7.4, 3H). 13C NMR (75 
MHz, CD3OD) 156.6, 138.2, 130.3, 117.6, 102.2, 77.5, 77.3, 74.5, 70.9, 62.1, 35.5, 34.8, 
23.0, 14.2. 
The target 8n was prepared from 16 using the same procedure as that for 5b. Yield 
51%. 1H NMR (300 MHz, D2O/CD3OD (v/v, 1/1)) 7.21-7.06 (m, 4H), 4.99 (d, J = 6.9, 1H), 
4.39-4.35 (m, 1H), 4.24 (dd, J1 = 11.1, J2 = 5.1, 1H), 3.78-3.77 (m, 1H), 3.59-3.56 (m, 3H), 
2.59 (t, J = 7.7, 2H), 1.63-1.53 (m, 2H), 1.40-1.30 (m, 2H), 0.93 (t, J = 7.4, 3H). 13C NMR 
(75 MHz, D2O/CD3OD (v/v, 1/1)) 156.1, 138.8, 130.4, 117.6, 102.1, 76.7, 75.1, 74.1, 70.4, 
67.8, 35.2, 34.4, 22.7, 14.2. HRMS (ESI) calcd for C16H24O9S [M-H]
－ m/z 391.1063, found 
391.1075. 
4-n-Hexylphenyl β-D-Glucopyranoside (17) and 4-n-Hexylphenyl α-D-
Glucopyranoside (18).17 To a solution of penta-O-benzoyl-D-glucose (2.8 g, 4 mmol) and 
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4-n-hexylphenol (1.42 g, 8 mmol) in dichloromethane (28 ml) under argon at 0 °C was 
added BF3·Et2O (1.67 mL, 13.2 mmol). The mixture was stirred at 50 °C for 48 h, diluted 
with water (30 mL) and stirred for 15 min. The mixture was diluted with dichloromethane 
(60 mL), washed with water, brine, and concentrated in vacuo, giving a residue that was 
dissolved in THF/MeOH (100 mL/20 mL) and cooled to 0 °C. A 3N solution of aq NaOH 
(9.52 mL) was added and the mixture was stirred for 9 h at room temperature, diluted with 
water (40 mL), neutralized with AG 50W-X8 resin (Bio-Rad), filtered, and concentrated in 
vacuo, giving a residue that was subjected to silica gel chromatography, giving 4-n-
hexylphenyl β-D-glucopyranoside (17) (237 mg, 17%) and 4-n-hexylphenyl α-D-
glucopyranoside (18) (639 mg, 47%).  
17: 1H NMR (300 MHz, CDCl3/CD3OD (v/v, 1/1)) 7.59-7.45 (m, 4H), 5.39 (d, J = 
6.9, 1H), 4.39-4.26 (m, 2H), 4.06-4.04 (m, 3H), 3.93-3.92 (m, 1H), 3.04 (t, J = 7.7, 2H), 
2.07-2.05 (m, 2H), 1.84-1.79 (m, 6H), 1.38 (t, J = 6.6, 3H). 13C NMR (75 MHz, 
CDCl3/CD3OD (v/v, 1/1)) 155.1, 137.0, 129.0, 116.3, 100.8, 76.1, 75.9, 73.1, 69.4, 61.0, 
34.8, 31.4, 31.4, 28.6, 22.3, 13.6. 
18: 1H NMR (300 MHz, CDCl3/CD3OD (v/v, 1/1)) 7.36-7.29 (m, 4H), 5.75 (d, J = 
3.6, 1H), 4.19 (t, J = 9.3, 1H), 4.10-3.98 (m, 3H), 3.93-3.82 (m, 2H), 2.81 (t, J = 7.7, 2H), 
1.86-1.84 (m, 2H), 1.58-1.57 (m, 6H), 1.56 (t, J = 6.6, 3H). 13C NMR (300 MHz, 
CDCl3/CD3OD (v/v, 1/1)) 154.7, 136.8, 129.0, 116.6, 97.7, 73.4, 72.2, 71.6, 69.3, 60.7, 
34.8, 31.4, 31.3, 28.6, 22.3, 13.6. 
4-n-Hexylphenyl β-D-Glucopyranoside-6-sulfonate (8o). This substance was 
prepared from 4-n-hexylphenyl β-D-glucopyranoside (17) using the same procedure as that 
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for 5b. Yield 46 %. 1H NMR (300 MHz, D2O/CD3OD (v/v, 1/1)) 7.19-7.09 (m, 4H), 4.99 
(d, J = 6.6, 1H), 4.43-4.40 (m, 1H), 4.29 (dd, J1 = 11.1, J2 = 5.4, 1H), 3.80-3.76 (m, 1H), 
3.65-3.57 (m, 3H), 2.60 (t, J = 7.5, 2H), 1.65-1.60 (m, 2H), 1.38-1.35 (m, 6H), 0.95 (t, J = 
6.6, 3H). 13C NMR (75 MHz, CDCl3/CD3OD (v/v, 1/1)) 156.6, 138.3, 130.2, 117.7, 102.4, 
77.0, 75.4, 74.4, 70.7, 67.9, 35.8, 32.6, 32.5, 29.6, 23.4, 14.4. HRMS (ESI) calcd for 
C18H28O9S [M-H]
－ m/z 419.1376, found 419.1388. 
4-n-Hexylphenyl α-D-Glucopyranoside-6-sulfonate (9b). This substance was 
prepared from 4-n-hexylphenyl α-D-glucopyranoside (18) using the same procedure as that 
for 5b. Yield 55 %. 1H NMR (300 MHz, CD3OD) 7.12-7.05 (m, 4H), 5.44 (d, J = 3.6, 1H), 
4.29-4.17 (m, 2H), 3.94-3.88 (m, 2H), 3.65-3.52 (m, 2H), 2.56 (t, J = 7.7, 2H ), 1.61-1.54 
(m, 2H), 1.33-1.31 (m, 6H), 0.91 (t, J = 6.6, 3H). 13C NMR (75 MHz, CD3OD) 156.5, 138.0, 
130.2, 118.2, 99.5, 74.5, 73.1, 72.3, 71.1, 67.8, 36.0, 32.8, 29.9, 23.2, 14.4. HRMS (ESI) 
calcd for C18H28O9S [M-H]
－ m/z 419.1376, found 419.1375. 
4-n-Octylphenyl β-D-Glucopyranoside (19) and 4-n-Octyl phenyl α-D-
Glucopyranoside (20).17 These substances were prepared using the same procedure as 
those for 4-n-hexylphenyl β-D-glucopyranoside (17) and 4-n-hexylphenyl α-D-
glucopyranoside (18). 
19: Yield 25 %. 1H NMR (300 MHz, CD3OD) 7.03-6.92 (m, 4H), 4.80 (d, J = 6.6, 
1H), 3.84-3.80 (m, 1H), 3.64 (dd, J1 = 11.4, J2 = 3.6, 1H ), 3.40-3.35 (m, 4H), 2.47 (t, J = 
7.5, 2H), 1.54-1.48 (m, 2H), 1.24-1.23 (m, 10H), 0.83 (t, J = 6.3, 3H). 13C NMR (75 MHz, 
CD3OD) 157.2, 137.9, 130.2, 117.7, 102.5, 78.0, 77.9, 74.9, 71.3, 62.5, 36.1, 33.0, 32.9, 
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30.6, 30.4, 30.2, 23.7, 14.4. 
20: Yield 44 %. 1H NMR (300 MHz, CD3OD) 7.10-7.09 (m, 4H), 5.46 (d, J = 3.6, 
1H), 3.90 (t, J = 9.3, 1H), 3.77-3.71 (m, 3H), 3.59 (dd, J1 = 9.6, J2 = 3.6, 1H ), 3.47 (t, J = 
9.2, 1H ), 2.57 (t, J = 7.7, 2H), 1.62-1.58 (m, 2H), 1.33-1.32 (m, 10H), 0.92 (t, J = 6.8, 3H). 
13C NMR (75 MHz, CD3OD) 156.7, 138.0, 130.2, 118.2, 99.6, 74.9, 74.2, 73.3, 71.5, 62.3, 
36.1, 33.0, 32.9, 30.6, 30.4, 30.3, 23.7, 14.4. 
4-n-Octylphenyl β-D-Glucopyranoside-6-sulfonate (8p). This substance was 
prepared from 4-n-octylphenyl β-D-glucopyranoside (19) using the same procedure as that 
for 5b. Yield 42 %. 1H NMR (300 MHz, D2O) 6.97-6.90 (m, 4H), 4.72 (d, J = 6.3, 1H), 
4.30-4.27 (m,1H), 4.17-4.13 (m, 1H ), 3.61-3.43 (m, 4H), 2.37 (t, J = 7.1, 2H), 1.44-1.43 
(m, 2H), 1.24-1.23 (m, 10H), 0.88 (t, J = 6.2, 3H). 13C NMR (75 MHz, D2O) 155.2, 137.3, 
129.3, 117.3, 101.7, 75.2, 73.8, 72.8, 68.7, 66.3, 35.0, 31.9, 31.5, 29.5, 29.4, 22.6, 13.9. 
HRMS (ESI) calcd for C20H32O9S [M-H]
－ m/z 447.1689, found 447.1693. 
4-n-Octylphenyl α-D-Glucopyranoside-6-sulfonate (9a). This substance was 
prepared from 4-n-octylphenyl α-D-glucopyranoside (20) using the same procedure as that 
for 5b. Yield 68 %. 1H NMR (300 MHz, D2O) 6.96-6.83 (m, 4H), 5.38 (d, J = 3.6, 1H), 
4.28-4.19 (m, 1H), 3.96-3.90 (m, 2H), 3.76-3.59 (m, 3H), 2.3 (t, J = 7.7, 2H), 1.43-1.42 (m, 
2H), 1.24-1.23 (m, 10H), 0.87 (t, J = 6.6, 3H). 13C NMR (75 MHz, D2O) 154.8, 136.7, 
129.1, 117.0, 97.8, 72.8, 71.2, 70.5, 68.7, 66.2, 35.0, 31.9, 31.6, 29.6, 29.5, 22.7, 13.9. 
HRMS (ESI) calcd for C20H32O9S [M-H]
－ m/z 447.1689, found 447.1695. 
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4.5 Site-Directed Mutagenesis 
Site directed mutagenesis was carried out using a PCR-based strategy with the WT-
Mt-T6PP/pET-15-TEV plasmid and commercial primers. Reaction solutions also 
contained dNTP (Invitrogen) and Deep Vent DNA polymerase. The PCR was carried out 
using the Techgene thermal cycler manufactured by TECHNE. The PCR products were 
treated with DpnI for 1 h at 37°C to remove the wild type plasmid before transformation 
of T7 Express Iq Competent E. coli (High Efficiency) cells. The sequence of the mutated 
gene was confirmed by DNA sequencing carried out by GENEWIZ, Inc. The plasmid was 
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prepared using a QIAprep Spin Minniprep kit (Qiagen). The expression levels of the genes 
encoding T6PP mutants were examined by SDS-PAGE analysis of the cellular protein. 
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CHAPTER FIVE 
IRREVERSIBLE INHIBITION OF HAD FAMILY MEMBER 
TREHALOSE-6-PHOSPHATE PHOSPHATASE WITH ACTIVE SITE 
DIRECTED BIOMODULAR INHIBITORS 
 
5.1 Abstract 
            Molecules that bind selectively to a given drug target and then undergo a rapid 
chemoselective reaction to form a covalent conjugate have utility in drug development. 
The design of these molecules to generate irreversible inhibitors for biological research and 
drug discovery is an important challenge in carbohydrate chemistry. Herein a library of 
known Trehalsoe-6-phosphate phosphatase (T6PP) inhibitors with nucleophilic warheads 
was conceived of by structure-based design principles and was chemically synthesized. 
When bound in T6PP active site, the aryl sulfonyl fluorides of 26 react rapidly and 
chemoselectively with highly conserved Lys residues which located in cap domain. Our 
results suggest that development of broad-range anthelmintic and antibacterial therapeutics 
employing targeting this highly conserved Lys may be possible. 
 
5.2. Introduction 
           Trehalose, a natural alpha-linked disaccharide formed by an α,α-1,1-glucoside bond 
between two α-glucose units, is synthesized and stored in a wide variety of organisms such 
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as bacteria, plants, fungi and invertebrates to support cell survival by functioning as a fuel, 
a metabolic regulator or a protectant against environmental stress [1-3]. Unlike these other 
organisms, humans are unable to produce trehalose but can utilize trehalose through a 
trehalase enzyme [4-6]. Five different trehalose biosynthetic pathways are known to exist 
[7], one of which, the OtsA/B pathway is common among pathogenic bacteria and fungi 
as well as in parasitic nematodes. The OtsA/B pathway, which utilizes glucose and glucose-
6-phosphate to generate trehalose-6-phosphate catalyzed by trehalose synthase, then 
hydrolyzed to trehalose by trehalose-6- phosphate phosphatase (T6PP). Previously 
reported otsA and otsB gene knockout (or knockdown) experiments have shown that both 
pathway enzymes are essential for Mycobacterium tuberculos’s growth in laboratory 
culture and for its virulence in a mouse model [8]. The T6P synthase and phosphatase are 
also required for trehalose production in the filamentous fungus Fusarium graminearum, 
however only the T6PP proved to be indispensable for development and virulence [9]. It is 
also required for cell wall integrity and fungal virulence in the human fungal pathogen 
Aspergillus fumigatus [10] Disruption of the TPS2Gene which encode Trehalose-6-
Phosphate Phosphatase Decreases Candida albicans’s Infectivity [11]. Silencing of tpp 
gene in Caenorhabditis elegans and Brugia malayi caused the arrested growth of larvae 
revealed that the T6PP is essential, however only when the T6P synthase-encoding gene is 
functional [12, 13]. 
          Based on these findings we concluded that trehalose synthesizing pathogens are 
likely to be vulnerable to the action of small molecule inhibitors of their T6PPs. Moreover, 
the ranking of potential drug targets for the parasitic nematode Brugia malayi placed T6PP 
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among the most attractive candidates [14]. T6PP belongs to HADSF, its active site is 
formed by substrate-induced association of a mobile cap domain with the catalytic site of 
the Rossmann-fold catalytic domain. For phosphatase-specific targeting, one end of the 
inhibitor is to be optimized for complementation of the catalytic site common to each 
phosphatase, and the other end optimized to complement the interfaced region of the cap 
domain, unique to each phosphatase. Phosphate-like functional groups were screened for 
binding affinity to the catalytic site by using trehalose as the carrier; the sulfate group 
proved to be most effective (Chapter 3). The ability of trehalose-6-sulfate to induce cap 
closure was examined by SAXS, and shown to occur in the bacterial T6PP, but not in the 
nematode T6PP.The X-ray structure determined for the nematode T6PP is consistent with 
restricted cap movement. Organic groups, attached to glucose-6-sulfate, were then 
screened for binding affinity towards the cap domain, with promising results for future lead 
inhibitor development (Chapter 4). In general, to design inhibitors for carbohydrate 
processing proteins is challenging, since carbohydrates themselves do not bind to proteins 
with great affinity, for which the monomeric KD values are typically in the micromolar to 
millimolar range [15-17]. This low affinity is likely due to the extensive hydrophilic 
character of these polyhydroxylated compounds. In order to overcome this limitation, we 
turn onto use irreversible inhibitor design strategy. Compared to reversible inhibitors, 
irreversible inhibitors has important and potentially advantageous consequences for drug 
pharmaco-dynamics in which the level and frequency of doing relates to the extent and 
duration of the resulting pharmacological effect. In particular, when covalent modification 
of a drug target is irreversible, the restoration of pharmacological activity requires re-
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synthesis of the protein target. Some highly nucleophilic warheads, which are widely used 
in irreversible inhibitor design, were attached to one of highest ranking reversible inhibitors 
we have synthesized (Scheme 5.2), they were screened for their inactivation activities. An 
irreversible inhibitor which has fluorosulfonylbenzoate group can inactivate all the T6PPs 
we tested. It is possible that the fluorosulfonylbenzoate can selectively react with active 
residues in the interface between cap and core domains of the T6PPs. To directly 
demonstrate that inhibitor 26 inactivates the T6PPs by covalent modification, we analyzed 
T6PPs treated with or without 26 using mass spectrometry. It shows that this compound 
lead to covalent labelling of the enzyme within the enzyme substrate binding site residues. 
This results are promising for the discovery of broad-range anthelmintic and antibacterial 
drugs. 
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Scheme 5.2. Structure-based covalent inhibitor design using trehalose-6-sulfate, 4-
n-Octyl phenyl- glucopyranoside 6-sulfate and phenyl a-D glucopyranoside 6-sulfate 
as the platform. 
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5.3. Results  
5.3.1 Synthesis of T6PP irreversible inhibitors  
         The routes utilized for preparation of the members of the T6PP irreversible inhibitor 
library, displayed in Schemes 5.3-5.5 below and described completely in the Experimental, 
begin with either commercially available or previously synthesized starting materials. Each 
substance was shown to be >95% pure by using NMR spectroscopy. 
 
 
 
 
 
Scheme 5.3. Synthesis of T6S analogs irreversible inhibitors 4, 5, 6, 9. 
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Scheme 5.4. Synthesis of phenyl -D glucopyranoside 6-sulfate analogs 
irreversible inhibitors 13, 14, 15, 16, 17. 
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5.3.2 Biological activity of irreversible inhibitors 
5.3.2.1 Screening the irreversible inhibitors’ inactivation and inhibition activities on 
T6PPs 
            In order to get their inhibitory information, I set up a HTS assay to screen the 
inhibitors on the T6PPs. In general, In an incubation reaction mixture containing: T6PP, 
Scheme 5.5. Synthesis of 4-n-Octyl phenylD glucopyranoside 6-sulfate 
analogs irreversible inhibitors 26, 28, 30, 31. 
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with inhibitor or without inhibitor (control), it was incubated at room temperature for half 
hour, then took 5 μL of this reaction mixture to a 96 well plate, each well contains 45 μL 
reaction mixture: buffer, [T6P] = Km. The reaction mixture was sit at room temperature 
for 5 min, then 100 μL biomol green dye (Enzo Life science). And the resulting mixture 
was incubated at room temperature for 30 min to allow development of the green color, 
and measured OD620nm on a microtiter-plate reader. The percentage inactivation was 
calculated using the ratio of OD620nm’ / OD620nm, where OD620nm’ is the absorption of the 
reaction mixture with inhibitor, and the OD620nm is the absorption without inhibitor.  The 
inhibition constants were measured using Enzchek phosphate assay kit (Life Technologies). 
For the quick inhibition constants measurements, when the initial reaction rate with Ki 
inhibitor is half of that rate without inhibitor when the substrate concentration is Km. The 
following is their inhibitory results:  
a : Incubation reaction conditions: T6PP (1 eq), inhibitors (200 eq), incubated at r.t. for 30 min. 
b :Incubation reaction conditions: As-T6PP (1 eq), inhibitors (25 eq), incubated at r.t. for 30 min. 
c : Incubation reaction conditions: Mt-T6PP (1 eq), inhibitors (300 eq), incubated at r.t. for 30 min. 
d: Incubation reaction conditions: St-T6PP (1 eq), inhibitors (40 eq), incubated at r.t. for 30 min. 
Background colors: percentage of inactivation. 
No background: no inactivation observed. 
Yellow background: less than 20 % activity lost after 1 hour incubation. 
Orange background: more than 20 % and less than 80% activity lost after 1 hour incubation. 
Red: more than 80% activity lost after 1 hour incubation. 
 
Table 5.1. HTS for inhibitors’ inactivation activities on T6PPS and reversible 
inhibition constants (Kis). 
Enzyme Inhibition Constant (KI) and Relative Activity after Incubation 
 5 4 9 6 14 15 13 17 16 31 30 28 26 
Bm-T6PPa > 1 mM 1 mM 1 mM 1 mM > 1 mM 0.04 mM None 0.5 mM 1 mM 0.02 mM 0.1 mM 0.1 mM 0.02 mM 
As-T6PP b > 1 mM > 1 mM 1 mM > 1 mM > 1 mM 0.2 mM 1 mM 1 mM > 1 mM 0.2 mM 0.2 mM > 0.2 mM 0.2 mM 
Mt-T6PP c > 1 mM > 1 mM > 1 mM None None None > 1 mM > 1 mM None 0.4 mM 0.4 mM 0.2 mM 0.05 mM 
Sb-T6PP a None None None None 0.5 mM 0.017 mM 1 mM 0.33 mM 1 mM 0.017 mM 0.008 mM 0.033 mM 0.013 mM 
St-T6PP d None None None None 1 mM 0.08 mM > 2 mM 0.4 mM > 1 mM 0.1 mM 0. 1mM 0.2 mM 0.01 mM 
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          As we can see in table 5.1, some inhibitors are neither reversible inhibitors nor 
irreversible inhibitors, such as: 5, 6, 9. Inhibitor 4 can selectively inactivate Mt-T6PP, 
however, it shows low binding affinity to this enzyme. Inhibitors 13, 14, 16, 17, 28, 30, 31 
show moderate inactivation activities on some of the T6PPs, they may selectivity react with 
some poorly conserved residues in T6PPs. Both 15 and 26 can inactivate T6PPs we have 
tested, however, inhibitor 15 shows poor binding affinity on Mt-T6PP. Then inhibitor 26 
was selected for further characterization of its inactivation mechanism. 
 
5.3.2.2 Kinetic analysis of T6PPs inactivation by 26. 
        In general, the action of a target-specific covalent inhibitor can be described by the 
mechanism shown below: 
 
           It occurs at two steps in the inhibition: the first step is the compound (I) binds to the 
target protein (E) non-covalently, and places its moderately reactive electrophile close to a 
specific nucleophile on the protein; the second step is that the resulting complex (E·I) then 
undergoes specific bond formation, which gives rise to the inhibited complex (E-I). 
           Incubation of 26 with T6PPs, results in a time- and concentration-dependent loss of 
phosphatase activity (Figs 5.1-5, a). The simplest kinetic scheme consistent with the data 
Scheme 5.6. General inactivation mechanism. 
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is reversible binding of the inactivator to the enzyme active sit to give a Michaelis complex 
(E·I). The stability of this complex is governed by a dissociation constant (Ki) and a 
chemical inactivation step (Kinact) (scheme 7). Extensive dialysis and buffer exchange of 
the reaction mixture failed to restore enzyme activities, which also suggests the inactivation 
of the T6PPs by 26 is irreversible. We also found that the rate of inactivation decreased in 
the presence of the competitive inhibitor trehalose-6-sulfate (Figs 5.1-5, b), indicating the 
inactivation is driven by action occurring at the enzymatic active site, these results also 
suggest that 26 inactivation action involves at least two steps: binding to the T6PPs active 
site, followed by covalent modification of active site residue(s). Analysis of pseudo-first-
order rate constant (Appendix A5.10) as a function of inhibitor concentration reveals a 
hyperbolic curve, yielding values for the binding constant Ki and inactivation rate constant 
kinact (Table 5.2). 
 
 
 
 
 
Table 5.2. Kinetic analyses T6PPs’ inactivation by 26 at 25 ℃ and pH 7.5. 
T6PP Source kinact (min-1) KI (μM) kinact/KI (M-1min-1) 
Ascaris suum 0.12±0.02 332±87 3.6×102  
Brugia malayi 0.11±0.01 85±18 1.3×103  
Mycobacterium tuberculosis 0.33±0.07 310±80 1.1×103  
Shigella boydii 0.42±0.09 252±62 1.7×103  
Salmonella typhimurium  0.053±0.009 242±48 2.2×102 
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Figure 5.2. Kinetic analysis of Bm-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26 
mediate Bm-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Bm-T6PP inactivation by T6S. Bm -T6PP (1 μM) was 
incubated with 50 μM 26 in the presence or absence of 200 μM T6S, respectively (c) Concentration dependence of the pseudo-
first-order rate constants kobs for 26 mediated Bm-T6PP inactivation. The points are experimental and the line connecting them 
is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI  and the inactivation rate 
constant kinact of 86 μM and 0.11 min
-1, respectively.  
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Figure 5.3. Kinetic analysis of Mt-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26 
mediate Mt-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Mt -T6PP inactivation by T6S. Mt-T6PP (1 μM) was 
incubated with 50 μM 26 in the presence or absence of 180 μM T6S, respectively (c) Concentration dependence of the pseudo-
first-order rate constants kobs for 26 mediated Mt-T6PP inactivation. The points are experimental and the line connecting them is 
the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI  and the inactivation rate constant 
kinact of 310 μM and 0.33 min
-1, respectively.  
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Figure 5.1. Kinetic analysis of As-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26 
mediate As-T6PP (1 μM) inactivation. (b) Protection of 26 mediated As-T6PP inactivation by T6S. As-T6PP (1 μM) was 
incubated with 120 μM 26 in the presence or absence of 100 μM T6S, respectively (c) Concentration dependence of the pseudo-
first-order rate constants kobs for 26 mediated As-T6PP inactivation. The points are experimental and the line connecting them 
is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI  and the inactivation rate 
constant kinact of 332 μM and 0.12 min
-1, respectively.  
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5.3.2.3 Mass spectrometry analysis of T6PPs inactivation by 26. 
          In order to directly demonstrate that inhibitor 26 inactivates the T6PPs by covalent 
modification, I analyzed T6PPs treated with or without 26 using mass spectrometry. In the 
case of Mt-T6PP, the mass of unmodified Mt-T6PP measured by ESI mass spectrometer 
was 44052 Da (Figue 5.6, left), which is consistent with the theoretical value (44051 Da). 
Figure 5.4. Kinetic analysis of Sb-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26 
mediate Sb-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Sb-T6PP inactivation by T6S. Sb-T6PP (1 μM) was 
incubated with 30 μM 26 in the presence or absence of 660 μM T6S, respectively. (c) Concentration dependence of the pseudo-
first-order rate constants kobs for 26 mediated Sb-T6PP inactivation. The points are experimental and the line connecting them is 
the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI  and the inactivation rate 
constant kinact of 252 μM and 0.42 min
-1, respectively.  
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Figure 5.5. Kinetic analysis of St-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 
26 mediate St-T6PP (5.7 μM) inactivation. (b) Protection of 26 mediated St-T6PP inactivation by T6S. St-T6PP (5.7 μM) 
was incubated with 80 μM 26 in the presence or absence of 400 μM T6S, respectively. (c) Concentration dependence of 
the pseudo-first-order rate constants kobs for 26 mediated St-T6PP inactivation. The points are experimental and the line 
connecting them is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI  and 
the inactivation rate constant kinact of 242 μM and 0.053 min
-1, respectively.  
 
T im e  (m in )
R
e
la
ti
v
e
 A
c
ti
v
it
y
0 2 0 4 0 6 0 8 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
I  (μ M )
R
e
la
t
iv
e
 A
c
ti
v
it
y
0 2 0 4 0 6 0 8 0 1 0 0
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
T im e  (m in )
R
e
la
t
iv
e
 A
c
t
iv
it
y
0 3 0 6 0 9 0 1 2 0 1 5 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
a                                                 b                                               c 
  
145 
 
Mt-T6PP treated with 26 showed an altered mass of 44666 Da (Figue 5.6, right). This 
corresponds to a mass difference of 614 Da (Table 5.2), consistent with the formation of a 
sulfide covalent adduct between Mt-T6PP and 26 (The theoretical mass shift is 614 Da). 
 
 
 
 
 
Figure 5.6. Mass spectrometry analysis of Mt-T6PP inactivation by 26. ESI mass 
spectra of Mt-T6PP treated with (right) or without (left) 26. 
Figure 5.7. Mass spectrometry analysis of Sb-T6PP inactivation by 26. ESI mass 
spectra of Sb-T6PP treated with (right) or without (left) 26. 
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T6PP Source (Theoretical Mass 
(Da)) 
Unmodified 
(Da) 
Modified 
(Da) 
Mass Difference 
(Da) 
Brugia malayi (57450) 57448 58060 612  
Mycobacterium tuberculosis 
(44052) 
44052 44666 614  
Shigella boydii (31298) 
31297, 31475a 
31912, 
32089a 
615, 616a 
Salmonella typhimurium (31577) 
31576, 31754a 
32191, 
32209a   
615, 615a 
Figure 5.8. Mass spectrometry analysis of Bm-T6PP inactivation by 26. ESI mass 
spectra of Bm-T6PP treated with 26. 
Figure 5.9. Mass spectrometry analysis of St-T6PP inactivation by 26. ESI mass 
spectra of St-T6PP treated with 26. 
Table 5.3. Mass of covalent modification of T6PPs by 26 
a : The protein has been modified by alpha-N-6-phosphogluconoylation of a "his tag" with an extra mass of 178             
Da in the fusion protein.  
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5.3.3. Identification of modified residues by compound 26. 
           In order to explore the mechanism of T6PPs inactivation mediated by compound 26, 
we need to determine which residue reacted with the sulfonyl fluoride of compound 26. 
Base on the binding model of Bm-T6PP with T6P substrate in Figure 5.10 [18], there are 
several residues which may interact with the substrate D336, R337, K334, Q332, and Y221. 
However, the residue Y221 is far away from the trehalose unit, it is difficult for it to contact 
with sulfonyl fluoride group of compound 26. As previously reported, sulfonyl fluoride can 
modify reactive serines, context-specific threonine, lysine, tyrosine, cysteine and histidine 
residues [19]. Thus residue K334 is highly possible to be modified by compound 26. In 
 
 
Order to confirm this hypothesis, we analyzed Bm-T6PP-K334A mutant [18] treated with 
or without 26 using mass spectrometry. The results shown in Figure 5.11 indicate that 
compound 26 is unable to modify Bm-T6PP-K334A mutant, consistent with the formation 
Figure 5.10 Substrate interacting residues in B. malayi analyzed by mutagenesis and kinetic. 
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of a covalent adduct between Bm-T6PP and 26 involving the Lys334 residue. 
 
 
 
               
            Interestingly, Lys334 in Bm-T6PP is highly conserved in nematode and bateria 
Figure 5.11 Mass spectrometry analysis of the Bm-T6PP Lys334 to Ala mutant (1 μM) in 
the presence and absence of 20 μM 26 under the same incubation conditions used for the 
wild type enzyme. The ESI mass spectra of Bm-T6PP-K334A treated with (bottom) or 
without (top) 26. 
Figure 5.12 Sequence alignments of nematode and bactera T6PP enzymes. Sb (Shigella boydii); 
St (Salmonella typhimurium); Mt (Mycobacterium tuberculosis); Bm (Brugia malayi); 
As (Ascaris suum). The Lys highlighted in red is highly conserved. 
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T6PPs base on the sequennce alignments(Figure 5.12). In order to further confirm that 
compound 26 selectively react with highly conserved Lys in T6PPs, we analyzed Mt-
T6PP-K253A mutant (chapter 3) treated with or without 26 using mass spectrometry 
(Figure 5.13). We got the same results as for Bm-T6PP-K253A, the mutant Mt-T6PP-
K253A could be modified by compound 26 under the same incubation conditions used 
for the wild type enzyme. 
 
5.3.4. Molecular Modeling 
            In order to better to understand how the compound 26 inactivate, molecular docking 
Figure 5.13 Mass spectrometry analysis of the Mt-T6PP Lys253 to Ala mutant (1 μM) in the 
presence and absence of 20 μM 26 under the same incubation conditions used for the wild 
type enzyme. The ESI mass spectra of Mt-T6PP-K253A treated with (bottom) or without 
(top) 26. 
  
150 
 
studies were performed on this compound with Bm-T6PP by using AutoDock Vina.          
Bm-T6PP (PDB ID: 4OFZ) is in complex withe Mg2+ ions required for catalytic activity. 
According to docking results (Figure 5.14), 26 sits in the interface of cap and catalytic 
domains. The phosphate mimic sulfate group sits in the phosphate binding site, and the 4-
n-Octyl phenyl hydrophobic group is sitting in the hydrophobic pocket of Bm-T6PP. 
 
Figure 5.14. Docking model generated pose of 26 bound to Bm-T6PP. 
Hydrophobicity surface: dodger blue for the most hydrophilic, to white, to 
orange red for the most hydrophobic. 
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             From Figure 5.15, we can see the cofactor Mg2+ is coordinated by the carboxylate 
group of the loop 1 Asp213 nucleophile and Asp424 on loop 4, and sulfate oxygen anion 
of the inhibitor 26. The Mg2+ functions to prevent charge repulsion between the sulfate and 
the Asp213, Asp424. Besides coordination of the metal center, additional key interactions 
are established by compound 26 within the active site.  The sulfate warhead forms 
hydrogen binding with Lys398 and Tyr221 and Thr425. And the 4 position hydroxyl group 
can interact with Ser427 via hydrogen bond. More importantly, the 4-n-octyl-phenyl group 
of 26 establishes hydrophobic contacts with the hydrophobic side chains of Leu383, Val 
345, Tyr 221 and Tyr225 in order to increase the binding affinity. In the cap domain, there 
are several hydrogen bond formed with the sulfonyl fluoride warhead group (Figure 5.14, 
right). In the inactivation reaction, Lys334 was deprotonated by Glu383, and then 
Figure 5.15.  Binding mode of compound 26 (light blue) within the Bm-T6PP 
substrate binding site. 
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nucleophilic attack sulfonyl fluoride which was activated by Gln332 via hydrogen bonding 
(Figure 5.16) to form covalent adduct. 
 
 
 
 
5.3.4 Inactivation specificity of 26. 
           In order to test the inactivation specificity by 26, I tested its inactivation activities 
on several sugar phosphatases. Yibv [19], which is from E. coli, can hydrolyze a wide scope 
of sugar phosphates, substrates like glucose-6-phosphate, imido-di-phosphate, fructose-1-
phophate, ribose-5-phosphate, acetyl-phosphate, glycerol-1-phospahte, glycerol-2-
phospahte. BT1713 [20], which is from Bacteroides thetaiotaomicron, is a 2-keto-3-deoxy-
D-glycero-D-galacto-9-phosphonononic acid (KDN-9-P) phosphatase in the biosynthetic 
pathway of the 9-carbon alpha-keto acid, 2-keto-3-deoxy-D-glycero-D-galactonononic 
acid (KDN). It can also hydrolyze 2-keto-3-deoxy-8-phospho-d-manno-octulosonicacid 
(KDO-8-P), N-acetylneuraminate-9-phosphate (Neu5Ac-9-P), pNPP, glucose-6-phosphate, 
Figure 5.16.  Proposed mechanism of 26 mediated Bm-T6PP inactivation. 
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PEP, tyrosine phosphate, and gluconate-6-phosphate. The other enzyme that we tested is 
GmhB (EFI 501036) [21], from Pseudomonas putida KT2440, is a D,D-heptose 1,7-
bisphosphate phosphatase, it can convert the D-glycero-beta-D-manno-heptose 1,7-
bisphosphate intermediate into D-glycero-beta-D-manno-heptose 1-phosphate. D-
Fructose-1,6-bisphosphate is also its substrate. I didn’t observe significant inactivation in 
the presence of 30 eq of 26 (Figue 5.17). 
 
 
5.5 Conclusion 
          Trehalose -6-phosphate phosphatase involved in the biosynthesis of trehalose, one 
of the important molecule that exist in a wide variety of organisms to support cell survival 
by functioning as a fuel, a metabolic regulator or a protectant against environmental stress. 
T6PP is a potential drug target in pathogenic bacteria and fungi as well as in parasitic 
nematodes. Here, we describe the discovery of a novel class of covalent inhibitors that 
broadly inhibit T6PP through the generation of a reactive sulfonyl fluoride group within 
their T6P substrate binding site. Until the discovery of this compound, there were no 
generally applicable irreversible inhibitors for T6PP. The reactive sulfonyl fluoride 
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Figure 5.17. Inactivation specificity of 26. Incubation conditions: In 1 mL reaction mixture, containing 1 eq enzyme 
(BT1713, or GmhB, or Yibv), 30 eq inhibitor 26 in a buffer of 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT, 
5% glycerol. Their catalytic hydrolysis of sugar phosphate activity were measured by using EnzChek Phosphate Assay. The 
substrates that were used: KDN-9-P for BT1713, D-Fructose-1,6-bisphosphate for GmhB, and ribose-5-phosphate for Yibv. 
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primarily remain localized within the interface between the core and cap domains 
(substrate binding site), since its inactivation activity decreased in the presence of 
reversible competitive T6PP inhibitor T6S. No significant inactivation on other sugar 
phosphatases were observed show that this inhibitor has its selective inhibition on T6PPs. 
This inhibitor will serve as powerful research tools for further exploration of T6PP drug 
target. In addition, these inhibitors will serve as starting points for the generation of T6PP-
selective inhibitors through systematic modification of their aryl substituents to take 
advantage of the unique active site topologies of T6PPs. These observation highlight the 
potential for developing broad-range anthelmintic and antibacterial therapeutics employing 
targeting this highly conserved Lys may be possible.  
 
5.5 Material and Methods 
5.5.1 Inhibitor Synthesis 
        General. Except when specified, all solvents and reagents were purchased and used 
without further purification. Analytical thin-layer chromatography (TLC) was performed 
on silica gel plates containing F254 fluorescence indicator and column chromatography was 
performed using the indicated eluants on silica gel (230-400 mesh). 1H (300 MHz), 13C 
NMR (75 MHz), and 31P (121.5 MHz) NMR spectra were recorded on Bruker Avance III 
300 spectrometers. 1H, 13C and 31P NMR data are reported as follows: for 1H NMR 
chemical shifts are reported in ppm relative to HDO, multiplicities are given as s = singlet, 
d = doublet, t = triplet, q = quartet, td = triplet of doublets, br = broad signal, m = multiplet, 
and coupling constant (J) are in Hz; 13C NMR chemical shifts are reported in ppm relative 
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to NH4HCO3 as a standard; 
31P NMR chemical shifts are reported in ppm relative to 50% 
aq H3PO4 as a standard.  
                               
       6-O-vinyl sulfonate-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-α,α-trehalose (2) and 
6,6’ Di-O-vinyl sulfonate-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-α,α-trehalose (3). 
To a solution of 11 (1.2 g, 1.55 mmol) in anhydrous dichloromethane (9 mL) at 0 ℃ was 
added DIPEA (1.2 g, 9.3 mmol). 2-chloroethane-sulfonyl chloride (0.33 g, 1.86 mmol) was 
added over half hour. The resulting solution was stirred at 0 ℃ for 4 h and concentrated in 
vacuo, giving a residue that was subjected to silica gel chromatograph to give 0.52 g (34%) 
of 2 and 0.41 g (27%) of 3. 
2: 1H NMR (300 MHz, CDCl3) 6.55 (dd, J1 = 9.6 Hz, J2 = 16.8 Hz, 1H), 6.40 (d, J 
= 16.8 Hz, 1H), 6.11 (dd, J1 = 9.6 Hz, J2 = 4.4 Hz, 1H), 4.89 (d, J = 3.0 Hz, 2H), 4.20-4.19 
(m, 2H), 4.03-4.0 (m, 1H), 3.91-3.89 (m, 3H), 3.72-3.68 (m, 2H), 3.50-3.40 (m, 4H), 1.73 
(br, 1H), 0.17-0.12 (m, 54H). 13C NMR (75 MHz, CDCl3) 132.7, 130.1, 94.9, 94.7, 73.5, 
73.2, 72.9, 72.6, 71.6, 71.5, 70.8, 69.6, 61.7, 1.13, 1.07, 0.98, 0.28, 0.21. 
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3: 1H NMR (300 MHz, CDCl3) 6.54 (dd, J1 = 9.6 Hz, J2 = 16.5 Hz, 2H), 6.40 (d, J 
= 16.5 Hz, 2H), 6.13 (d, J = 9.6 Hz, 2H), 4.88 (d, J = 3.0 Hz, 2H), 4.20-4.19 (m, 4H), 4.03-
3.98 (m, 2H), 3.86 (t, J = 9.0 Hz, 2H), 3.45-3.40 (m, 4H), 0.16-0.12 (m, 54H). 13C NMR 
(75 MHz, CDCl3) 132.6, 130.2, 94.8, 73.4, 72.6, 71.6, 70.9, 69.5, 1.15, 1.07, 0.29. 
  6-O-vinyl sulfonate-α,α-trehalose (4). 2 (200 mg, 0.21 mmol) was dissolved in a 
mixture of TFA/THF/H2O (8/17/3, V/V/V, 2.5 mL), The resulting solution was stirred at 
r.t. for 1 h and concentrated in vacuo, giving a residue that was subjected to silica gel 
chromatograph to give 108 mg (98%) of 4. 1H NMR (300 MHz, D2O) 6.80 (dd, J1 = 10.2 
Hz, J2 = 16.5 Hz, 1H), 6.50 (d, J = 16.5 Hz, 1H), 6.37 (d, J = 10.2 Hz, 1H), 5.19 (d, J = 3.9 
Hz, 1H), 5.16 (d, J = 3.9 Hz, 1H), 4.44-4.43 (m, 2H), 4.07-4.0 (m, 1H), 3.87-3.73 (m, 5H), 
3.67-3.60 (m, 2H), 3.51-3.43 (m, 2H). 13C NMR (75 MHz, D2O) 133.1, 130.5, 93.6, 93.4, 
72.5, 72.3, 72.2, 70.9, 70.8, 69.7, 69.6, 69.1, 60.5. HRMS (ESI+) calcd for C14H24O13S 
[M+Na]+ m/z 455.0830, found 455.0836. 
  6,6’ Di-O-vinyl sulfonate-α,α-trehalose (5). This substance was prepared from 3 
using the same procedure as that for 4. Yield 99 %. 1H NMR (300 MHz, D2O) 6.79 (dd, J1 
= 9.9 Hz, J2 = 16.8 Hz, 2H), 6.50 (d, J = 16.8 Hz, 2H), 6.36 (d, J = 9.9 Hz, 2H), 5.16 (d, J 
= 3.6 Hz, 2H), 4.44-4.43 (m, 4H), 4.14-4.02 (m, 2H), 3.83 (t, J = 9.6 Hz, 2H), 3.64 (dd, J1 
= 3.6 Hz, J2 = 10.2 Hz, 2H), 3.48 (t, J = 9.6 Hz, 2H). 
13C NMR (75 MHz, D2O) 133.1, 
130.5, 93.8, 72.4, 70.7, 69.8, 69.6, 69.1. HRMS (ESI+) calcd for C16H25O15S2 [M+Na]+ m/z 
545.0611, found 545.0613. 
   6-O-vinyl sulfonate-6’-sulfate-α,α-trehalose (6). To a solution of compound 3 
(640 mg, 0.74 mmol) in anhydrous pyridine (20 mL) at 0 ℃，was added a solution of 
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SO3.pyridine (141 mg, 0.89 mmol) in 1 mL anhydrous pyridine, The resulting solution was 
warmed to room temperature and stirred for 12 h, then concentrated in vacuo, the resulting 
residue was dissolved in a mixture of TFA/THF/H2O (8/17/3, V/V/V, 1 mL), The resulting 
solution was stirred at r.t. for 1 h and concentrated in vacuo giving a residue that was 
subjected to silica gel chromatograph to give 82 mg (22%) of 6. 1H NMR (300 MHz, D2O) 
6.80 (dd, J1 = 9.9 Hz, J2 = 16.5 Hz, 1H), 6.52 (d, J = 16.5 Hz, 1H), 6.38 (d, J = 9.9 Hz, 1H), 
5.20 (d, J = 3.6 Hz, 1H), 5.16 (d, J = 3.6 Hz, 1H), 4.47-4.44 (m, 2H), 4.28-4.25 (m, 2H), 
4.08-4.00 (m, 2H), 3.85 (t, J = 9.6 Hz, 2H), 3.67 (dd, J1 = 3.6 Hz, J2 = 9.9 Hz, 2H), 3.55-
3.46 (m, 2H). 13C NMR (75 MHz, D2O) 133.1, 130.5, 93.8, 93.7, 72.4, 72.3, 70.7, 70.3, 
69.8, 69.6, 69.3, 69.2, 66.9. HRMS (ESI-) calcd for C14H23O16S2 [M]- m/z 511.0428, found 
511.0411. 
 
 
 
   6-O-(Ethylphosphorylfluoro)-2,3,4,2',3',4,6’-hepta-O-benzyl-α,α-D-trehalose 
(8).3 To a solution of compound 72 (0.47 g, 0.48 mmol) in anhydrous pyridine (10 mL), 
was added ethylphosphonic dichloride (0.71 g, 4.8 mmol). The resulting solution was 
stirred at r.t. overnight. The reaction mixture was concentrated under reduced pressure and 
the resulting residue was dissolved in a mixture of dichloromethane and H2O (5 mL/10 
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mL), and stirred at r.t. for 1 hour, then acidified with 1 N HCl, and extracted with 
dichloromethane, dried over Na2SO4 and concentrated in vacuo, giving a residue, which 
was dissolved in anhydrous DMF under argon atmosphere, and fluoro-N,N,N',N'-bis 
(tetramethylene) formamidinium hexafluorophosphate (466 mg, 1.48 mmol) was added. 
Then DIPEA (190 mg, 1.48 mmol) was added, the resulting mixture was stirred overnight 
at room temperature and concentrated in vacuo, giving a residue that was subjected to silica 
gel chromatograph to give 387 mg (77%) of 8. 1H NMR (300 MHz, CDCl3) 7.38-7.16 (m, 
35H), 5.26 (d, J = 3.3 Hz, 1H), 5.24 (d, J = 3.9 Hz, 1H), 5.06 (d, J = 8.4 Hz, 1H), 5.02 (d, 
J = 8.4 Hz, 1H), 4.96-4.84 (m, 4H), 4.80-4.41 (m, 8H), 4.23-4.04 (m, 6H), 3.76-3.69 (m, 
1H), 3.65 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz, 1H), 3.60-3.52 (m, 3H), 3.45-3.40 (m, 1H), 1.96-
1.81 (m, 2H), 1.30-1.15 (m, 3H). 13C NMR (75 MHz, CDCl3) 138.9, 138.6, 138.4, 138.1, 
138.0, 137.9,128.5, 128.2, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 94.7, 94.5, 94.2, 94.0, 
81.9, 81.9, 81.6, 81.5, 79.5, 77.8, 77.4, 77.0, 75.8, 75.7, 75.3, 75.2, 73.6, 73.2, 73.1, 72.8, 
70.9, 69.6 (d, JC,P = 4.4 Hz ), 68.2, 65.2 (d, JC,P = 17.3 Hz ), 65.1 (d, JC,P = 17.5 Hz ), 17.8 
(dd, JC,P = 146.0 Hz, JC,F = 25.4 Hz), 17.7 (dd, JC,P = 144.5 Hz, JC,F = 25.4 Hz), 6.3, 6.2. 
31P NMR (121.5 MHz, D2O) 33.9 (d, JP,F = 1071.5 Hz), 33.3 (d, JP,F = 1077.9 Hz). 
   6-O-(Ethylphosphorylfluoro-α,α-D-trehalose (9). Compound 8 (367 mg, 0.34 
mmol) was dissolved in ethanol (35 mL). Pd/C (10% w/w, 700 mg) was added and the 
resulting suspension was stirred under an atmosphere of hydrogen (30 psi) at room 
temperature for 24 h. The catalyst Pd/C was removed by filtration and the reaction was 
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to 
give 107 mg (71%) of 9. 1H NMR (300 MHz, D2O) 5.20 (d, J = 3.6 Hz, 1H), 5.16 (d, J = 
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3.6 Hz, 1H), 4.45-4.39 (m, 2H), 4.01-3.96 (m, 1H), 3.88-3.71 (m, 5H), 3.66-3.60 (m, 2H), 
3.51 (dd, J1 = 9.6 Hz, J2 = 2.7 Hz, 1H), 3.43 (t, J = 9.6 Hz, 1H), 2.18-2.05 (m, 2H), 1.34-
1.04 (m, 3H). 13C NMR (75 MHz, D2O) 93.6, 93.5, 93.4, 72.6, 72.4, 72.3, 72.2, 71.0, 70.9, 
70.5, 70.4, 69.7, 69.2, 69.1, 69.0, 66.1, 66.0, 60.5, 16.6 (dd, JC,P = 138.6 Hz, JC,F = 18.4 
Hz), 16.5 (dd, JC,P = 140.2 Hz, JC,F = 18.0 Hz), 5.0, 4.9. 
31P NMR (121.5 MHz, D2O) 38.9 
(d, JP,F = 1075.6 Hz), 38.7 (d, JP,F = 1078.2 Hz). HRMS (ESI+) calcd for C14H26FO12P 
[M+Na]+ m/z 459.1044, found 459.1028. 
             
4-Nitrophenyl α-D-glucopyranoside-6-sulfate (11). To a solution of 4-Nitrophenyl α-D-
glucopyranoside (4.0 g, 13.3 mmol) in anhydrous DMF (40 mL) at -20 ℃，was added a 
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solution of SO3·pyridine (2.2 g, 14 mmol) in 4 mL anhydrous DMF, The resulting solution 
was stirred at r.t. for 12 h and concentrated in vacuo, giving a residue that was subjected to 
silica gel chromatograph to give 2.92 g (58%) of 11. 1H NMR (300 MHz, CD3OD) 8.23 (d, 
J = 9.3 Hz, 2H), 7.34 (d, J = 9.3 Hz, 2H), 5.64 (d, J = 3.6 Hz, 1H), 4.18-4.16 (m, 2H), 3.86 
(t, J = 9.3 Hz, 1H), 3.76 (td, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.65 (dd, J1 = 9.9 Hz, J2 = 3.6 
Hz, 1H), 3.50 (t, J = 9.9 Hz, 1H). 13C NMR (75 MHz, CD3OD) 163.6, 144.1, 126.7, 118.1, 
99.3, 74.5, 73.2, 72.9, 71.1, 67.8. 
    4-Aminophenyl α-D-glucopyranoside-6-sulfate (12). Compound 11 (2.4 g, 6.31 
mmol) was dissolved in methanol/H2O mixture (50 mL/25 mL). Pd/C (10% w/w, 300 mg) 
was added and the resulting suspension was stirred under an atmosphere of hydrogen (30 
psi) at room temperature for 3 h. The catalyst Pd/C was removed by filtration and the 
reaction was concentrated in vacuo, giving a residue that was subjected to silica gel 
chromatograph to give 2.2 g (99%) of 12. 1H NMR (300 MHz, D2O) 7.07 (d, J = 8.7 Hz, 
2H), 6.88 (d, J = 8.7 Hz, 1H), 5.45 (d, J = 3.6 Hz, 1H), 4.27-4.25 (m, 2H), 4.10-4.06 (m, 
1H), 3.92 (t, J = 9.6 Hz, 1H), 3.74 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.59 (dd, J1 = 9.9 Hz, 
J2 = 9.0 Hz, 1H). 13C NMR (75 MHz, D2O) 150.3, 140.5, 119.1, 118.1, 98.5, 72.9, 71.0, 
70.5, 69.1, 66.8. 
     4-Acrylaminophenyl α-D-glucopyranoside-6-sulfate (13). Compound 12 (105.3 
mg, 0.3 mmol) was dissolved in a THF/H2O mixture (1 mL/2 mL) and cooled to 0 ℃. 
Acryloyl chloride (54.3 mg, 0.6 mmol) and K2CO3 (165.6 mg, 1.2 mmol) were added, the 
resulting solution was warmed to room temperature and stirred overnight. The reaction was 
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to 
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give 73 mg (60%) of 13. 1H NMR (300 MHz, D2O) 7.48 (d, J = 9.0 Hz, 2H), 7.22 (d, J = 
9.0 Hz, 2H), 6.45 (dd, J1 = 17.1 Hz, J2 = 9.9 Hz, 1H), 6.33 (dd, J1 = 17.1 Hz, J2 = 1.8 Hz, 
1H), 5.88 (dd, J1 = 9.9 Hz, J2 = 1.8 Hz, 1H), 5.62 (d, J = 3.6 Hz, 1H), 4.25-4.24 (m, 2H), 
4.05-4.00 (m, 1H), 3.92 (t, J = 9.6 Hz, 1H), 3.77 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.59 
(dd, J1 = 9.9 Hz, J2 = 9.2 Hz, 1H). 13C NMR (75 MHz, D2O) 166.7, 153.5, 131.8, 130.2, 
128.2, 123.4, 117.8, 97.5, 72.7, 70.8, 70.4, 68.9, 66.7. HRMS (ESI-) calcd for C15H18NO10S 
[M]- m/z 404.0651, found 404.0651. 
   4-(3-(Flurosulfonyl)benzoylamino)phenyl α-D-Glucopyranoside-6-sulfate (14). 
Freshly prepared 14a4 (66.6 mg, 0.3 mmol) in THF (366 μL) was added dropwise to the 
stirred solution of compound 12 (116 mg, 0.33 mmol) and trimethylamine (104 μL, 0.75 
mmol) in anhydrous THF (8 mL) at 0 ℃ under argon atmosphere. The resulting solution 
was stirred at 40 ℃ for 12 h and concentrated in vacuo, giving a residue that was subjected 
to silica gel chromatograph to give 97 mg (60%) of 14. 1H NMR (300 MHz, CD3OD) 8.62 
(d, J = 1.5 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.27 (d, J = 7.8 Hz, 1H), 7.90 (t, J = 7.8 Hz, 
1H), 7.66 (dd, J1 = 6.9 Hz, J2 = 2.1 Hz, 2H), 7.22 (dd, J1 = 6.9 Hz, J2 = 2.1 Hz, 2H), 5.46 
(d, J = 3.6 Hz, 1H), 4.22-4.21 (m, 2H), 3.91-3.85 (m, 2H), 3.61 (dd, J1 = 9.6 Hz, J2 = 3.6 
Hz, 1H), 3.52 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz,, 1H). 13C NMR (75 MHz, CD3OD) 165.7, 155.8, 
138.3, 135.9, 135.0, 134.1, 132.0, 131.6, 128.6, 123.8, 118.7, 99.8, 74.7, 73.2, 72.6, 71.3, 
67.9. HRMS (ESI-) calcd for C19H19FNO12S2 [M]- m/z 536.0333, found 536.0333. 
    tert-Butyl 3-((octyloxy)sulfonyl)benzoate.5 To a solution of 1-octanol (916 mg, 
7.05 mmol) in anhydrous dichloromethane (2 mL), DIPEA (546 mg, 4.23 mmol) and 
DMAP (17.2 mg, 0.1 mmol) was added at 0 ℃ under argon atmosphere.  tert-Butyl 3-
  
162 
 
(chlorosulfonyl) benzoate5 (390 mg, 1.41 mmol) in anhydrous dichloromethane (1 mL) was 
added dropwise and stirred for 30 min at 0 ℃. The reaction mixture was warmed to room 
temperature and stirred for 24 h and concentrated in vacuo, giving a residue that was 
subjected to silica gel chromatograph to give 370 mg of tert-butyl 3-
((octyloxy)sulfonyl)benzoate (71 %). 1H NMR (300 MHz, CDCl3) 8.48 (s, 1H), 8.26 (d, J 
= 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 4.08 (t, J = 6.6 Hz, 2H), 
1.70-1.58 (m, 2H), 1.61 (s, 9H), 1.32-1.20 (m, 10 H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) 163.9, 137.0, 134.5, 133.6, 131.4, 129.4, 128.8, 82.6, 71.4, 31.8, 29.2, 
29.0, 28.3, 25.5, 22.7, 14.2. 
   3-((Octyloxy)sulfonyl)benzoic acid.5 To a solution of tert-Butyl 3-((octyloxy) 
sulfonyl)benzoate (300 mg, 0.81 mmol) in anhydrous dichloromethane (11 mL), TFA (3.7 
mL) was added. After stirring for 1 h at room temperature, the mixture was c concentrated 
in vacuo to give 245 mg of 3-((octyloxy)sulfonyl)benzoic acid (98%). 1H NMR (300 MHz, 
CDCl3) 8.65 (s, 1H), 8.40 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 7.5 Hz, 1H), 7.71 (t, J = 7.5 Hz, 
1H), 4.11 (t, J = 6.8 Hz, 2H), 1.70-1.65 (m, 2H), 1.26-1.20 (m, 10 H), 0.86 (t, J = 6.8 Hz, 
3H). 13C NMR (75 MHz, CDCl3) 169.6, 136.8, 135.2, 132.4, 131.0, 129.8, 129.5, 71.8, 
31.7, 29.0, 28.9, 25.3, 22.6, 14.0. 
   Octyl 3-(chlorocarbonyl)benzenesulfonate (15a). 3-((octyloxy)sulfonyl) benzoic 
acid (254 mg, 0.81 mmol) was dissolved in thionyl chloride ( 6 mL).The reaction mixture 
was heated under reflux for 4 h. The solvent was evaporated and then co-evaporated with 
anhydrous toluene to give unstable 15a, which was dissolved in anhydrous THF (1 mL) to 
make 0.81 M solution. 
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   4-(3-((octyloxy)sulfonyl)benzoylamino)phenyl α-D-Glucopyranoside-6- 
sulfate (15). Freshly prepared 15a (370 μL, 0.81M, 0.3 mmol) was added dropwise to the 
stirred solution of compound 12 (116 mg, 0.33 mmol) and trimethylamine (104 μL, 0.75 
mmol) in anhydrous THF (6 mL) at 0 ℃ under argon atmosphere. The resulting solution 
was stirred at 40 ℃ for 12 h and concentrated in vacuo, giving a residue that was subjected 
to silica gel chromatograph to give 86.5 mg (45%) of 15. 1H NMR (300 MHz, D2O) 8.30 
(s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.59 (t, J = 7.8 Hz, 1H), 7.32 (d, 
J = 8.4 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 5.41 (d, J = 3.0 Hz, 1H), 4.26-4.23 (m, 1H), 4.10-
4.07 (m, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.93-3.87 (m, 2H), 3.66-3.55 (m, 2H), 1.55-1.45 (m, 
2H), 1.09-1.05 (m, 10 H), 0.72 (t, J = 6.6 Hz, 3H) . 13C NMR (75 MHz, D2O) 164.9, 153.8, 
135.8, 135.3, 132.0, 130.3, 130.0, 126.8, 123.5, 117.6, 98.0, 72.8, 71.8, 71.2, 70.6, 68.8, 
66.5, 31.7, 29.0, 28.9, 28.7, 25.2, 22.5, 13.8. HRMS (ESI-) calcd for C27H36NO13S2 [M]- 
m/z 646.1628, found 646.1660. 
           4-(6-Bromohexanoylamino) phenyl α-D-Glucopyranoside-6-sulfate (16). A 
solution of compound 12 (105.3 mg, 0.3 mmol), 6-bromohexanoyl chloride (64.1 mg, 0.3 
mmol), triethylamine (209 μL, 1.5 mmol) in anhydrous THF (15 mL) was heated under 
reflux for 4 h under argon atmosphere. The reaction mixture was cooled to room 
temperature and concentrated in vacuo, giving a residue that was subjected to silica gel 
chromatograph to give 52 mg (33%) of 16. 1H NMR (300 MHz, D2O) 7.39 (d, J = 9.0 Hz, 
2H), 7.18 (d, J = 9.0 Hz, 2H), 5.57 (d, J = 3.6 Hz, 1H), 4.27-4.19 (m, 2H), 4.03-3.90 (m, 
2H), 3.75 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz 1H), 3.66-3.56 (m, 2H), 3.50 (t, J = 6.6 Hz, 1H), 
2.40 (t, J = 7.2 Hz, 2H), 1.90-1.77 (m, 2H), 1.75-1.64 (m, 2 H), 1.55-1.44 (m, 2 H). 13C 
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NMR (75 MHz, D2O) 175.4, 153.4, 131.8, 123.7, 117.7, 97.5, 72.7, 70.8, 70.4, 68.8, 66.5, 
45.3, 34.7, 31.5, 26.6, 24.3. HRMS (ESI-) calcd for C18H25BrNO10S [M]- m/z 526.0383, 
found 526.0378. 
         4-(2-Bromoacetylamino) phenyl α-D-Glucopyranoside-6-sulfate (17). To a 
solution of compound 12 (70.2 mg, 0.2 mmol) and triethylamine (27.8 μL, 0.2 mmol) in 
anhydrous dichloromethane (2.5 mL), was added 2-bromoacetic anhydride (114.3 mg, 0.44 
mmol) in one portion. The resulting solution was stirred at room temperature for 40 min 
and concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph 
to give 62 mg (66%) of 17. 1H NMR (300 MHz, CD3OD) 7.54 (d, J = 9.0 Hz, 2H), 7.18 (d, 
J = 9.0 Hz, 2H), 5.45 (d, J = 3.6 Hz, 1H), 4.24-4.23 (m, 2H), 4.01 (s, 2H), 3.92-3.86 (m, 
2H), 3.62 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz, 1H), 3.54 (dd, J1 = 9.6 Hz, J2 = 9.0 Hz, 1H). 13C 
NMR (75 MHz, CD3OD) 167.4, 155.5, 134.1, 122.7, 118.7, 99.7, 74.6, 73.2, 72.5, 71.2, 
67.8, 29.7. HRMS (ESI-) calcd for C14H18BrNO10S [M]- m/z 469.9757, found 469.9748. 
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   4-n-Octylphenyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy α-D-glucopyranoside (19) 
and 4-n-Octylphenyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy β-D-glucopyranoside (20). To 
a solution of  1,3,4,6-tetraacetate-2-azido-2-deoxy-D-glucopyranose 186 (3.56 g, 9.54 
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mmol) and 4-n-octylphenol (2.36 g, 11.45 mmol) in  anhydrous dichloromethane (50 ml) 
under argon at 0 °C was added BF3·Et2O (4.8 mL, 38.16 mmol). The mixture was stirred 
at 50 °C for 48 h, diluted with water and stirred for 15 min. The mixture was diluted with 
dichloromethane, washed with water, brine, and concentrated in vacuo, giving a residue 
that was subjected to silica gel chromatography, giving compound 19 (2.07 g, 42%) and 
compound 20 (1.29 g, 26%). 
19: 1H NMR (300 MHz, CDCl3) 7.11 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.7 Hz, 2H), 
5.69 (dd, J1 = 10.5 Hz, J2 = 9.3 Hz, 1H), 5.58 (d, J = 3.6 Hz, 1H), 5.13 (dd, J1 = 10.2 Hz, 
J2 = 9.3 Hz, 1H), 4.28 (dd, J1 = 12.3 Hz, J2 = 4.5 Hz, 1H), 4.20-4.14 (m, 1H), 4.05 (dd, J1 
= 12.3 Hz, J2 = 2.1 Hz, 1H), 3.44 (dd, J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 2.55 (t, J = 7.7, 2H), 
2.12 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H), 1.60-1.55 (m, 2H), 1.33-1.23 (m, 10H), 0.87 (t, J = 
6.8, 3H). 13C NMR (75 MHz, CDCl3) 170.5, 170.1, 169.8, 154.1, 138.1, 129.6, 116.6, 97.0, 
70.4, 68.5, 68.3, 61.7, 60.9, 35.2, 32.0, 31.7, 29.5, 29.3, 22.7, 20.8, 20.7, 20.7, 14.2. 
20: 1H NMR (300 MHz, CDCl3) 7.11 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 
5.08-4.91 (m, 2H), 4.90 (d, J = 8.1 Hz, 1H), 4.30 (dd, J1 = 12.3 Hz, J2 = 5.4 Hz, 1H), 4.14 
(dd, J1 = 12.3 Hz, J2 = 2.4 Hz, 1H), 3.83-3.75 (m, 2H), 2.56 (t, J = 10.8, 2H), 2.10 (s, 3H), 
2.08 (s, 3H), 2.03 (s, 3H), 1.60-1.55 (m, 2H), 1.30-1.26 (m, 10H), 0.87 (t, J = 6.8, 3H). 13C 
NMR (75 MHz, CDCl3) 170.6, 170.0, 169.7, 154.8, 138.4, 129.5, 117.1, 100.9, 72.5, 72.0, 
68.5, 63.6, 62.1, 35.2, 32.0, 31.7, 29.5, 29.3, 22.7, 20.8, 20.7, 14.2. 
  4-n-Octylphenyl-2-azido-2-deoxy α-D-glucopyranoside (21). To a solution of 
compound 19 (2.0 g, 3.85 mmol) in anhydrous methanol (40 mL), was added freshly 
prepared 0.1 M NaOMe solution in methanol (1.5 mL) dropwise. The resulting solution 
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was stirred at room temperature for 25 min, then quenched with 8 drops of acetic acid and 
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to 
give 1.36 g (90%) of 21. 1H NMR (300 MHz, CDCl3) 7.07 (d, J = 8.7 Hz, 2H), 6.98 (d, J 
= 8.7 Hz, 2H), 5.50 (d, J = 3.3 Hz, 1H), 5.11 (br, 2H), 4.29-4.23 (m, 1H), 3.98-3.80 (m, 
4H), 3.64 (br, 1H), 3.41 (dd, J1 = 10.5 Hz, J2 = 3.3 Hz, 1H), 2.53 (t, J = 7.8 Hz, 2H), 1.59-
1.54 (m, 2H), 1.29-1.27 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
154.5, 137.9, 129.6, 116.9, 97.7, 72.2, 71.6, 70.0, 62.7, 61.2, 35.3, 32.0, 31.8, 29.6, 29.5, 
29.4, 22.8, 14.2. 
4-n-Octylphenyl -2-amino-2-deoxy α-D-glucopyranoside (22). Compound 21 
(912 mg, 2.32 mmol) was dissolved in methanol (66 mL). Pd/C (10% w/w, 347 mg) was 
added and the resulting suspension was stirred under an atmosphere of hydrogen (16 psi) 
at room temperature for 2 h. The catalyst Pd/C was removed by filtration and the reaction 
was concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph 
to give 851 mg (99%) of 22. 1H NMR (300 MHz, CDCl3) 7.11-7.09 (m, 4H), 5.46 (d, J = 
3.6 Hz, 1H), 3.76-3.66 (m, 4H), 3.43 (t, J = 9.0 Hz, 1H), 2.78 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz, 
1H), 2.56 (t, J = 7.5 Hz, 2H), 1.61-1.57 (m, 2H), 1.33-1.30 (m, 10H), 0.91 (t, J = 6.8 Hz, 
3H). 13C NMR (75 MHz, CDCl3) 156.6, 138.2, 130.3, 118.1, 99.9, 76.0, 74.7, 71.7, 62.4, 
57.2, 36.1, 33.0, 32.9, 30.6, 30.4, 30.3, 23.7, 14.4. 
4-n-Octylphenyl-3,4,6-tri-O-trimethylsilyl-2-azido-2-deoxy α-D-glucopyra- 
noside (23). To a solution of compound 22 (0.84 g, 2.29 mmol) in dry pyridine (8.4 mmol) 
at 0 °C, was added a mixture of hexamethyldisilazane (1.48 g, 9.16 mmol) and 
chlorotrimethylsilane (3.98 g, 36.64 mmol) dropwise. The resulting solution was warmed 
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to room temperature and stirred overnight. The reaction was concentrated in vacuo, giving 
a residue that was subjected to silica gel chromatograph to give 1.18 g (88%) of 23. 1H 
NMR (300 MHz, CD3OD) 7.07 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 5.39 (d, J = 
3.3 Hz, 1H), 3.76-3.66 (m, 4H), 3.58 (t, J = 8.7 Hz, 1H), 2.75 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz, 
1H), 2.54 (t, J = 7.8 Hz, 2H), 1.60-1.55 (m, 2H), 1.30 (br, 2H) 1.30-1.27 (m, 10H), 0.88 (t, 
J = 6.8 Hz, 3H), 0.24 (s, 9H), 0.18 (s, 9H), 0.08 (s, 9H). 13C NMR (75 MHz, CD3OD) 155.2, 
137.0, 129.3, 117.2, 99.6, 78.0, 73.7, 72.0, 62.0, 57.1, 35.3, 32.1, 31.8, 29.6, 29.4, 22.8, 
14.3, 1.6, 1.0, -0.1. 
4-n-Octylphenyl-3,4,6-tri-O-trimethylsilyl-2-azido-2-deoxy β -D-glucopyra- 
noside (24). The target 24 was prepared starting with compound 20 using the same 
procedure as that for 23. Yield 83% over three steps. 1H NMR (300 MHz, CDCl3) 7.06 (d, 
J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 4.69 (d, J = 7.8 Hz, 1H), 3.82 (dd, J1 = 11.4 Hz, 
J2 = 2.1 Hz, 1H), 3.73 (dd, J1 = 11.4 Hz, J2 = 4.8 Hz, 1H), 3.61 (t, J = 9.0 Hz, 1H), 3.45 (t, 
J = 9.0 Hz, 1H), 3.32-3.27 (m, 1H), 2.93 (dd, J1 = 9.3 Hz, J2 = 8.1 Hz, 1H), 2.54 (t, J = 7.7 
Hz, 2H), 1.61-1.51 (m, 4H), 1.32-1.24 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H), 0.23 (s, 9H), 0.18 
(s, 9H), 0.08 (s, 9H),. 13C NMR (75 MHz, CDCl3) 156.0, 137.3, 129.3, 117.4, 103.0, 79.2, 
77.4, 71.7, 62.2, 58.0, 35.3, 32.1, 31.8, 29.7, 29.5, 29.4, 22.8, 14.3, 1.4, 1.0, -0.1. 
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4-n-Octylphenyl-2-(3-(flurosulfonyl)benzoylamino)-2-deoxy α-D-Glucopy- 
ranoside (25). To a solution of compound 23 (150 mg, 0.257 mmol), triethylamine (71.2 
μL, 0.514 mmol) in anhydrous dichloromethane (15 mL), was added a solution of 14a (97 
mg, 0.437 mmol) in anhydrous dichloromethane (2 mL) dropwise at room temperature. 
The resulting mixture was stirred for 4 h and concentrated in vacuo, giving a residue that 
was dissolved in a mixture of TFA/THF/H2O (0.4 mL/2.85 mL/0.15 mL) and stirred for 25 
min at room temperature. The reaction mixture was concentrated in vacuo, giving a residue 
that was subjected to silica gel chromatograph to give 103 mg (74%) of 25. 1H NMR (300 
MHz, CD3OD/CDCl3 (1/1, v/v)) 9.3 (d, J = 7.8 Hz, 1H), 8.6 (s, 1H), 8.33 (d, J = 7.8 Hz, 
1H), 8.22 (d, J = 7.8 Hz, 1H),7.83 (t, J = 7.8 Hz, 1H), 7.10-7.03 (m, 4H), 5.60 (d, J = 3.6 
Hz, 1H), 4.33-4.26 (m, 1H), 4.11 (dd, J1 = 10.8 Hz, J2 = 8.7 Hz, 1H), 3.85-3.74 (m, 3H), 
3.59 (t, J = 9.2 Hz, 1H), 2.53 (t, J = 7.5 Hz, 2H), 1.60-1.54 (m, 2H), 1.29-1.27 (m, 10H), 
0.89 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CD3OD/CDCl3 (1/1, v/v)) 168.3, 156.8, 138.4, 
137.8, 135.9, 134.6 (d, JC,F = 25.2 Hz), 132.0, 131.5, 130.4, 128.7, 118.1, 98.3, 74.6, 72.2, 
72.2, 62.4, 56.6, 36.1, 33.0, 32.8, 30.5, 30.3, 30.2, 23.7, 14.4. 
    4-n-Octylphenyl-2-(3-(flurosulfonyl)benzoylamino)-2-deoxy α-D-Glucopyran- 
oside-6-sulfate (26) This substance was prepared starting with compound 25 using the 
same procedure employed for the preparation of 11. Yield 63%. 1H NMR (300 MHz, 
CD3OD) 9.05 (d, J = 8.1 Hz, 1H), 8.57 (s, 1H), 8.34 (d, J = 7.8 Hz, 1H), 8.23 (d, J = 7.8 
Hz, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.11-7.03 (m, 4H), 5.57 (d, J = 3.6 Hz, 1H), 4.33-4.27 
(m, 3H), 4.10 (dd, J1 = 10.8 Hz, J2 = 8.7 Hz, 1H), 4.03-3.97 (m, 1H), 3.66 (t, J = 9.5 Hz, 
1H),  2.54 (t, J = 7.5 Hz, 2H), 1.60-1.57 (m, 2H), 1.30-1.28 (m, 10H), 0.90 (t, J = 6.8 Hz, 
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3H). 13C NMR (75 MHz, DMSO-d6) 166.0, 155.8, 137.5, 136.4, 136.1, 132.5 (d, JC,F = 
23.2 Hz), 131.7, 131.6, 130.1, 127.8, 118.0, 97.6, 72.2, 70.9, 70.5, 66.4, 55.7, 34.9, 31.8, 
31.6, 29.4, 29.2, 29.1, 22.7, 14.6. HRMS (ESI-) calcd for C27H35FNO11S2 [M]- m/z 
632.1636, found 632.1631. 
  4-n-Octylphenyl-2-(2-bromoacetylamino)-2-deoxy α-D-Glucopyranoside (27). 
To a solution of compound 23 (160 mg, 0.27 mmol), trimethylamine (65.1 μL, 0.47 mmol) 
in anhydrous dichloromethane (20 mL), was added a solution of 2-bromoacetic anhydride 
(121.2 mg, 0.47 mmol) in anhydrous dichloromethane (2 mL) dropwise at room 
temperature. The resulting mixture was stirred for 1.5 h and concentrated in vacuo, giving 
a residue that was dissolved in a mixture of TFA/THF/H2O (0.4 mL/4.85 mL/0.15 mL) and 
stirred for 30 min at room temperature. The reaction mixture was concentrated in vacuo, 
giving a residue that was subjected to silica gel chromatograph to give 130 mg (98%) of 
27. 1H NMR (300 MHz, CD3OD) 8.57 (d, J = 8.1 Hz, 1H), 7.12-7.04 (m, 4H), 5.45 (d, J = 
3.3 Hz, 1H), 4.08-4.03 (m, 1H), 3.98-3.87 (m, 3H), 3.82-3.72 (m, 3H), 3.55-3.47 (m, 1H), 
2.56 (t, J = 7.5 Hz, 2H), 1.59-1.56 (m, 2H), 1.32-1.30 (m, 10H), 0.93 (t, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CD3OD/CDCl3 (2/1, v/v)) 167.4, 154.6, 137.6, 129.3, 116.9, 96.8, 72.5, 
71.7, 70.3, 61.2, 54.2, 35.0, 31.8, 31.6, 29.4, 29.2, 28.4, 22.6, 13.9. 
         4-n-Octylphenyl-2-(2-bromoacetylamino)-2-deoxy α-D-Glucopyranoside-6-
sulfate (28). This substance was prepared starting with compound 27 using the same 
procedure employed for the preparation of 11. Yield 65%. 1H NMR (300 MHz, CD3OD)  
7.13-7.04 (m, 4H), 5.42 (d, J = 3.6 Hz, 1H), 4.25-4.23 (m, 2H), 4.06 (dd, J1 = 10.8 Hz, J2 
= 3.3 Hz, 1H) 3.98-3.86 (m, 4H), 3.58 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz, 1H), 2.57 (t, J = 7.7 
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Hz, 2H), 1.62-1.57 (m, 2H), 1.33-1.30 (m, 10H), 0.91 (t, J = 6.8 Hz, 3H). 13C NMR (75 
MHz, CD3OD/D2O (5/1, v/v)) 170.2, 156.4, 138.6, 130.4, 118.5, 98.4, 72.4, 72.1, 71.3, 
67.7, 55.7, 35.9, 32.8, 32.6, 30.3, 30.2, 30.0, 28.7, 23.5, 14.4. HRMS (ESI-) calcd for 
C22H33BrNO9S [M]- m/z 566.1059, found 566.1069. 
4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy α-D-Glucopyranoside (29). To 
a solution of compound 23 (130 mg, 0.22 mmol), triethylamine (92 μL, 0.66 mmol), 4-
DMAP (2.7 mg, 0.022 mmol) in anhydrous dichloromethane (1.5 mL), was added 2-
chloroethanesulfonyl chloride (51 mg, 0.31 mmol) dropwise over 30 min at 0 ℃. The 
resulting mixture was warmed to room temperature and stirred for 2 h. The reaction was 
diluted dichloromethane, washed with water and dried over Na2SO4 and concentrated in 
vacuo, giving a residue that was dissolved in a mixture of TFA/THF/H2O (0.4 mL/2.85 
mL/0.15 mL) and stirred for 30 min at room temperature. The reaction mixture was 
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to 
give 92 mg (92%) of 29. 1H NMR (300 MHz, CD3OD) 7.12-7.05 (m, 4H), 6.77 (dd, , J1 = 
16.5 Hz, J2 = 10.2 Hz, 1H ), 6.17 (d, J = 16.5 Hz, 1H), 5.82 (d, J = 10.2 Hz, 1H), 5.45 (d, 
J = 3.6 Hz, 1H), 3.85-3.70 (m, 4H), 3.47 (t, J = 8.3 Hz, 1H), 3.38-3.33 (m, 1H), 2.55 (t, J 
= 7.5 Hz, 2H), 1.61-1.56 (m, 2H), 1.32-1.29 (m, 10H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR 
(75 MHz, CD3OD) 156.5, 139.0, 138.3, 130.3, 125.2, 118.3, 99.7, 74.3, 72.7, 72.0, 62.3, 
59.3, 36.1, 33.0, 32.9, 30.5, 30.4, 30.3, 23.7, 14.2. 
           4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy α-D-Glucopyranoside-6- 
sulfate (30). This substance was prepared starting with compound 28 using the same 
procedure employed for the preparation of 11. Yield 79%. 1H NMR (300 MHz, CD3OD) 
  
173 
 
7.16-7.08 (m, 4H), 6.80 (dd, , J1 = 16.5 Hz, J2 = 10.2 Hz, 1H ), 6.21 (d, J = 16.5 Hz, 1H), 
5.87 (d, J = 10.2 Hz, 1H), 5.44 (d, J = 3.3 Hz, 1H), 4.26-4.24(m, 2H), 3.95-3.90 (m, 1H), 
3.86 (dd, J1 = 10.5 Hz, J2 = 9.0 Hz, 1H), 3.57 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz, 1H), 3.39 (dd, 
J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 2.59 (t, J = 7.7 Hz, 2H), 1.64-1.60 (m, 2H), 1.36-1.33 (m, 
10H), 0.93 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CD3OD) 156.6, 138.9, 138.4, 130.3, 
125.3, 118.4, 99.8, 72.4, 71.7, 67.8, 59.2, 36.1, 33.0, 32.8, 30.5, 30.4, 30.3, 23.7, 14.4. 
HRMS (ESI-) calcd for C22H34NO10S2 [M]- m/z 536.1624, found 536.1638. 
            4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy β-D-Glucopyranoside-6- 
sulfate (31). This substance was prepared starting with compound 24 using the same 
procedure employed for the preparation of 30. Yield 66% over 3 steps. 1H NMR (300 MHz, 
CD3OD) 7.14 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.88 (dd, J1 = 16.5 Hz, J2 = 
10.2 Hz, 1H ), 6.19 (d, J = 16.5 Hz, 1H), 5.87 (d, J = 10.2 Hz, 1H), 4.96 (d, J = 8.1 Hz, 
1H), 4.42 (dd, J1 = 10.8 Hz, J2 = 1.5 Hz, 1H), 4.21(dd, J1 = 10.8 Hz, J2 = 5.7 Hz, 1H), 3.72-
3.67 (m, 1H), 3.52-3.42 (m, 2H), 3.40-3.36 (m, 1H), 2.60 (t, J = 7.5 Hz, 2H), 1.64-1.61 (m, 
2H), 1.36-1.27 (m, 10H), 0.94 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CD3OD) 156.8, 
140.0, 138.1, 130.3, 124.2, 117.7, 101.0, 76.2, 75.8, 71.7, 68.1, 61.1, 36.1, 33.0, 32.8, 30.5, 
30.4, 30.3, 23.7, 14.4. HRMS (ESI-) calcd for C22H34NO10S2 [M]- m/z 536.1624, found 
536.1634. 
 
5.5.2 Reference for synthesis 
1. Sarpe, V.  A.; Kulkarni, S. S. Synthesis of Maradolipid. J. Org. Chem. 2011, 76, 
6866–6870. 
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2. Berndt, F.; Sajadi, M.; Ernsting, N. P.; Mahrwald, R. Covalent linkage of N-methyl-
6-oxyquinolinium betaine to trehalose. Carbohydr Res. 2011, 346, 2960–2964. 
3. Barry, C. S.; Backus, K. M.; Barry, III, C. E.; Davis, B. G. ESI-MS Assay of M. 
tuberculosis Cell Wall Antigen 85 Enzymes Permits Substrate Profiling and Design 
of a Mechanism-Based Inhibitor. J. Am. Chem. Soc., 2011, 133 (34), 13232–13235. 
4. Grimster, N. P.; Connelly, S.; Baranczak, A.; Dong, J.; Krasnova, L. B.; Sharpless, 
K. B.; Powers, E. T.; Wilson, I. A.; Kelly, J. W.  Aromatic Sulfonyl Fluorides 
Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while 
Affording a Fluorescent Conjugate. J. Am. Chem. Soc., 2013, 135 (15), 5656–5668. 
5. Masuya, T.; Murai, M.; Ifuku, K.; Morisaka, H.; Miyoshi, H. Site-Specific 
Chemical Labeling of Mitochondrial Respiratory Complex I through Ligand-
Directed Tosylate Chemistry. Biochemistry, 2014, 53 (14), 2307–2317. 
6. Yan, R.-B.; Yang, F.; Wu, Y.; Zhang, L.-H. and Ye, X.-S. An efficient and 
improved procedure for preparation of triflyl azide and application in catalytic 
diazotransfer reaction. Tetrahedron Letters, 2005, 46, 8993–8995. 
 
 
5.5.3 Expression and Purification of T6PPs. 
  All T6PPs mentioned were expressed in E.coli and purified as described in chapter 2. 
 
5.5.4 Kinetic Characterization of T6PPs Inactivation by 26. 
       Time and Concentration Dependence of T6PP Inactivation by 26. T6PP 
inactivation by 26 was studied at 25 ℃ and in the buffer containing: 50 mM Tris pH 7.5, 
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50 mM NaCl, 5 mM MgCl2, 1 mM DTT. Incubating enzyme with various concentrations 
of inactivator 26 in the buffer mentioned above and periodically measuring the activity of 
the enzyme by removing an aliquot (5μL) of the inactivation stock solution and adding it 
to EnzChek phosphate assay reaction mixture, which contains 1 mM MgCl2, 0.1 mM 
sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG in 50 mM 
Tris-HCl (pH 7.5). The enzyme activity was measured by using EnzChek phosphate assay 
kit which was described in chapter 4 in detail. The pseudo-first-order rate constant for 
inactivation (kobs) (Appendix A5.10) was derived from the slope of the plot of ln (t/o) vs 
t, where t is the velocity of the trehalose-6-phospahte hydrolysis reaction catalyzed by 
T6PP incubated with 26 for time (t) and o is the velocity of the trehalose-6-phospahte 
hydrolysis reaction catalyzed by T6PP in buffer. The resulting kobs values were plotted 
against 26 concentration. The data were fitted by using Graphpad Prism 6 to the equation 
kobs = (kinact[I]/(KI +[I]) to obtain KI and kinact values. 
           Trehalose-6-Sulfate (T6S) Partially Protect T6PP from Inhibitor 26 Mediated 
Inactivation. The effect of T6S, a reversible and competitive T6PP inhibitor, on inhibitor 
26-mediated T6PP inactivation was studied at 25 ℃ in a pH 7.0 buffer containing: 50 mM 
Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT. T6PP was incubated with 26 in the 
presence or absence of T6S respectively. At appropriate time intervals, aliquots 5μL were 
removed from the reaction and added into EnzChek phosphate assay reaction mixture 
containing: 1 mM MgCl2, 0.1 mM sodium azide 1.0 unit/mL purine nucleoside 
phosphorylase, and 0.2 mM MESG in 50 mM Tris-HCl (pH 7.5) for phosphatase activity 
measurements. 
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5.5.5 ES-MS Analysis of T6PP Modification by Inhibitor 26. 
           T6PPs were treated with or without 26 (10-20 eq) in a buffer containing 50 mM Tris 
pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT at room temperature for 30 minutes. Then 
the reaction mixture were transferred to amicon ultra centrifugal filters and exchanged with 
buffer 50 mM Tris 7.5 four times and concentrated for Mass spectrometry. 
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APPENDIX 
A.1 Published Collaborative Work 
A.1.1 Covalent docking predicts substrates for haloalkanoate dehalogenase 
superfamily phosphatases. 
London N, Farelli JD, Brown SD, Liu C, Huang H, Korczynska M, Al-Obaidi NF, 
Babbitt PC, Almo SC, Allen KN, Shoichet BK. 
Abstract 
Enzyme function prediction remains an important open problem. Though structure-
based modeling, such as metabolite docking, can identify substrates of some enzymes, it is 
ill-suited to reactions that progress through a covalent intermediate. Here we investigated 
the ability of covalent docking to identify substrates that pass through such a covalent 
intermediate, focusing particularly on the haloalkanoate dehalogenase superfamily. In 
retrospective assessments, covalent docking recapitulated substrate binding modes of 
known cocrystal structures and identified experimental substrates from a set of putative 
phosphorylated metabolites. In comparison, noncovalent docking of high-energy 
intermediates yielded nonproductive poses. In prospective predictions against seven 
enzymes, a substrate was identified for five. For one of those cases, a covalent docking 
prediction, confirmed by empirical screening, and combined with genomic context analysis, 
suggested the identity of the enzyme that catalyzes the orphan phosphatase reaction in the 
riboflavin biosynthetic pathway of Bacteroides. 
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A.1.2 Structure of the trehalose-6-phosphate phosphatase from Brugia malayi 
reveals key design principles for anthelmintic drugs. 
Farelli JD, Galvin BD, Li Z, Liu C, Aono M, Garland M, Hallett OE, Causey TB, Ali-
Reynolds A, Saltzberg DJ, Carlow CK, Dunaway-Mariano D, Allen KN. 
 
Abstract 
 
Parasitic nematodes are responsible for devastating illnesses that plague many of 
the world's poorest populations indigenous to the tropical areas of developing nations. 
Among these diseases is lymphatic filariasis, a major cause of permanent and long-term 
disability. Proteins essential to nematodes that do not have mammalian counterparts 
represent targets for therapeutic inhibitor discovery. One promising target is trehalose-6-
phosphate phosphatase (T6PP) from Brugia malayi. In the model nematode Caenorhabditis 
elegans, T6PP is essential for survival due to the toxic effect(s) of the accumulation of 
trehalose 6-phosphate. T6PP has also been shown to be essential in Mycobacterium 
tuberculosis. We determined the X-ray crystal structure of T6PP from B. malayi. The 
protein structure revealed a stabilizing N-terminal MIT-like domain and a catalytic C-
terminal C2B-type HAD phosphatase fold. Structure-guided mutagenesis, combined with 
kinetic analyses using a designed competitive inhibitor, trehalose 6-sulfate, identified five 
residues important for binding and catalysis. This structure-function analysis along with 
computational mapping provided the basis for the proposed model of the T6PP-trehalose 
6-phosphate complex. The model indicates a substrate-binding mode wherein shape 
  
182 
 
complementarity and van der Waals interactions drive recognition. The mode of binding is 
in sharp contrast to the homolog sucrose-6-phosphate phosphatase where extensive 
hydrogen-bond interactions are made to the substrate. Together these results suggest that 
high-affinity inhibitors will be bi-dentate, taking advantage of substrate-like binding to the 
phosphoryl-binding pocket while simultaneously utilizing non-native binding to the 
trehalose pocket. The conservation of the key residues that enforce the shape of the 
substrate pocket in T6PP enzymes suggest that development of broad-range anthelmintic 
and antibacterial therapeutics employing this platform may be possible. 
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A.1.3 An improved method for the large scale preparation of α, α′-trehalose-6-
phosphate. 
Liu C, Mariano PS. 
Abstract 
An improved method was developed for the efficient, large-scale synthesis of α,α′-
trehalose-6-phosphate starting with α,α′-trehalose. In the sequence, octa-trimethylsilylation 
of α,α′-trehalose is followed by selective removal of the 6-O-trimethylsilyl protecting 
group. Reaction of the mono-alcohol with (PhO)2POCl is then followed by simultaneous 
hydrogenolysis and per-desilylation to generate α,α′-trehalose-6-phosphate, free of 
contamination by inorganic phosphate. 
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A.1.4 Panoramic view of a superfamily of phosphatases through substrate profiling. 
Huang H, Pandya C, Liu C, Al-Obaidid N, Wang M, Zheng L, Keating ST,  Aono M, 
Loved JD, Evans B, Seidel R, Hillerich BS, Garforth S, Almo SC, Mariano PS, Dunaway-
Mariano D, Allen KN, and Farelli JD. 
Abstract  
Large-scale activity profiling of enzyme superfamilies provides information about 
cellular functions as well as the intrinsic binding capabilities of conserved folds. Herein, 
the functional space of the ubiquitous haloalkanoate dehalogenase superfamily (HADSF) 
was revealed by screening a customized substrate library against >200 enzymes from 
representative prokaryotic species, enabling inferred annotation of ~35% of the HADSF. 
An extremely high level of substrate ambiguity was revealed, with the majority of HADSF 
enzymes utilizing >5 substrates. Substrate profiling allowed assignment of function to 
previously unannotated enzymes with known structure, uncovered potential new pathways, 
and identified iso-functional orthologs from evolutionarily distant taxonomic groups. 
Intriguingly, the HADSF subfamily having the least structural elaboration of the Rossmann 
fold catalytic domain was the most specific, consistent with the concept that domain 
insertions drive the evolution of new functions and that the broad specificity observed in 
HADSF may be a relic of this process. 
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A.2  Plots in Chapter Two 
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[Mt-T6PP]= 66 nM; Vmax= 0.6687 µM/s; Km= 544 ±106 µM 
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[Sb-T6PP]= 22.8 nM; Vmax= 0.3644 µM/s; Km= 687 ±73 µM 
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[As-T6PP]= 240 nM; Vmax= 0.8667 µM/s; Km= 228 ±72 µM 
 
[St-T6PP]= 33 nM; Vmax= 0.2047 µM/s; Km= 314 ±43 µM 
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Enzyme: Mt-T6PP(50 μM); Substrate: α-D-Glucose-1-phosphate; 
kcat: 0.0022±0.0002 S
-1 Km: 8 ± 1 mM;  kcat/Km: 0.28 M
-1S-1. 
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A.3 Plots in Chapter Three 
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[Bm-T6PP]= 20 nM; Ki = 4.0 ± 0.6 µM 
Bm-T6PP with T6P and inhibitor K2WO4 
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[Bm-T6PP]= 20 nM; Ki = 82 ± 7 µM 
Bm-T6PP with T6P and inhibitor compound 1 
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[Bm-T6PP]= 20 nM; Ki = 487 ± 85 µM 
Bm-T6PP with T6P and inhibitor compound 2 
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[Bm-T6PP]= 20 nM; Ki = 279 ± 53 µM 
Bm-T6PP with T6P and inhibitor compound 3 
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[Mt-T6PP]= 66 nM; Ki = 19 ± 2 µM 
Mt-T6PP with T6P and inhibitor K2WO4 
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[Mt-T6PP]= 66 nM; Ki = 130 ± 20 µM 
Mt-T6PP with T6P and inhibitor compound 1 
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[Mt-T6PP]= 33 nM; Ki = 517 ± 19 µM 
Mt-T6PP with T6P and inhibitor compound 2 
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[Mt-T6PP]= 33 nM; Ki = 474 ± 94 µM 
Mt-T6PP with T6P and inhibitor   compound 3 
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[Sb-T6PP]= 22.8 nM; Ki = 334 ± 37 µM 
Sb-T6PP with T6P and inhibitor compound 1 
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[As-T6PP]= 9.4 nM; Ki = 120 ± 20 µM 
As-T6PP with T6P and inhibitor K2WO4 
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[As-T6PP]= 9.4 nM; Ki = 55 ± 9 µM 
As-T6PP with T6P and inhibitor Na3VO4 
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[As-T6PP]= 9.4 nM; Ki = 49 ± 5 µM 
As-T6PP with T6P and inhibitor compound 1 
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[As-T6PP]= 9.4 nM; Ki = 522 ± 78 µM 
As-T6PP with T6P and inhibitor compound 2 
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[As-T6PP]= 9.4 nM; Ki = 496 ± 71 µM 
As-T6PP with T6P and inhibitor compound 3 
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[St-T6PP]= 33 nM; Ki = 183 ± 15 µM 
Sb-T6PP with T6P and inhibitor compound 1 
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A. 4 Plots in Chapter Four 
A.4.1 Bm-T6PP kinetic Plots in Table 4.1 
 
Bm-F148A, kcat = 0.28±0.02 s
-1, Km = 2200±400 μM, Ki = 360±70 μM. 
  
204 
 
 
Bm-E157A, kcat = 25±0.6 s
-1, Km = 230±20 μM, Ki = 71±6 μM. 
 
Bm-R187A, kcat = 0.11± 0.01s
-1, Km = 3800±400 μM, Ki > 4 mM. 
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Bm-E251A, kcat = 0.99± 0.06 s
-1, Km = 1500±200 μM, Ki > 4 Mm. 
 
Bm-K253A, kcat = 0.098± 0.002 s
-1, Km = 6800±300 μM, Ki > 4 Mm. 
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Bm-H260A, kcat = 0.28± 0.03 s
-1, Km = 1100±300 μM, Ki = 780±170 μM. 
 
Bm-R262A, kcat = 0.13± 0.01 s
-1, Km = 2100±300 μM, Ki = 2400±500 μM. 
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Bm-N263A, kcat = 23± 0.7 s
-1, Km = 890±70 μM, Ki = 320 ± 40 μM. 
 
Bm-T288A, kcat = 11± 0.6 s
-1, Km = 1400 ± 200 μM, Ki = 1700 ± 200 μM. 
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Bm-R291A, kcat = 0.39 ± 0.07 s
-1, Km = 2900 ± 900 μM, Ki > 4 mM. 
 
Bm-E292A, kcat = 15 ± 0.5 s
-1, Km = 540 ± 60 μM, Ki = 380 ± 50 μM. 
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Bm-E295A, kcat = 0.16 ± 0.01 s
-1, Km = 1500 ± 200 μM, Ki = 190 ± 20 μM. 
 
Bm-R297A, kcat = 3 ± 0.2 s
-1, Km = 730 ± 90 μM, Ki = 460 ± 40 μM. 
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A.4.2 Bm-T6PP kinetic Plots in Table 4.4 
 
Enzyme: Bm-T6PP, Inhibitor: 5c, Ki = 320±30 μM. 
 
Enzyme: Bm-T6PP, Inhibitor: 6a, Ki = 160±20 μM. 
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Enzyme: Bm-T6PP, Inhibitor: 8a, Ki = 830±100 μM. 
 
Enzyme: Bm-T6PP, Inhibitor: 8p, Ki = 61±10 μM. 
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Enzyme: Bm-T6PP, Inhibitor: 9a, Ki = 5.3±0.6 μM. 
 
Enzyme: Bm-T6PP, Inhibitor: 9b, Ki = 82±10 μM. 
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Enzyme: Mt-T6PP, Inhibitor: 8b, Ki = 1600±270 μM. 
 
Enzyme: Mt-T6PP, Inhibitor: 8i, Ki = 1700±350 μM. 
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Enzyme: Sb-T6PP, Inhibitor: 8o, Ki = 140±20 μM. 
 
Enzyme: Sb-T6PP, Inhibitor: 8p, Ki = 13±2 μM. 
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Enzyme: Sb-T6PP, Inhibitor: 9a, Ki = 21±3 μM. 
 
Enzyme: Sb-T6PP, Inhibitor: 9b, Ki = 78±9 μM. 
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Enzyme: As-T6PP, Inhibitor: 8a, Ki = 1800±260 μM. 
 
Enzyme: As-T6PP, Inhibitor: 8p, Ki = 180±20 μM. 
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Enzyme: As-T6PP, Inhibitor: 9a, Ki = 84±10 μM. 
 
Enzyme: As-T6PP, Inhibitor: 9b, Ki = 350±30 μM. 
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Enzyme: St-T6PP, Inhibitor: 8p, Ki = 120±20 μM. 
 
Enzyme: St-T6PP, Inhibitor: 9a, Ki = 56±6 μM. 
  
219 
 
 
Enzyme: St-T6PP, Inhibitor: 9b, Ki = 280±30 μM. 
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A.5 ESI mass spectra In Chapter Five 
A.5.1 ESI mass spectra of Bm-T6PP treated with 26 
 
 
 
 
 
 
 
  
221 
 
A.5.2 ESI mass spectra of Sb-T6PP treated with 26 
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A.5.3 ESI mass spectra of Mt-T6PP treated with 26 
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A.5.4 ESI mass spectra of St-T6PP treated with 26 
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A.5.5 ESI mass spectra of Mt-T6PP-K253A 
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A.5.6 ESI mass spectra of Mt-T6PP-K253A treated with 26 
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A.5.7 ESI mass spectra of Bm-T6PP-K334A 
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A.5.8 ESI mass spectra of Bm-T6PP-K334A treated with 26 
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A.5.9 Sequence alignments of nematode and bactera T6PP enzymes 
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A.5.10 Plots of pseudo-first order rate constant for inactivation (kobs) 
A.5.10.1 Plots of kobs for 26 mediated As-T6PP inactivation. 
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A.5.10.2 Plots of kobs for 26 mediated Bm-T6PP inactivation. 
 
A.5.10.3 Plots of kobs for 26 mediated Mt-T6PP inactivation. 
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A.5.10.4 Plots of kobs for 26 mediated Sb-T6PP inactivation. 
 
A.5.10.5 Plots of kobs for 26 mediated St-T6PP inactivation. 
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